Toxicology Research Laboratory

UIC The University of Illinois at Chicago

Department of Pharmacology (M/C 868)
1940 W. Taylor St.
Chicago, Illinois 60612-7353

20100915172

DRAFT

Contract No.: DAMD17-92-C-2001
Task Order No.: UIC-18A
UIC/TRL Study No.: 193

Title Page

Volume 1 of 2

Study Report for Task Order No. UIC-18A

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Sponsor: US Army Medical Materiel Development Activity

Test Article: WR242511 Tartrate

Contract No.: DAMD17-92-C-2001

Study Director

Barry S. Levine, D.Sc., D.A.B.T.

In-Life Phase Completed On

March 07, 1996

Performing Laboratory

TOXICOLOGY RESEARCH LABORATORY (TRL)
University of Illinois at Chicago (UIC)
Department of Pharmacology
1940 W. Taylor St.
Chicago, IL 60612-7353

The views, opinions, and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy, or decision, unless so designated by other documentation.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE

DRAFT

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION	1b. RESTRICTIVE MARKINGS
2a. SECURITY CLASSIFICATION AUTHORITY Unclassified	3. DISTRIBUTION/AVAILABILITY OF REPORT Unlimited
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE	
4. PERFORMING ORGANIZATION REPORT NUMBER(S) UIC-18A (UIC/TRL Study No. 193)	5. MONITORING ORGANIZATION REPORT NUMBER(S)
6a. NAME OF PERFORMING ORGANIZATION Toxicology Research Laboratory University of Illinois at Chicago 6b. OFFICE SYMBOL (If applicable)	7a. NAME OF MONITORING ORGANIZATION U.S. Army Medical Materiel Development Activity
6c. ADDRESS (City, State, and ZIP Code) Department of Pharmacology (M/C 868) 1940 W. Taylor Street Chicago, IL 60612-7353	7b. ADDRESS (City, State, and ZIP Code) ATTN: MCMR-RMA-RD Fort Detrick Frederick, MD 21702-5014
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Materiel Development Activity 8b. OFFICE SYMBOL (If applicable) MCMR-UMP	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-92-C-2001
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, MD 21702-5009	10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 63807A; PROJECT NO. 30463807; TASK NO. QC; WORK UNIT ACCESSION NO. 073

11. TITLE (Include Security Classification)
Thirteen Week Oral Toxicity Study of WR242511 with a Thirteen Week Recovery Period in Dogs

12. PERSONAL AUTHOR(S)
Levine, B.S., Brown, A.P., and Morrissey, R.L. (PAI)

13a. TYPE OF REPORT	13b. TIME COVERED	14. DATE OF REPORT (Year, Month, Day)	15. PAGE COUNT
Study	FROM 10/6/95 TO _____		

16. SUPPLEMENTARY NOTATION

17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)
FIELD	GROUP	SUB-GROUP	

19. ABSTRACT (Continue on reverse if necessary and identify by block number)

This study evaluated the toxicity of WR242511 in male and female beagle dogs following thirteen weeks of daily oral administration by gelatin capsule. A thirteen week recovery period was included for all groups. WR242511 tartrate is being developed as an anticyanide agent. Dose levels studied were 0, 0.1, 0.3 and 1.0 mg base/kg/day and were based on a one month toxicity study in beagle dogs in which 1.0 mg base/kg/day resulted in toxicity to RBCs, lungs and platelets and a no-observed effect level (NOEL) of 0.1 mg base/kg/day was seen (UIC/TRL Study No. 134). The dogs were ≈ 7 - 8 months old and weighed 10.3 - 13.6 kg (males) and 7.4 - 11.3 kg (females) at dosing initiation.

In the present investigation, the primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain were seen in mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state. Administration of WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatment-related effects had resolved except for residual pulmonary lesions that were of such low severity as to be considered biologically insignificant. Because the aforementioned toxic responses were limited to the mid and high dose levels, the no-observed effect level (NOEL) of WR242511 tartrate was 0.1 mg base/kg/day.

20. DISTRIBUTION/AVAILABILITY OF ABSTRACT	21. ABSTRACT SECURITY CLASSIFICATION
☐ UNCLASSIFIED/UNLIMITED ☒ SAME AS RPT. ☐ DTIC USERS	Unclassified
22a. NAME OF RESPONSIBLE INDIVIDUAL Barry S. Levine	22b. TELEPHONE (Include Area Code) (312) 996-5543 22c. OFFICE SYMBOL N/A

DD Form 1473, JUN 86 *Previous editions are obsolete.*

SECURITY CLASSIFICATION OF THIS PAGE

UNCLASSIFIED

Contract No.: DAMD17-92-C-2001
Task Order No.: UIC-18A
UIC/TRL Study No.: 193

DRAFT

STATEMENT OF COMPLIANCE

Study No. 193 entitled "Thirteen Week Oral Toxicity Study of WR242511 with a Thirteen Week Recovery Period in Dogs" was conducted in compliance with the Good Laboratory Practices regulations as published in 21 CFR 58, 40 CFR 160 and 40 CFR 792 in all material aspects.

The protocol for this study was approved by the UIC Animal Care Committee.

Signature

Study Director

_____ _____

Barry S. Levine, D.Sc., D.A.B.T. Date

QUALITY ASSURANCE STATEMENT

STUDY TITLE: THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

STUDY NUMBER: 193

STUDY DIRECTOR: BARRY S. LEVINE

INITIATION DATE: 7/3/95

This study has been divided into a series of phases. Using a random sampling approach, Quality Assurance personnel monitors each of these phases over a series of studies. Procedures, equipment, documentation, etc., are examined in order to assure that the study is performed in accordance with the Good Laboratory Practice regulations of the Food and Drug Administration and the Environmental Protection Agency to assure that the study is conducted according to the protocol.

The following are the inspection dates, phases inspected, and report dates of QA inspections of the study.

INSPECT ON 7/5/95, TO STUDY DIR 7/5/95, TO MGMT 7/5/95
PHASES: PROTOCOL REVIEW

INSPECT ON 8/17/95, TO STUDY DIR 8/17/95, TO MGMT 8/18/95
PHASES: ANIMAL RECEIPT, PHYSICAL EXAMINATION, BODY WEIGHT AND IMPLANTATION OF ID MICROCHIP

INSPECT ON 9/6/95, TO STUDY DIR 9/6/95, TO MGMT 9/7/95
PHASES: TEST ARTICLE PREPARATION

INSPECT ON 12/5/95, TO STUDY DIR 12/7/95, TO MGMT 12/13/95
PHASES: ANIMAL IDENTIFICATION, ORAL DOSING, AND OPHTHALMIC EXAMINATION

INSPECT ON 4/8-9/96, TO STUDY DIR 4/9/96, TO MGMT 4/9/96
PHASES: RAW DATA AND DRAFT REPORT FROM ANALYTICAL LAB

INSPECT ON 4/23-26/96, TO STUDY DIR 4/26/96, TO MGMT 5/30/96
PHASES: RAW DATA

INSPECT ON 5/21-22/96, TO STUDY DIR 5/22/96, TO MGMT 5/30/96
PHASES: PATHOLOGY DRAFT REPORT

INSPECT ON 5/31-6/3/96, TO STUDY DIR 6/3/96, TO MGMT 6/6/96
PHASES: DRAFT REPORT

Ronald Schaenleck 6/6/96

QUALITY ASSURANCE DATE

Signature Page DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

TRL Chemical No.: 1720614

Sponsor: US Army Medical Materiel
Development Activity
Fort Detrick
Frederick, MD 21702-5014

Sponsor
Representative: George J. Schieferstein, Ph.D.

Testing Facility: TOXICOLOGY RESEARCH LABORATORY (TRL)
University of Illinois at Chicago (UIC)
Department of Pharmacology
1940 W. Taylor St.
Chicago, IL 60612-7353

_____ _____
Barry S. Levine, D.Sc., D.A.B.T. Date
Study Director

Study Initiation: July 3, 1995
Dosing Initiation: September 6, 1995
In-Life Completion: March 7, 1996

DRAFT

TABLE OF CONTENTS

VOLUME 1

TITLE PAGE 1

STATEMENT OF COMPLIANCE 2

QUALITY ASSURANCE STATEMENT 3

SIGNATURE PAGE 4

TABLE OF CONTENTS 5

1. SUMMARY 7

2. INTRODUCTION 7

3. MATERIALS AND METHODS 8

3.1 Test Article 8
3.2 Animals 8
3.3 Experimental Design 9
3.4 Statistical Analyses 13

4. RESULTS 14

4.1 Mortality/Clinical Signs 14
4.2 Body Weights 14
4.3 Food Consumption 15
4.4 Clinical Pathology 15
4.5 Electrocardiography 17
4.6 Ophthalmology 17
4.7 Organ Weights 17
4.8 Pathology 17

5. DISCUSSION/CONCLUSION 18

6. PERSONNEL 21

7. ARCHIVES 21

TABLE OF CONTENTS (contd.)

LIST OF TABLES

1 Summary of Toxic Responses 22
2 Summary of Clinical Signs 23
3 Summary of Body Weights 25
4 Summary of Weight Gains 31
5 Summary of Daily Mean Food Consumption 39
6 Summary of Clinical Chemistry Tests 43
7 Summary of Hematology Tests 87
8 Summary of Urinalysis Tests 127
9 Organ Weight Summary (% Brain Weight) 131
10 Summary of Microscopic Lesions 135

FIGURES

1 Summary of Male Body Weights 136
2 Summary of Female Body Weights 137

APPENDICES

A Analytical Chemistry Report A-1
B Clinical Pathology Methodology B-1
C Individual Observations (Clinical Signs) C-1
D Individual Body Weights and Body Weight Gains D-1
E Individual Food Consumption Data E-1
F Individual Clinical Chemistry Data F-1

VOLUME 2

APPENDICES (contd.)

G Individual Hematology Data G-1
H Individual Urinalysis Data H-1
I Cardiology Report I-1
J Ophthalmology Report J-1
K Individual Organ Weights K-1
L Pathology Report L-1
M Protocol and Protocol Amendments M-1
N Study Deviations N-1

DRAFT

1. SUMMARY

This study evaluated the toxicity of WR242511 in male and female beagle dogs following thirteen weeks of daily oral administration by gelatin capsule. A thirteen week recovery period was included for all groups. WR242511 tartrate is being developed as an anticyanide agent. Dose levels studied were 0, 0.1, 0.3 and 1.0 mg base/kg/day and were based on a one month toxicity study in beagle dogs in which 1.0 mg base/kg/day resulted in toxicity to RBCs, lungs and platelets and a no-observed effect level (NOEL) of 0.1 mg base/kg/day was seen (UIC/TRL Study No. 134). The dogs were ≈ 7 - 8 months old and weighed 10.3 - 13.6 kg (males) and 7.4 - 11.3 kg (females) at dosing initiation.

In the present investigation, the primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain were seen in mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state. Administration of WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatment-related effects had resolved except for residual pulmonary lesions that were of such low severity as to be considered biologically insignificant. Because the aforementioned toxic responses were limited to the mid and high dose levels, the no-observed effect level (NOEL) of WR242511 tartrate was 0.1 mg base/kg/day.

2. INTRODUCTION


This study was conducted to determine the specific target organ toxicity, dose-response relationships and a potential no-adverse effect level of WR242511 tartrate in dogs following thirteen weeks of daily oral (capsule) administration. A thirteen week recovery period was included for all groups to assess the reversibility of toxic effects. WR242511 tartrate is being developed as an anticyanide agent. The study was conducted in accordance with the specifications of the Sponsor, as indicated in Task Order UIC-18A. The FDA requires the use of two animal species, one which is a non-rodent, in preclinical toxicology studies. The dog is a standard and accepted non-rodent species for regulatory toxicology studies, and was specified by the Sponsor. Oral administration is the intended clinical route and was also specified by the Sponsor. All methods and procedures were conducted in accordance with the Quality Assurance Programs of the Toxicology Research Laboratory, University of Illinois at Chicago and Pathology Associates, Intl. and designed to conform with FDA Good Laboratory Practices Regulations. No unforeseen circumstances affected the integrity of the study. Dosing was initiated on September 6, 1995 and the in-life portion was terminated on March 7, 1996.

DRAFT

3. MATERIALS AND METHODS

3.1 Test Article

WR242511 tartrate (Bottle Lot No. BM 05816), a yellow powder, was provided by the Sponsor and was initially received on June 16,1993, and a second shipment was received on November 15, 1995 from Herner & Co., Rockville, MD. The chemical name of the test article is 8-[(4-Amino-1-methylbutyl)amino]5-(1-hexyloxy)-6-methoxy-4-methylquinoline DL tartrate and the base mole fraction is 0.71. It was stored at -20 to -15°C, ambient humidity and protected from light in an amber bottle. The chemical structure is shown below.



WR242511 tartrate

The Analytical Chemistry Report is contained in Appendix A. The test article was initially identified by GC-MS and the purity was determined by HPLC to be 99.32 ± 0.03%. The purity was re-determined following the completion of the in-life portion of the study. At that time, the purity was 99.20 ± 0.10%. Thus, the test article was stable under storage conditions.

3.2 Animals

Thirty seven male and thirty seven female Beagle dogs were obtained from Marshall Farms, North Rose, NY on August 17,1995. The animals were approximately 7 months old (dates of birth between 1/18/95 and 1/30/95) upon arrival at the UIC AAALAC-accredited animal facility. Each animal was given a facility-unique animal number upon arrival. This number was coded on a subcutaneously implanted microchip and also appeared on a cage card visible on the front of each cage. Animals were singly housed in runs, except as subsequently noted, in a temperature (65 - 84°F) and humidity (50 ± 20%) controlled room with a 12 hour light/12 hour dark cycle. Eight dogs were housed two/run (within sex) during the quarantine/pretest period, but were singly housed prior to initiation of the dosing phase. The run size, typically at least 15 square feet, was adequate to house dogs at the upper weight range as described in the *Guide for the Care*

DRAFT

and Use of Laboratory Animals, DHHS (NIH) No. 86.23. All runs were cleaned and bedding was replaced daily. The runs were sanitized once every two weeks.

Certified Canine Diet No. 5007 (PMI Feeds Inc., St. Louis, MO), approximately 400 g on a daily basis (exactly 400 g on days when food consumption was measured), and tap water *ad libitum* from an automatic watering system in which the room distribution lines were flushed daily were provided from arrival until termination. The water was untreated with additional chlorine or HCl. The food was removed for an overnight fast (≈ 16 - 20 hours) prior to blood collection for clinical pathology, overnight urine collection, and/or scheduled sacrifice. There were no known contaminants in the feed or water which were expected to influence the study. The results of the most current comprehensive chemical analyses of Chicago water are documented in files maintained by Quality Assurance.

The animals were quarantined for three weeks. During that time, the animals were observed daily for signs of illness and all unusual observations were reported to the Study Director or Clinical Veterinarian. Body weights and preliminary physical examinations were done upon arrival at the animal facility. Each dog was lightly sprayed with Para Pyrethrin Mist upon arrival for fleas, lice, and ticks. All dogs were previously vaccinated by the animal supplier against canine distemper, infectious canine hepatitis, oral papilloma, leptospirosis, parainfluenza, parvo and rabies. Blood samples were collected within three days of arrival for quarantine clinical chemistry and hematology tests, and fecal samples were collected for internal parasites examinations. Animals were examined during quarantine and approved for use by the Clinical Veterinarian prior to being placed on test. Quarantine release was documented on the Clinical Veterinarian Log by the veterinarian prior to study initiation.

3.3 Experimental Design

Near the end of the quarantine/pretest period, 32 animals of each sex were selected for study on the basis of quarantine data including body weight, food consumption, clinical pathology, electrocardiograms, and ophthalmology examinations. These animals were randomized within sex into the groups shown in the following table using a restricted randomized procedure stratified by body weight. No litter mates were included in the same dose group, except for a half litter mate male (recovery) and female (non-recovery) in treatment group 4. Following allocation to treatment groups, the animals were randomly assigned to one of six animal rooms used for this study.

Treatment Group	Dose Level (mg base/kg/day)	Number of Males	Number of Females
1	0	4 + 4*	4 + 4*
2	0.1	4 + 4*	4 + 4*
3	0.3	4 + 4*	4 + 4*
4	1.0	4 + 4*	4 + 4*

*Recovery Animals

DRAFT

Dose levels were selected in consultation with the sponsor based upon the results of an earlier four week oral toxicity study in the dog (UIC/TRL Study No. 134). Dose levels refer to the base.

Four animals/sex/dose were necropsied in week 14 after 91 or 92 days of dosing. All remaining animals were held for a thirteen week recovery period, at which time they were necropsied. The number of animals/sex/group was necessary for adequate statistical analysis.

Following treatment group allocation, the animal's number appeared on a card visible on the front of each run. The run card additionally contained the study number, test article identification, treatment group number, sex and dose level. Run cards were color-coded as a function of treatment group.

The test article was administered once daily by gelatin capsule starting with day 1 for 91 or 92 days. All animals received an empty gelatin capsule for at least 3 days during week -1 to acclimate them to the procedure. The specific quantity of the test article (weighed to the nearest 0.1 mg) was adjusted for purity and the base mole fraction, and was based on each animal's most recent body weight (twice weekly in weeks 1 - 4 and weekly thereafter). The control animals received empty gelatin capsules. The animals were dosed up to and including the day prior to scheduled necropsy except for the recovery animals, which were dosed for 91 days. The dogs weighed 10.3 - 13.6 kg (males) and 7.4 - 11.3 kg (females) on day -5 and were approximately 7 - 8 months old at initiation of treatment.

Non-fasted body weights were recorded on days -9 and -5, twice weekly during the first four study weeks, weekly thereafter during the remainder of treatment and during the recovery period. Fasted weights were collected at scheduled termination. Clinical signs were recorded once daily, approximately 1 - 2 hours after dosing. The general behavior, posture, locomotion, breathing pattern and coat were observed for all animals. The animals were also observed immediately prior to dosing and in the afternoon for moribundity/mortality. During the recovery period, clinical signs were recorded once daily in the morning and moribundity/mortality checks were conducted in the morning and afternoon. Physical examinations (clinical observations) which included examination of eyes and all orifices were conducted on day -9, on day 1 prior to dosing, and once weekly thereafter. Food consumption was measured for all animals over an approximate 24 hour period once weekly commencing with week -2. All dogs were examined by indirect ophthalmoscopy prior to study initiation (week -2) and during week 13, and in week 26 for the recovery animals. The eyes were dilated with 1% atropine sulfate prior to the examination.

Hematology and clinical chemistry parameters were measured following an overnight fast in weeks -3, -1, 4, 8, and 13. Hematology and clinical chemistry tests were also performed for the recovery animals in weeks 18 and 26. The overnight fasted animals

DRAFT

were unanesthetized and sufficient blood was collected from the jugular vein to measure the following parameters. The samples were processed in the same random order as collected. Water was available *ad libitum* during all fasting periods. Clinical pathology methodology is contained in Appendix 2.

Clinical Chemistry

Alanine aminotransferase (ALT)
Albumin
Albumin/globulin ratio (calc.)
Alkaline phosphatase
Aspartate aminotransferase (AST)
Calcium
Chloride
Cholesterol
Creatinine
Creatine kinase (CK)
Gamma glutamyl transferase (GGT)
Globulin (calculated)
Glucose
Haptoglobin
Lactate dehydrogenase (LDH)
Inorganic phosphorus
Potassium
Sodium
Total bilirubin
Total protein
Triglycerides
Urea nitrogen (BUN)

Hematology

Activated partial thromboplastin time (APTT)
[a]Erythrocyte count and morphology
Heinz bodies
Hematocrit
Hemoglobin
Leukocyte count, total and differential
Mean corpuscular hemoglobin (MCH)
Mean corpuscular hemoglobin concentration (MCHC)
Mean corpuscular volume (MCV)
[b]Methemoglobin
Platelet count
Prothrombin time
Reticulocyte count

[a]Includes nucleated RBCs.

[b]Measured with a Co-oximeter (Instrumentation Laboratory). The assay was performed within one hour of sample collection. The specimens were kept on wet ice prior to analysis.

Urine specimens were collected in weeks -1, 4, 8 and 13, and during the recovery period in weeks 18 and 26 following an overnight fast. During the overnight fasting period, the animals were placed in a metabolism cage for urine collection. Water was available *ad libitum* during all fasting periods. The following parameters were measured.

DRAFT

Urinalysis Parameters

Qualitative
- Bilirubin
- Glucose
- Ketones
- Occult Blood
- Leukocytes
- Nitrite
- pH
- Protein
- Urobilinogen

Color
Specific Gravity
Microscopic examination of spun sediment

ECG tracings were collected from all dogs during the pretest period and in week 13, and in week 26 for the recovery animals. The following leads were measured: I, II, III, aV_R, aV_L, and aV_F. Analysis included heart rate, the duration of the P wave, and PR, QRS and QT intervals. All recordings had a sensitivity of 1 mV/cm and a recording rate of 50 mm/sec. The recordings were made with the animal in the standard position of right lateral recumbency. In order to obtain all of the ECG's within a few days at each time point, the recordings were collected throughout the day during the baseline and recovery periods, but were performed in week 13 in the afternoon, at least 2 hours after dosing.

Four animals/dose/sex were killed and necropsied in random order over a two consecutive day period (days 92 and 93). The remaining recovery animals were killed and necropsied in random order at the onset of week 27, after a thirteen week recovery period. This was accomplished by sodium pentobarbital anesthesia and exsanguination. An extensive necropsy was performed under the direction and supervision of the pathologist. Terminal body weights were collected prior to routine sacrifice.

The necropsy procedure was a thorough and systematic examination and dissection of the animal viscera and carcass to include the external surface, all orifices, the cranial cavity, external surface of the brain, cross section of the spinal cord, the nasal cavity and nasal turbinates, thoracic, abdominal and pelvic cavities and their viscera, and cervical tissues and organs. The following tissues and organs were collected and fixed in 10% neutral buffered formalin (NBF), except for the eyes which were fixed in 2.5% phosphate buffered glutaraldehyde.

*Adrenal glands	Muscle (skeletal)
Aorta (thoracic)	*Ovaries
*Brain (fore-, mid-, and hind-)	Pancreas
Cecum	Pituitary
Colon	Prostate
Diaphragm	Rib with marrow
Duodenum	Salivary gland (mandibular)
Esophagus	Sciatic Nerve
Eyes and optic nerve	Skin
Gallbladder	Spinal cord (cervical, thoracic)
Gross lesions	*Spleen
*Heart	Stomach
Ileum	*Testes
Jejunum	Thymus
*Kidneys	*Thyroid gland with parathyroids
*Liver (with gallbladder drained)	Tongue
Lungs/Bronchi	Tonsil
Lymph node (submandibular and mesenteric)	Trachea
Mammary gland	Ureter
	Urinary bladder
	Uterus

*Weighed at scheduled necropsy. Paired organs were weighed as a unit.

The above tissues from all dogs sacrificed at scheduled necropsy in week 14 were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Those tissues/organs for which treatment-related lesions were observed were examined microscopically for all recovery animals.

Myeloid:erythroid (M:E) ratios were determined from a rib bone marrow smear for all animals at the week 14 necropsy. Because treatment-related changes were seen at the end of the dosing period, M:E ratios were also determined for the recovery animals.

3.4 Statistical Analyses

For each sex, Analysis of Variance tests were conducted on body weight, weekly body weight gain, total body weight gains, ECG measurements, hematology, clinical chemistry, urinary specific gravity and pH, and organ weight data. Organ weight analyses included weights relative to brain weights. If a significant F ratio was obtained ($p \leq 0.05$), Dunnett's test was used for pair-wise comparisons with the concurrent control group . Food consumption data were analyzed by the Kruskal-Wallis test. If a significant effect was obtained ($p \leq 0.05$), the Mann-Whitney U test was used for pair-wise comparisons

DRAFT

with the concurrent control group. All statistical analyses procedures compared treated to control animals at each time point. Data were not corrected for baseline values, except that body weight analysis included absolute values, weekly changes and total weight changes.

4. RESULTS

4.1 Mortality/Clinical Signs

The summaries of clinical signs are presented in Table 2. Individual clinical signs and daily incidence of clinical signs are contained in Appendix C.

No animals died during the study. Treatment related signs of cyanosis were observed as blue gums, blue sclera, and blue tongue. During the treatment period, blue tongue was observed in 2/8 males and 2/8 females in the low dose group, 7/8 males and 8/8 females in the mid dose group, and all animals in the high dose group. This was first seen in high dose animals in week 1, whereas blue tongue was initially observed in mid and low dose animals in the 3rd and 6th weeks respectively. Animals in the low and mid dose groups had blue tongues that were mild in severity (easily seen blue color) while animals in the high dose group had blue tongues that were mild to severe (intense, harsh blue-purple color) in discoloration. Animals in the high dose group also demonstrated blue sclera and blue gums during the treatment period.

During the recovery period, signs of cyanosis were not seen in the low and mid dose animals except for one male dog in the mid dose group on days 96 - 97. Clinical signs of cyanosis were still present in the high dose group during the recovery period up to day 131 (week 19).

4.2 Body Weights

Summaries of body weights are presented in Tables 3.1 - 3.6. Summaries of weight gains are presented in Tables 4.1 - 4.8. Summaries of male and female body weights are also graphically depicted in Figures 1 and 2. Individual body weights and weight gains are contained in Appendix D.

During the treatment and recovery periods, high dose females and mid and high dose males tended to have lower body weights than the corresponding vehicle control group, although these differences were not statistically significant. Statistically significant reductions in weight gains were seen during the latter half of week 1 in mid and high dose females. By the end of the treatment period, body weight loss was evident in mid and high dose males and females, which was statistically significant in mid dose males and high dose females. Body weight gains during the recovery period were similar

among the control and treatment groups.

DRAFT

4.3 Food Consumption

Summaries of daily food consumption are in Tables 5.1 - 5.4. Individual food consumption data are shown in Appendix E.

Food intake was significantly decreased on days 14 and 21 in high dose males. Although similar reductions occurred in high dose females, the decreases were not significant. Food consumption was apparently not affected thereafter in these animals, nor was it altered in the lower dose groups.

4.4 Clinical Pathology

Summaries of clinical chemistry tests are presented in Tables 6.1 - 6.44. Individual clinical chemistry data are in Appendix F. Summaries of hematological tests are presented in Tables 7.1 - 7.40 and individual hematology data are in Appendix G. Individual urinalysis data are contained in Appendix H.

Clinical Chemistry

Clinical chemistry alterations in drug-treated male and female dogs were suggestive of treatment-related hepatic effects. In week 4, serum albumin content and the A/G ratio were decreased in high dose males and females; however, total protein levels were unaffected (Tables 6.5 - 6.12). Serum haptoglobin content was increased 203% and 297% in high dose male and female dogs, respectively, in week 4 (Tables 6.43 and 6.44). The occurrence of increased levels of haptoglobin, which is synthesized by hepatocytes, is indicative of an inflammatory response, i.e., an acute phase reaction. Serum albumin, haptoglobin, and the A/G ratio in WR242511-treated dogs in week 8 and thereafter were similar to control animal values. In high dose males, increases in serum activity of AST and serum triglyceride concentration occurred in weeks 8 and 13 (Tables 6.3 and 6.21). In week 13, serum activity of AST was increased 33% in high dose females (Table 6.4). Serum activity of LDH was elevated 51% and 78% in high dose male and female dogs, respectively, in week 4 (Tables 6.23 and 6.24). Serum LDH activity was normal in week 8 and thereafter in female dogs. Activity of LDH were increased 69% in high dose males in week 8 and but was similar to control animal values thereafter. All of these changes suggest the presence of mild hepatocellular injury.

In week 4, serum total bilirubin concentrations were elevated slightly in mid and high dose male but not female dogs (50% and 43% elevations, respectively) (Table 6.13). Serum total bilirubin concentrations were still slightly elevated (36%) in mid dose male dogs in week 8, but were similar to control animals thereafter. These changes may suggest mild hepatobiliary dysfunction in these animals, or more likely relate to excessive amounts of hemoglobin undergoing degradation, i.e., secondary to hemolytic anemia (see following hematology section).

Biologically significant changes in clinical chemistry parameters were not observed in drug-treated male or female dogs during the recovery period (weeks 18 and 26).

Hematology

Methemoglobinemia, the desired pharmacologic effect of WR242511, was observed in male and female dogs exposed to WR242511 (Tables 7.19 and 7.20). During the treatment period, methemoglobin occurred in a dose-dependent fashion in male and female dogs and averaged 2%, 7% and 23% in the low, mid and high dose groups, respectively. During the recovery period, levels of methemoglobin in WR242511-exposed dogs did not differ from control animals.

Both male and female dogs administered WR242511 had changes in erythrocyte parameters during the treatment period indicative of mild anemia. In week 4, RBC counts were decreased in high dose male and female dogs and hemoglobin concentration was decreased in high dose males and mid and high dose females (Tables 7.1 - 7.4). RBC counts and hemoglobin were also decreased in week 8 in mid dose males. Although RBCs from high dose males in week 4 were hypochromic, macrocytosis and a corresponding increase in MCH were seen (Tables 7.7, 7.9, and 7.11). MCV was increased in week 4 and MCH was decreased in week 8 in high dose females and MCHC was decreased slightly in weeks 4 and 8 in mid and high dose females (Tables 7.8, 7.10, and 7.12). As a result of the mild anemia, compensatory increases in reticulocyte counts were seen in week 4 in mid and high dose males and in week 8 in high dose males (Table 7.13). High dose females also had increased reticulocyte counts throughout the treatment period. Compensatory increases in nucleated RBCs were also observed in high dose males and females in week 4 (Tables 7.15 and 7.16). Slight polychromasia (typically due to increased numbers of degenerating RBCs) was observed periodically during the treatment period in high dose animals (Appendix G). During the recovery period, RBC hematologic parameters in drug-treated male and female dogs were similar to control animal values.

Total leukocyte counts in high dose females were increased 35% and 59% in weeks 8 and 13, respectively, and this was essentially due to elevated mature neutrophil counts of 36%, 43% and 77% in weeks 4, 8 and 13, respectively (Tables 7.28 and 7.30). The only significant change in leukocyte counts observed in drug-treated male dogs was a slight increase in monocyte counts in weeks 4 and 13 in the high dose group (Table 7.35). Hematologic parameters in drug-treated dogs were similar to control animal values during the recovery period.

Administration of WR242511 resulted in significant thrombocytopenia during the treatment period in male and female dogs in both the mid and high dose groups (Tables 7.21 and 7.22). Thrombocytopenia was most severe in week 4 (platelet counts were decreased 51 - 66%), but improved thereafter. Platelet counts in WR242511-treated male

and female dogs were similar to control animal values during the recovery period.

No other changes in clinical pathology parameters were considered to be related to WR242511 treatment. Sporadic increases and decreases were seen, but were considered to be biologically insignificant. This included minimal alterations in PT and/or APTT in WR242511-treated animals.

Urinalysis

There were no treatment-related changes in urinalysis parameters.

4.5 Electrocardiography

The Cardiology Report is contained in Appendix I.

There were no electrocardiographic changes which were considered to be treatment-related.

4.6 Ophthalmology

The Ophthalmology Report is contained in Appendix J.

There were no treatment-related ophthalmic changes.

4.7 Organ Weights

Organ weight summaries expressed as % brain weight values are in Table 9. Individual organ weight data are contained in Appendix K.

Organ weights were not affected by test article treatment.

4.8 Pathology

The Pathology Report is contained in Appendix L. A summary of microscopic lesions is shown in Table 10.

At necropsy in week 14, multiple white foci were observed in lungs from animals in the high dose group. Wet tissue review of unperfused lung revealed that they failed to collapse normally in 3/4 males and 2/4 females in the high dose group. Also, enlarged bronchial lymph nodes were observed in high dose males and mid and high dose females. These gross necropsy observations were supported histologically as mid and high dose dogs demonstrated lung lesions (alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material) and

DRAFT

bronchial lymph node lesions (macrophage accumulation). Accumulation of alveolar macrophages was characterized by the presence of numerous macrophages in the lumen of the affected alveoli. Macrophages were relatively large with a small nucleus and copious vacuolated cytoplasm. Chronic perivascular inflammation consisted of infiltration of lymphocytes around small vessels, and was generally found in or near collections of alveolar macrophages. Chronic interstitial inflammation was generally associated with more severe cases of alveolar macrophage accumulation. Basophilic granular material denoted the presence of fine basophilic granular material in the lumen of the alveoli.

Mid and high dose animals necropsied in week 14 also demonstrated bone marrow hyperplasia and splenic erythropoiesis. Bone marrow hyperplasia was characterized by an increased number of hematopoietic cells and a reduced proportion of large vacuoles that were interpreted as fat cells. Erythropoiesis in spleen was characterized by the presence of colonies of deeply basophilic erythrocyte precursor cells in the splenic parenchyma. The bone marrow hyperplasia was primarily erythroid in nature, as a decrease in the M:E (myeloid:erythroid) ratio of the rib bone marrow was seen. Administration of WR242511 at 0.1 mg base/kg/day did not result in clinically significant treatment-related effects.

The lung lesions seen in week 14 had essentially resolved by the end of the 13 week recovery period. The residual effects in the mid and high dose groups after the 13 week recovery period were of such minimal severity that they were not considered to be clinically significant. Treatment-related effects observed in week 14 in the spleen, bone marrow, and bronchial lymph nodes had also resolved by the end of the 13 week recovery period.

No other microscopic changes were considered to be related to WR242511 treatment.

5. DISCUSSION/CONCLUSION

This study evaluated the toxicity of WR242511 tartrate in Beagle dogs following thirteen weeks of daily oral administration by gelatin capsule. The dose levels were 0, 0.1, 0.3 and 1.0 mg base/kg/day. A thirteen week recovery period was included for all groups. The results are summarized in Table 1. No animals died during the study. Biologically significant clinical signs of cyanosis, characterized by blue gums, sclera and/or tongue, were seen in all WR242511 treatment groups and occurred in a dose-dependent fashion. During the recovery period, signs of cyanosis were not seen in the low and mid dose animals except for one male dog in the mid dose group on days 96 - 97. Clinical signs of cyanosis were still present in the high dose group during the recovery period up to day 131 (week 19). No treatment-related ophthalmic or ECG changes were observed during the study.



During the treatment and recovery periods, high dose females and mid and high dose males tended to have lower body weights than the corresponding vehicle control group, although these

differences were not statistically significant. Food intake was only marginally affected in high dose animals. By the end of the treatment period, body weight loss was evident in mid and high dose males and females. Body weight gains during the recovery period were similar among the control and treatment groups.

Changes in clinical chemistry parameters during the treatment period in male and female dogs administered WR242511 suggested mild treatment-related hepatic effects. Decreased serum albumin and A/G ratio and increased serum activity of AST were seen in high dose male and female dogs. Serum triglyceride concentration and LDH activity were also elevated in high dose males. Serum haptoglobin content was increased in high dose male and female dogs which is suggestive of the presence of an inflammatory event, i.e., an acute phase reaction. These alterations suggest the presence of mild hepatocellular injury in male and female dogs. However, accompanying histopathologic evidence of hepatic injury were not seen, suggesting that WR242511 was marginally hepatotoxic. Clinical chemistry parameters in animals given WR242511 did not differ from control animal values during the 13 week recovery period.

Mid and high dose male and female dogs had changes in erythrocyte parameters during the 13 week treatment period indicative of mild anemia. These changes included decreased RBC counts and decreased hemoglobin concentration in mid and high dose animals. The anemia may have been hemolytic in origin as elevated serum total bilirubin concentrations, indicative of excessive hemoglobin degradation, were seen in mid and high dose males. As a result of the mild anemia, compensatory increases in reticulocyte counts and nucleated RBCs were observed. The anemia was accompanied by secondary histologic changes including splenic erythropoiesis in mid and high dose females and bone marrow hyperplasia in mid and high dose animals. The increased M:E ratio of the bone marrow indicated that the hyperplasia was primarily erythroid in nature and likely a physiologic response to the anemia. These data suggest that hemolysis may have played a role in the development of the anemia, although hemosiderosis was not seen microscopically in the liver, spleen and or bone marrow. During the recovery period, RBC parameters in animals given WR242511 did not differ from control animal values.

Exposure to WR242511 resulted in significant thrombocytopenia during the entire treatment period in male and female dogs in both the mid and high dose groups. This was apparently in response to the mild drug-induced anemia. Thrombocytopenia was most severe in week 4, but improved thereafter. Platelet counts in WR242511-treated animals were similar to control animal values during the recovery period.

Methemoglobinemia, the desired pharmacologic effect of WR242511, was observed in male and female dogs during the treatment period and occurred in a dose-dependent fashion. The production of methemoglobin indicates an oxidant nature of the drug, which supports the mild anemia as being hemolytic in origin. During the recovery period, levels of methemoglobin in WR242511-exposed dogs did not differ from control animals.

Lungs from several high dose animals failed to deflate normally in the week 14 necropsy, suggesting the presence of edema. Histopathologic evaluation indicated that animals in the mid and high dose group had developed pulmonary lesions by the end of the treatment period. These lesions were characterized by alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. The severity and incidence of these lesions was greater in the high dose group. Chronic interstitial inflammation was generally associated with more severe cases of alveolar macrophage accumulation. However, accumulation of alveolar macrophages was not always associated with interstitial changes that were detectable by light microscopy. A possible mechanism for the pulmonary lesions could be subtle changes or injury to the capillary endothelium and/or alveolar type I pneumocytes resulting in chronic hemorrhage and edema. These events could produce the alveolar interstitial changes as a secondary response. Although specific staining was not performed, the basophilic granular material observed in the alveoli is consistent with the presence of bacterial growth, which is a frequently encountered complication of pulmonary edema. This lesion was observed in 3/4 high dose females and 1/4 high dose males. High dose females had elevated mature neutophil counts during the treatment period, which is consistent with the presence of a bacterial infection. The pulmonary lesions seen in week 14 had essentially resolved by the end of the 13 week recovery period and the residual effects were of such minimal severity that they were considered to be clinically insignificant.

In summary, the primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain were in the mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state. Administration of WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatment-related effects had resolved except for residual pulmonary lesions that were of such low severity as to be considered biologically insignificant. Because the aforementioned toxic responses were limited to the mid and high dose levels, the no-observed effect level (NOEL) of WR242511 tartrate was 0.1 mg base/kg/day.

6. PERSONNEL

Study Director	Barry S. Levine, D.Sc., D.A.B.T.
Pathologist	Robert L. Morrissey, D.V.M., Ph.D., D.A.C.V.P.
Clinical Veterinarian	Terry Hewett, D.V.M., D.A.C.L.A.M.
Ophthalmologist	Samuel J. Vainisi, D.V.M., D.A.C.V.O.
Cardiologist	Robert L. Hamlin, D.V.M., Ph.D., D.A.C.V.I.M.
Clinical Laboratory	Maria Lang, A.H.T., C.V.T.
Chemistry Specialist	Thomas Tolhurst, B.S.
Tox. Lab Supervisor	Soudabeh Soura, B.S.
Lead Technician	Teresa O'Neill, B.S.
Quality Assurance	Ronald Schoenbeck

Report preparation was assisted by Soudabeh Soura, B.S., , Teresa O'Neill, B.S., Mukesh Pitroda, B.A., and Alan P. Brown, Ph.D.

7. ARCHIVES

The raw data, specimens, test article reserves, and final report are archived at the Toxicology Research Laboratory (TRL), University of Illinois at Chicago (UIC), Department of Pharmacology, 1940 W. Taylor St., Chicago, IL 60612-7353.

Table 1
THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511
WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Toxic Responses

Dose (mg base/kg/day)	0	0.1	0.3	1.0
Dogs/Sex	4 + 4[a]	4 + 4[a]	4 + 4[a]	4 + 4[a]
Deaths	0	0	NE	NE
Body Weight Gain	-	NE	↓	↓
Food Consumption	-	NE	NE	↓ (M)
Clinical Signs	-	Blue Tongue (2M/2F)	Blue Tongue (7M/8F)	Blue Gums (5M/6F) Blue Sclera (2M/3F) Blue Tongue (8M/8F)
Clinical Chemistry[b]	-	NE	↑ TBILI (M)	↑ AST ↓ ALB ↑ TBILI (M) ↑ TRIG (M) ↑ LDH ↑ HAPT ↓A/G
Hematology[c]	-	↑ METHGB (?)	↑ METHGB ↓ RBC (M) ↓ HGB ↓ MCH (M) ↑ RETICS (M) ↓ PLT ↓ MCHC (F)	↑ METHGB ↓ RBC (F/M?) ↓ HGB (F/M?) ↓ MCHC ↑ RETICS ↓ PLT ↓ MCH (F) ↑ MCV ↑ NRBC ↑ WBC (F) ↑ MNEUT (F)
Urinalysis	-	NE	NE	NE
Electrocardiography	-	NE	NE	NE
Ophthalmology	-	NE	NE	NE
Organ Weights	-	NE	NE	NE
Histopathology[d]	-	NE	LUNG - Accumulation, alveolar macrophage (1M/2F) - Chronic, perivascular inflammation (1M/2F) - Chronic, interstitial inflammation (1M/1F) BRONCHIAL LYMPH NODE - Macrophage accumulation (1F) BONE MARROW - Hyperplasia (4M/2F) SPLEEN - Erythropoiesis (2F)	LUNG - Accumulation, alveolar macrophage (4M/4F) - Chronic, perivascular inflammation (4M/4F) - Chronic, interstitial inflammation (3M/4F) - Basophilic granular material (1M/3F) BRONCHIAL LYMPH NODE - Macrophage accumulation (2M/3F) BONE MARROW - Hyperplasia (4M/4F) - ↓ M/E Ratio SPLEEN - Erythropoiesis (2F)

RECOVERY PERIOD: During the recovery period, clinical signs of cyanosis were generally not seen except in high dose animals. Treatment-related effects on body weights, food intake, and clinical pathology parameters were not seen. Histopathology changes seen in week 14 generally resolved by the end of the recovery period.

CONCLUSIONS: The primary toxic effects of WR242511 tartrate were seen in the lungs, RBCs and platelets. Mild reductions in body weight gain was seen in the mid and high dose animals. Methemoglobin, the desired pharmacologic effect, was produced in a dose-dependent fashion and was accompanied by clinical signs of cyanosis (blue gums, tongue and sclera). Mild anemia as supported by reticulocytosis, secondary splenic hematopoiesis and bone marrow hyperplasia occurred primarily in high dose animals. Significant thrombocytopenia was seen during the treatment period in the mid and high dose animals, presumably in response to the anemic state. WR242511 resulted in pulmonary lesions in mid and high dose animals consisting of alveolar macrophage accumulation, chronic perivascular inflammation, chronic interstitial inflammation, and basophilic granular material in the alveoli. Minimal, but statistically significant changes in clinical chemistry parameters suggestive of liver injury were seen. However, histopathologic evidence of liver injury was not observed, suggesting that WR242511 is marginally hepatotoxic. By the end of the 13 week recovery period, treatment-related effects had resolved except for residual pulmonary lesions that were of such low severity as to be considered biologically insignificant. Because the aforementioned toxic responses were limited to the mid and high dose levels, the no-observed effect level (NOEL) of WR242511 tartrate was 0.1 mg base/kg/day.

[a]Recovery animals

[b]AST = aspartate aminotransferase, ALB = albumin, A/G = albumin/globulin ratio, HAPT = haptoglobin, TRIG = triglycerides, LDH = lactate dehydrogenase, TBILI = total bilirubin.

[c]METHGB = methemoglobin, RBC = erythrocytes, HGB = hemoglobin, MCH = mean corpuscular hemoglobin, MCV = mean corpuscular volume, MCHC = mean corpuscular hemoglobin concentration, RETIC = reticulocytes, PLT = platelets, WBC = leukocytes, MNEUT = mature neutrophils, NRBC = nucleated red blood cells.

[d]Week 14 necropsy

NE = No effect

? = Marginal change

Table 2

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

Summary of Clinical Signs (Males)

Treatment Period

DOSE: (mg base/kg/day) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	0	5 (22,26-28,31-39,41,55,58-59,63-64,85-86)
Blue Sclera	0	0	0	2 (51,83-85,87,89)
Blue Tongue	0	2 (38-46,50,55-57,59,61)	7 (15-17,19-53,55-62,65,74-75,80-84,89-90,92)	8 (4-93)
Total Number of Animals	8	8	8	8

Recovery Period

DOSE: (mg base/kg/day) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	0	2 (94)
Blue Sclera	0	0	0	1 (94)
Blue Tongue	0	0	1 (96-97)	4 (94-113,118,124,129,131)
Total Number of Animals	8	8	8	8

*Number(s) in parentheses indicate the day(s) the adverse sign was observed

DRAFT

Table 2 (contd.)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

Summary of Clinical Signs (Females)

Treatment Period

DOSE: (mg base/kg/day) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	0	6 (16-36,38-42,44-45,48,50-68,70-72, 76-90,93)
Blue Sclera	0	0	0	3 (37,50-64,70-72,83-84,86-91)
Blue Tongue	0	2 (39,41)	8 (18,22,24-26,28-63,65-79, 81-82,92)	8 (6-93)
Total Number of Animals	8	8	8	8

Recovery Period

DOSE: (mg base/kg/day) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
Scheduled Sacrifice	4	4	4	4
Blue Gums	0	0	0	2 (94)
Blue Tongue	0	0	0	4 (94-99,101,103,105-116,118)
Total Number of Animals	8	8	8	8

*Number(s) in parentheses indicate the day(s) the adverse sign was observed

DRAFT

Table 3.1

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms)

STUDY: 193 Treatment Period SEX: MALE

PERIOD	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY -5	MEAN	11.4	11.5	11.4	11.3	
	S.D.	1.13	0.61	0.74	0.74	
	N	8	8	8	8	
DAY 3	MEAN	11.5	11.5	11.4	11.4	
	S.D.	1.15	0.56	0.96	0.79	
	N	8	8	8	8	
DAY 7	MEAN	11.6	11.6	11.4	11.4	
	S.D.	1.12	0.66	0.99	0.78	
	N	8	8	8	8	
DAY 10	MEAN	11.7	11.6	11.6	11.4	
	S.D.	1.06	D.62	0.96	0.75	
	N	8	8	8	8	
DAY 14	MEAN	11.5	11.6	11.4	11.2	
	S.D.	1.07	0.66	1.00	0.75	
	N	8	8	8	8	
DAY 17	MEAN	11.7	11.6	11.5	11.2	
	S.D.	1.17	0.70	1.12	0.76	
	N	8	8	8	8	
DAY 21	MEAN	11.7	11.7	11.6	11.1	
	S.D.	1.17	D.69	1.D9	D.71	
	N	8	8	8	8	
DAY 24	MEAN	11.7	11.6	11.5	11.0	
	S.D.	1.22	0.65	1.08	0.68	
	N	8	8	8	8	
DAY 28	MEAN	11.8	11.7	11.5	11.0	
	S.D.	1.28	0.67	1.03	0.67	
	N	8	8	8	8	
DAY 34	MEAN	11.7	11.6	11.3	10.8	
	S.D.	1.20	0.84	1.21	0.73	
	N	8	8	8	8	

Analysis of Variance using DUNNETT'S Procedure

Table 3.2

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms)

STUDY: 193 Treatment Period SEX: MALE

PERIOD	DOSE: / GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 41	MEAN	11.6	11.5	11.2	10.8	
	S.D.	1.20	0.75	1.12	0.72	
	N	8	8	8	8	
DAY 48	MEAN	11.9	11.6	11.2	11.0	
	S.D.	1.29	1.00	1.26	0.70	
	N	8	8	8	8	
DAY 54	MEAN	11.9	11.7	11.3	11.0	
	S.D.	1.15	1.08	1.31	0.70	
	N	8	8	8	8	
DAY 62	MEAN	11.9	11.7	11.1	11.0	
	S.D.	1.26	0.97	1.38	0.73	
	N	8	8	8	8	
DAY 69	MEAN	12.1	12.0	11.2	11.1	
	S.D.	1.30	0.99	1.45	0.83	
	N	8	8	8	8	
DAY 76	MEAN	12.0	11.8	11.0	11.0	
	S.D.	1.41	1.02	1.49	0.80	
	N	8	8	8	8	
DAY 83	MEAN	12.0	12.0	11.1	11.0	
	S.D.	1.37	0.99	1.61	0.88	
	N	8	8	8	8	
DAY 90	MEAN	12.0	11.9	10.7	10.9	
	S.D.	1.43	0.96	1.52	0.84	
	N	8	8	8	8	

Analysis of Variance using DUNNETT'S Procedure

Table 3.3

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF BODY WEIGHTS (Kilograms)

STUDY: 193 Treatment Period SEX: FEMALE

PERIOD	DOSE: / GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY -5	MEAN	9.8	9.7	9.8	9.8	
	S.D.	0.84	1.33	0.89	0.89	
	N	8	8	8	8	
DAY 3	MEAN	9.9	9.7	9.8	9.6	
	S.D.	0.89	1.33	1.02	0.80	
	N	8	8	8	8	
DAY 7	MEAN	10.0	9.7	9.8	9.4	
	S.D.	0.86	1.38	1.01	0.73	
	N	8	8	8	8	
DAY 10	MEAN	10.0	9.9	9.9	9.4	
	S.D.	0.90	1.40	1.14	0.83	
	N	8	8	8	8	
DAY 14	MEAN	10.0	9.8	9.8	9.2	
	S.D.	0.79	1.41	1.12	0.89	
	N	8	8	8	8	
DAY 17	MEAN	10.0	9.8	9.8	9.2	
	S.D.	0.86	1.45	1.24	0.98	
	N	8	8	8	8	
DAY 21	MEAN	10.2	9.9	9.8	9.2	
	S.D.	0.79	1.48	1.20	0.82	
	N	8	8	8	8	
DAY 24	MEAN	10.0	9.8	9.7	9.1	
	S.D.	0.76	1.53	1.15	0.79	
	N	8	8	8	8	
DAY 28	MEAN	10.0	9.8	9.8	9.1	
	S.D.	0.84	1.67	1.19	0.76	
	N	8	8	8	8	
DAY 34	MEAN	10.0	9.7	9.7	9.0	
	S.D.	0.81	1.46	1.31	0.66	
	N	8	8	8	8	

Analysis of Variance using DUNNETT'S Procedure

Table 3.4

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms)

STUDY: 193 Treatment Period SEX: FEMALE

PERIOD	DOSE: / GROUP:	0 mg base/kg/day 1-F	0.1 mg base/kg/day 2-F	0.3 mg base/kg/day 3-F	1.0 mg base/kg/day 4-F
DAY 41	MEAN	10.0	9.8	9.6	9.0
	S.D.	0.87	1.51	1.30	0.69
	N	8	8	8	8
DAY 48	MEAN	10.2	10.1	9.7	9.1
	S.D.	0.82	1.40	1.35	0.72
	N	8	8	8	8
DAY 54	MEAN	10.3	10.1	9.8	9.3
	S.D.	0.89	1.52	1.33	0.74
	N	8	8	8	8
DAY 62	MEAN	10.1	10.2	9.7	9.1
	S.D.	0.97	1.62	1.33	0.69
	N	8	8	8	8
DAY 69	MEAN	10.1	10.3	9.8	9.1
	S.D.	0.96	1.60	1.34	0.82
	N	8	8	8	8
DAY 76	MEAN	10.2	10.2	9.8	9.1
	S.D.	0.88	1.53	1.35	0.79
	N	8	8	8	8
DAY 83	MEAN	10.2	10.3	9.8	9.1
	S.D.	0.90	1.53	1.38	0.78
	N	8	8	8	8
DAY 90	MEAN	10.3	10.3	9.8	9.1
	S.D.	1.01	1.48	1.48	0.79
	N	8	8	8	8

Analysis of Variance using DUNNETT'S Procedure

Table 3.5

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF BODY WEIGHTS (Kilograms)

STUDY: 193 Recovery Period SEX: MALE

PERIOD	DOSE: / GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 97	MEAN	12.2	11.8	10.9	10.8	
	S.D.	1.78	0.37	1.90	0.86	
	N	4	4	4	4	
DAY 104	MEAN	12.4	12.1	11.1	11.1	
	S.D.	1.83	0.38	1.96	1.00	
	N	4	4	4	4	
DAY 111	MEAN	12.2	11.7	10.8	10.8	
	S.D.	1.78	0.37	1.80	0.94	
	N	4	4	4	4	
DAY 119	MEAN	12.5	12.1	11.1	11.1	
	S.D.	2.20	0.24	2.35	1.23	
	N	4	4	4	4	
DAY 125	MEAN	12.4	12.0	11.1	11.2	
	S.D.	2.25	0.29	2.03	1.17	
	N	4	4	4	4	
DAY 133	MEAN	12.6	12.1	11.2	11.3	
	S.D.	2.22	0.17	2.09	1.32	
	N	4	4	4	4	
DAY 139	MEAN	12.6	12.1	11.2	11.2	
	S.D.	2.27	0.15	2.11	1.35	
	N	4	4	4	4	
DAY 146	MEAN	12.4	11.9	11.1	11.1	
	S.D.	2.41	0.19	2.17	1.47	
	N	4	4	4	4	
DAY 153	MEAN	12.5	11.7	11.1	11.2	
	S.D.	2.48	0.10	2.00	1.38	
	N	4	4	4	4	
DAY 160	MEAN	12.6	11.9	11.3	11.4	
	S.D.	2.76	0.13	2.20	1.56	
	N	4	4	4	4	
DAY 167	MEAN	12.6	11.9	11.2	11.5	
	S.D.	2.75	0.26	2.16	1.56	
	N	4	4	4	4	
DAY 174	MEAN	13.0	12.1	11.5	11.8	
	S.D.	2.71	0.38	2.30	1.30	
	N	4	4	4	4	
DAY 181	MEAN	13.1	12.1	11.5	11.9	
	S.D.	2.54	0.38	2.05	1.47	
	N	4	4	4	4	

Analysis of Variance using DUNNETT'S Procedure

Table 3.6

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

SUMMARY OF BODY WEIGHTS (Kilograms)

STUDY: 193 Recovery Period SEX: FEMALE

PERIOD	DOSE: / GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY 97	MEAN	10.1	10.3	9.3	8.8	
	S.D.	1.09	1.53	1.47	0.64	
	N	4	4	4	4	
DAY 104	MEAN	10.3	10.5	9.5	9.1	
	S.D.	0.99	1.55	1.37	0.66	
	N	4	4	4	4	
DAY 111	MEAN	10.3	10.3	9.3	9.0	
	S.D.	1.26	1.67	1.51	0.74	
	N	4	4	4	4	
DAY 119	MEAN	10.5	10.4	9.6	9.3	
	S.D.	1.21	1.61	1.41	0.90	
	N	4	4	4	4	
DAY 125	MEAN	10.4	10.4	9.5	9.1	
	S.D.	1.39	1.57	1.40	0.87	
	N	4	4	4	4	
DAY 133	MEAN	10.7	10.6	9.7	9.3	
	S.D.	1.48	1.44	1.51	0.83	
	N	4	4	4	4	
DAY 139	MEAN	10.6	10.7	9.6	9.3	
	S.D.	1.36	1.48	1.66	0.96	
	N	4	4	4	4	
DAY 146	MEAN	10.5	10.6	9.4	9.2	
	S.D.	1.36	1.53	1.61	0.89	
	N	4	4	4	4	
DAY 153	MEAN	10.6	10.6	9.5	9.2	
	S.D.	1.33	1.55	1.61	0.88	
	N	4	4	4	4	
DAY 160	MEAN	10.9	10.8	9.6	9.4	
	S.D.	1.38	1.66	1.70	1.06	
	N	4	4	4	4	
DAY 167	MEAN	11.1	10.9	9.7	9.6	
	S.D.	1.44	1.63	1.57	1.22	
	N	4	4	4	4	
DAY 174	MEAN	11.1	11.0	10.0	9.7	
	S.D.	1.53	1.59	1.42	1.12	
	N	4	4	4	4	
DAY 181	MEAN	11.0	11.0	9.9	9.9	
	S.D.	1.52	1.55	1.54	1.20	
	N	4	4	4	4	

Analysis of Variance using DUNNETT'S Procedure

Table 4.1

THIRTEEN WEEK ORAL TOXICITY STUDY
OF WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Treatment Period SEX: MALE

PERIOD[a]	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 3[b]	MEAN	0.1	0.0	0.0	0.1	
	S.D.	0.24	0.19	0.31	0.28	
	N	8	8	8	8	
DAY 7	MEAN	0.1	0.1	0.0	0.0	
	S.D.	0.11	0.22	0.16	0.13	
	N	8	8	8	8	
DAY 10	MEAN	D.2	D.1	0.1	0.D	
	S.D.	0.27	0.17	0.13	0.22	
	N	8	8	8	8	
DAY 14	MEAN	-0.2	0.0	-0.1	-0.3	
	S.D.	0.23	0.17	0.28	0.17	
	N	8	8	8	8	
DAY 17	MEAN	0.2	0.1	0.0	0.0	
	S.D.	0.28	0.18	0.21	0.11	
	N	8	8	8	8	
DAY 21	MEAN	0.0	0.1	0.1	0.0	
	S.D.	0.25	0.14	0.13	0.12	
	N	8	8	8	8	
DAY 24	MEAN	-0.1	-0.2	-0.1	-0.1	
	S.D.	0.10	0.09	0.15	0.12	
	N	8	8	8	8	
DAY 28	MEAN	0.2	0.1	0.1	0.0	
	S.D.	0.10	0.24	0.17	0.16	
	N	8	8	8	8	
DAY 34	MEAN	-0.1	-0.1	-0.2	-0.2	
	S.D.	0.17	0.27	0.24	0.17	
	N	8	8	8	8	
DAY 41	MEAN	-0.1	-0.1	-0.1	0.0	
	S.D.	0.14	0.16	0.18	D.11	
	N	8	8	8	8	

Analysis of Variance using DUNNETT'S Procedure

[a]Weight gains compared to the previous period

[b]Baseline is day -5

Table 4.2

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Treatment Period SEX: MALE

PERIOD [a]	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 48	MEAN	0.3	0.1	0.0	0.2	
	S.D.	0.21	0.50	0.21	0.27	
	N	8	8	8	8	
DAY 54	MEAN	0.0	0.1	0.1	0.1	
	S.D.	0.32	0.18	0.17	0.30	
	N	8	8	8	8	
DAY 62	MEAN	0.0	-0.1	-0.2	0.0	
	S.D.	0.15	0.33	0.19	0.09	
	N	8	8	8	8	
DAY 69	MEAN	0.1	0.3	0.1	0.1	
	S.D.	0.13	0.20	0.21	0.14	
	N	8	8	8	8	
DAY 76	MEAN	0.0	-0.1	-0.2	-0.1	
	S.D.	0.19	0.24	0.18	0.09	
	N	8	8	8	8	
DAY 83	MEAN	0.0	0.1	0.0	0.0	
	S.D.	0.22	0.20	0.17	0.19	
	N	8	8	8	8	
DAY 90	MEAN	0.0	-0.1	-0.4	-0.1	
	S.D.	0.17	0.14	0.64	0.16	
	N	8	8	8	8	
TOTAL GAIN	MEAN	0.6	0.4	-0.7*	-0.4	
	S.D.	0.72	0.71	1.48	0.52	
	N	8	8	8	8	

* P less than .05 Analysis of Variance using DUNNETT'S Procedure

[a] Weight gains compared to the previous period

Table 4.3

THIRTEEN WEEK ORAL TOXICITY STUDY
OF WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Treatment Period SEX: FEMALE

PERIOD [a]	DOSE: / GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY 3 [b]	MEAN	0.1	-0.1	0.0	-0.2	
	S.D.	0.24	0.19	0.16	0.19	
	N	8	8	8	8	
DAY 7	MEAN	0.1	0.0	-0.1*	-0.2*	
	S.D.	0.13	0.15	0.11	0.13	
	N	8	8	8	8	
DAY 10	MEAN	0.D	0.2	0.2	D.0	
	S.O.	0.15	0.16	0.26	0.20	
	N	8	8	8	8	
OAY 14	MEAN	0.0	-0.1	-0.1	-0.2	
	S.D.	0.17	0.14	0.20	0.17	
	N	8	8	8	8	
OAY 17	MEAN	0.0	0.0	0.0	0.0	
	S.O.	0.23	0.21	0.22	0.39	
	N	8	8	8	8	
DAY 21	MEAN	0.2	0.1	0.0	-0.1	
	S.O.	0.14	0.25	0.19	0.40	
	N	8	8	8	8	
OAY 24	MEAN	-0.2	-0.2	-0.1	-0.1	
	S.D.	0.15	0.33	0.20	0.21	
	N	8	8	8	8	
DAY 28	MEAN	0.0	0.0	0.1	0.0	
	S.D.	0.24	0.22	0.16	0.19	
	N	8	8	8	8	
DAY 34	MEAN	0.0	-0.1	-0.2	-0.1	
	S.D.	0.15	0.29	0.23	0.19	
	N	8	8	8	8	
OAY 41	MEAN	0.1	0.1	-0.1	0.0	
	S.D.	0.16	0.14	0.15	0.09	
	N	8	8	8	8	

* P less than .D5 Analysis of Variance using DUNNETT'S Procedure

[a] Weight gains compared to the previous period

[b] Baseline is day -5

Table 4.4

THIRTEEN WEEK ORAL TOXICITY STUDY
OF WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Treatment Period SEX: FEMALE

PERIOD [a]	DOSE: / GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY 48	MEAN	0.1	0.3	0.1	0.1	
	S.D.	0.15	0.28	0.19	0.14	
	N	8	8	8	8	
DAY 54	MEAN	0.1	0.1	0.1	0.1	
	S.D.	0.33	0.23	0.13	0.18	
	N	8	8	8	8	
DAY 62	MEAN	-0.2	0.0	-0.1	-0.1	
	S.D.	0.20	0.28	0.12	0.18	
	N	8	8	8	8	
DAY 69	MEAN	0.1	0.1	0.1	-0.1	
	S.D.	0.23	0.15	0.15	0.21	
	N	8	8	8	8	
DAY 76	MEAN	0.1	-0.1	0.0	0.0	
	S.D.	0.17	0.21	0.20	0.23	
	N	8	8	8	8	
OAY 83	MEAN	0.1	0.0	0.0	0.0	
	S.O.	0.09	0.21	0.14	0.20	
	N	8	8	8	8	
DAY 90	MEAN	0.0	0.1	0.0	0.0	
	S.D.	0.25	0.27	0.16	0.07	
	N	8	8	8	8	
TOTAL GAIN	MEAN	0.5	0.6	-0.1	-0.7*	
	S.O.	0.46	0.69	0.77	0.63	
	N	8	8	8	8	

* P less than .05 Analysis of Variance using DUNNETT'S Procedure

[a]Weight gains compared to the previous period

Table 4.5

THIRTEEN WEEK ORAL TOXICITY STUDY
OF WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Recovery Period SEX: MALE

PERIOD [a]	DOSE: / GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 97 [b]	MEAN	-0.1	-0.1	0.0	-0.1	
	S.D.	0.22	0.13	0.14	0.26	
	N	4	4	4	4	
DAY 104	MEAN	0.3	0.3	0.3	0.3	
	S.D.	0.06	0.27	0.10	0.21	
	N	4	4	4	4	
DAY 111	MEAN	-0.3	-0.4	-0.3	-0.3	
	S.D.	0.17	0.22	0.34	0.19	
	N	4	4	4	4	
DAY 119	MEAN	0.3	0.3	0.3	0.3	
	S.D.	0.43	0.21	0.57	0.32	
	N	4	4	4	4	
DAY 125	MEAN	-0.1	-0.1	0.0	0.1	
	S.D.	0.20	0.12	0.33	0.24	
	N	4	4	4	4	
DAY 133	MEAN	0.2	0.1	0.1	0.2	
	S.D.	0.14	0.13	0.17	0.17	
	N	4	4	4	4	
DAY 139	MEAN	0.1	0.0	0.0	-0.1	
	S.D.	0.10	0.08	0.13	0.22	
	N	4	4	4	4	
DAY 146	MEAN	-0.2	-0.2	-0.1	-0.2	
	S.D.	0.15	0.13	0.10	0.13	
	N	4	4	4	4	
DAY 153	MEAN	0.1	-0.2	0.1	0.2	
	S.D.	0.26	0.28	0.19	0.10	
	N	4	4	4	4	
DAY 160	MEAN	0.0	0.1	0.2	0.2	
	S.D.	0.31	0.21	0.22	0.21	
	N	4	4	4	4	

Analysis of Variance using DUNNETT'S Procedure

[a] Weight gains compared to the previous period

[b] Baseline is day 90

Table 4.6 .

THIRTEEN WEEK ORAL TOXICITY STUDY
OF WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Recovery Period SEX: MALE

PERIOD [a]	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M	mg base/kg/day
DAY 167	MEAN	0.1	0.0	-0.1	0.1	
	S.D.	0.10	0.23	0.22	0.05	
	N	4	4	4	4	
DAY 174	MEAN	0.4	0.2	0.3	0.3	
	S.D.	0.13	0.14	0.19	0.29	
	N	4	4	4	4	
DAY 181	MEAN	0.1	0.1	0.0	0.1	
	S.D.	0.27	0.15	0.25	0.39	
	N	4	4	4	4	
TOTAL GAIN	MEAN	0.8	0.3	0.6	0.9	
	S.D.	0.71	0.57	0.33	1.12	
	N	4	4	4	4	

Analysis of Variance using DUNNETT'S Procedure

[a]Weight gains compared to the previous period

Table 4.7

THIRTEEN WEEK ORAL TOXICITY STUDY
OF WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Recovery Period SEX: FEMALE

PERIOD [a]	DOSE: GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY 97 [b]	MEAN	-0.1	-0.2	-0.1	-0.1	
	S.D.	0.19	0.13	0.05	0.13	
	N	4	4	4	4	
DAY 104	MEAN	0.2	0.1	0.2	0.4	
	S.D.	0.21	0.10	0.14	0.10	
	N	4	4	4	4	
DAY 111	MEAN	0.0	-0.2	-0.3	-0.2	
	S.D.	0.29	0.22	0.19	0.10	
	N	4	4	4	4	
DAY 119	MEAN	0.2	0.2	0.4	0.3	
	S.D.	0.13	0.22	0.13	0.22	
	N	4	4	4	4	
DAY 125	MEAN	-0.1	0.0	-0.2	-0.1	
	S.D.	0.22	0.05	0.06	0.05	
	N	4	4	4	4	
DAY 133	MEAN	0.2	0.2	0.2	0.1	
	S.D.	0.10	0.19	0.16	0.29	
	N	4	4	4	4	
OAY 139	MEAN	-0.1	0.1	-0.1	0.1	
	S.D.	0.29	0.22	0.25	0.13	
	N	4	4	4	4	
DAY 146	MEAN	-0.1	-0.1	-0.1	-0.1	
	S.O.	0.15	0.17	0.22	0.21	
	N	4	4	4	4	
DAY 153	MEAN	0.2	0.0	0.0	0.0	
	S.D.	0.10	0.14	0.13	0.22	
	N	4	4	4	4	
DAY 160	MEAN	0.3	0.2	0.1	0.2	
	S.O.	0.06	0.24	0.14	0.19	
	N	4	4	4	4	

Analysis of Variance using DUNNETT'S Procedure

[a] Weight gains compared to the previous period

[b] Baseline is day 90

Table 4.8

THIRTEEN WEEK ORAL TOXICITY STUDY
OF WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF WEIGHT GAINS (Kilograms)

STUDY: 193 Recovery Period SEX: FEMALE

PERIOD [a]	DOSE: / GROUP:	0 / 1-F	0.1 / 2-F	0.3 / 3-F	1.0 / 4-F	mg base/kg/day
DAY 167	MEAN	0.2	0.0	0.2	0.2	
	S.D.	0.15	0.05	0.13	0.18	
	N	4	4	4	4	
DAY 174	MEAN	0.0	0.2	0.3	0.2	
	S.D.	0.18	0.17	0.15	0.13	
	N	4	4	4	4	
DAY 181	MEAN	-0.2	-0.1	-0.1	0.2	
	S.D.	0.17	0.10	0.22	0.15	
	N	4	4	4	4	
TOTAL GAIN	MEAN	0.8	0.5	0.4	1.1	
	S.D.	0.84	0.14	0.33	0.68	
	N	4	4	4	4	

Analysis of Variance using DUNNETT'S Procedure

[a]Weight gains compared to the previous period

Table 5.1

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams)

STUDY: 193 Treatment Period SEX: MALE

PERIOD	DOSE: GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M mg base/kg/day
DAY -8	INTAKE (g)	312	293	295	297
	S.D.	60.7	75.1	97.0	89.2
	N	8	8	8	8
DAY -4	INTAKE (g)	349	292	348	349
	S.D.	53.8	63.6	55.4	73.7
	N	8	8	8	8
DAY 7	INTAKE (g)	384	347	327	322
	S.D.	33.0	62.3	65.1	84.3
	N	8	8	8	8
DAY 14	INTAKE (g)	365	356	310	264*
	S.D.	52.6	49.3	82.1	84.0
	N	8	8	8	8
DAY 21	INTAKE (g)	397	400	381	344*
	S.D.	5.2	0.7	40.1	109.4
	N	8	8	8	8
DAY 25	INTAKE (g)	365	362	352	265
	S.D.	61.7	53.4	82.8	115.7
	N	8	8	8	8
DAY 35	INTAKE (g)	393	400	378	349
	S.D.	12.7	0.0	51.9	125.3
	N	8	8	8	8
DAY 42	INTAKE (g)	391	395	399	363
	S.D.	26.2	13.8	2.1	52.9
	N	8	8	8	8
DAY 49	INTAKE (g)	352	400	377	388
	S.D.	72.0	0.0	64.3	32.9
	N	8	8	8	8
DAY 51	INTAKE (g)	377	364	369	373
	S.D.	39.0	67.0	38.6	69.8
	N	8	8	8	8
DAY 54	INTAKE (g)	364	361	386	396
	S.D.	47.7	53.6	29.9	8.2
	N	8	8	8	8
DAY 63	INTAKE (g)	360	391	362	385
	S.D.	62.8	19.6	91.4	40.8
	N	8	8	8	8
DAY 70	INTAKE (g)	379	382	376	376
	S.D.	59.4	49.9	57.1	68.2
	N	8	8	8	8
DAY 77	INTAKE (g)	355	400	384	391
	S.D.	113.6	0.0	30.7	26.2
	N	8	8	8	8
DAY 84	INTAKE (g)	396	391	400	400
	S.D.	10.3	26.5	0.0	0.0
	N	8	8	8	8
DAY 91	INTAKE (g)	380	400	400	400
	S.D.	56.9	0.0	0.0	0.0
	N	8	8	8	8

* P less than .05 Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test

Table 5.2

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams)

STUDY: 193 Treatment Period SEX: FEMALE

PERIOD	DOSE: GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY -8	INTAKE (g)	292	274	309	270	
	S.D.	55.6	89.0	59.6	86.6	
	N	8	8	8	8	
DAY -4	INTAKE (g)	310	307	329	268	
	S.D.	63.9	100.6	60.7	84.7	
	N	8	8	8	8	
DAY 7	INTAKE (g)	313	306	275	196	
	S.D.	83.5	73.7	93.4	100.0	
	N	8	8	8	8	
DAY 14	INTAKE (g)	282	310	332	205	
	S.D.	100.9	72.1	89.6	118.0	
	N	8	8	8	8	
DAY 21	INTAKE (g)	350	345	345	286	
	S.D.	53.6	65.9	83.0	84.1	
	N	8	8	8	8	
DAY 25	INTAKE (g)	330	311	319	272	
	S.D.	66.7	79.8	109.1	115.7	
	N	8	8	8	8	
DAY 35	INTAKE (g)	329	332	318	321	
	S.D.	77.9	75.1	92.9	84.0	
	N	8	8	8	8	
DAY 42	INTAKE (g)	330	363	373	351	
	S.D.	62.8	56.4	40.2	52.4	
	N	8	8	8	8	
DAY 49	INTAKE (g)	300	309	315	302	
	S.D.	123.8	117.2	97.7	104.5	
	N	8	8	8	8	
DAY 51	INTAKE (g)	315	312	332	317	
	S.D.	122.2	83.6	88.3	79.4	
	N	8	8	8	8	
DAY 54	INTAKE (g)	332	343	347	322	
	S.D.	119.4	59.7	61.3	52.3	
	N	8	8	8	8	
DAY 63	INTAKE (g)	335	316	341	292	
	S.D.	94.6	92.8	71.9	111.4	
	N	8	8	8	8	
DAY 70	INTAKE (g)	328	300	351	338	
	S.D.	123.0	87.9	63.9	89.0	
	N	8	8	8	8	
DAY 77	INTAKE (g)	345	373	373	370	
	S.D.	82.7	57.2	72.1	38.7	
	N	8	8	8	8	
DAY 84	INTAKE (g)	375	385	379	368	
	S.D.	48.0	30.7	33.6	65.1	
	N	8	8	8	8	
DAY 91	INTAKE (g)	381	335	330	375	
	S.D.	28.2	77.8	86.3	33.8	
	N	8	8	8	8	

Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test

Table 5.3

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams)

STUDY: 193 Recovery Period SEX: MALE

PERIOD	DOSE: GROUP:	0 mg base/kg/day 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 98	INTAKE (g)	388	380	400	400
	S.D.	24.0	39.5	0.0	0.0
	N	4	4	4	4
DAY 105	INTAKE (g)	354	400	400	400
	S.D.	91.5	0.0	0.0	0.0
	N	4	4	4	4
DAY 112	INTAKE (g)	400	400	400	400
	S.D.	0.0	0.0	0.0	0.0
	N	4	4	4	4
DAY 119	INTAKE (g)	400	400	400	400
	S.D.	0.0	0.0	0.0	0.0
	N	4	4	4	4
DAY 126	INTAKE (g)	400	400	400	400
	S.D.	0.0	0.0	0.0	0.0
	N	4	4	4	4
DAY 133	INTAKE (g)	400	400	400	400
	S.D.	0.0	0.0	0.0	0.0
	N	4	4	4	4
DAY 140	INTAKE (g)	400	400	386	400
	S.D.	0.0	0.0	29.0	0.0
	N	4	4	4	4
DAY 147	INTAKE (g)	400	400	400	400
	S.D.	0.0	0.0	0.0	0.0
	N	4	4	4	4
DAY 154	INTAKE (g)	400	400	400	400
	S.D.	0.0	0.0	0.0	0.0
	N	4	4	4	4
DAY 161	INTAKE (g)	400	390	400	400
	S.D.	0.0	19.5	0.0	0.0
	N	4	4	4	4
DAY 168	INTAKE (g)	400	400	390	400
	S.D.	0.0	0.0	21.0	0.0
	N	4	4	4	4
DAY 175	INTAKE (g)	400	400	353	349
	S.D.	0.0	0.0	93.5	103.0
	N	4	4	4	4
DAY 182	INTAKE (g)	354	400	361	400
	S.D.	56.3	0.0	79.0	0.0
	N	4	4	4	4

Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test

Table 5.4

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF DAILY MEAN FOOD CONSUMPTION (Grams)

STUDY: 193 Recovery Period SEX: FEMALE

PERIOD	DOSE: GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F	mg base/kg/day
DAY 98	INTAKE (g)	310	285	363	359	
	S.D.	104.3	86.6	74.0	68.1	
	N	4	4	4	4	
DAY 105	INTAKE (g)	345	318	336	400	
	S.D.	63.9	123.4	128.0	0.0	
	N	4	4	4	4	
OAY 112	INTAKE (g)	304	334	361	400	
	S.D.	166.4	83.8	78.5	0.0	
	N	4	4	4	4	
DAY 119	INTAKE (g)	358	309	362	400	
	S.D.	68.4	108.9	77.0	0.0	
	N	4	4	4	4	
DAY 126	INTAKE (g)	362	319	396	400	
	S.D.	45.3	66.6	9.0	0.0	
	N	4	4	4	4	
DAY 133	INTAKE (g)	354	321	400	400	
	S.D.	58.4	92.4	0.0	0.0	
	N	4	4	4	4	
OAY 140	INTAKE (g)	270	329	400	400	
	S.D.	45.1	99.9	0.0	0.0	
	N	4	4	4	4	
DAY 147	INTAKE (g)	400	359	400	400	
	S.D.	0.0	82.5	0.0	0.0	
	N	4	4	4	4	
DAY 154	INTAKE (g)	329	385	400	400	
	S.D.	99.0	30.5	0.0	0.0	
	N	4	4	4	4	
DAY 161	INTAKE (g)	352	338	400	400	
	S.D.	62.5	82.8	0.0	0.0	
	N	4	4	4	4	
DAY 168	INTAKE (g)	305	348	400	356	
	S.D.	121.5	104.0	0.0	87.5	
	N	4	4	4	4	
OAY 175	INTAKE (g)	265	292	378	383	
	S.D.	95.1	128.9	43.5	34.5	
	N	4	4	4	4	
DAY 182	INTAKE (g)	262	278	400	359	
	S.D.	111.5	83.8	0.0	51.6	
	N	4	4	4	4	

Statistical Analysis by Kruskal-Wallis test and Mann-Whitney U test

Table 6.1

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Alanine Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALT

SEX: MALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	42	25	33	37	39	39	36
SD	12.3	2.6	5.3	8.3	7.5	9.4	6.4
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	38	29	34	37	37	41	41
SD	11.3	4.9	8.5	7.9	7.9	8.4	3.9
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	43	29	32	35	36	39	45
SD	19.4	8.9	11.2	9.6	11.4	24.9	19.1
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	35	27	28	34	34	35	40
SD	6.4	6.9	4.1	4.4	5.0	4.4	8.4
N	8	8	8	8	8	4	4

Table 6.2

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Alanine Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALT

SEX: FEMALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	33	29	32	33	35	33	31
SD	4.5	3.8	8.3	8.9	12.4	4.2	6.6
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	32	29	31	32	31	27	30
SD	5.4	3.4	3.6	4.2	4.9	7.5	3.2
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	26	24*	26	29	29	25	35
SD	6.0	5.0	8.8	6.3	3.3	2.8	6.0
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	30	26	27	27	31	28	27
SD	5.7	2.9	4.8	3.7	6.6	6.2	5.0
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.3

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: AST

SEX: MALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	33	33	37	33	33	34	40
SD	3.3	6.5	12.0	6.5	4.2	4.9	6.5
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	32	38	37	36	37	37	42
SD	5.0	18.7	8.5	8.7	5.1	9.5	10.2
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	33	31	38	41	41	33	42
SD	5.0	4.3	6.1	10.6	8.8	7.4	10.2
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	34	35	47	52*	43*	36	39
SD	6.1	6.1	9.5	11.6	8.1	7.9	7.1
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.4

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: AST

SEX: FEMALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	36	33	39	39	40	36	38
SD	7.2	5.5	8.2	15.4	9.6	12.1	6.8
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	30	30	32	33	40	24	33
SD	8.4	7.4	6.6	6.6	4.6	4.1	4.4
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	29	32	39	37	39	41	48
SD	9.5	6.7	9.8	11.0	7.4	6.9	9.5
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	30	30	46	42	53*	28	35
SD	8.3	4.9	8.9	5.0	6.2	3.9	6.7
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.5

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Total Protein

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TP

SEX: MALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	6.4	5.7	5.9	6.2	6.0	6.3	6.6
SD	0.26	0.28	0.31	0.34	0.37	0.24	0.15
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	6.3	5.7	6.0	6.0	6.1	6.2	6.4
SD	0.24	0.28	0.49	0.27	0.35	0.38	0.21
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	6.2	5.6	5.9	6.2	6.0	6.2	6.5
SD	0.27	0.23	0.40	0.21	0.33	0.53	0.23
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	6.3	5.7	5.8	6.3	6.2	6.5	6.7
SD	0.28	0.23	0.44	0.37	0.29	0.10	0.31
N	8	8	8	8	8	4	4

Table 6.6

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Total Protein

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TP

SEX: FEMALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PRDCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	6.0	5.7	6.0	5.9	6.2	6.2	6.6
SD	0.45	0.36	0.33	0.29	0.31	0.24	0.38
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	6.3	5.8	5.9	6.0	6.3	6.4	6.6
SD	0.35	0.31	0.46	0.41	0.27	0.13	D.42
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	6.1	5.7	5.9	5.9	6.3	6.2	6.5
SD	0.28	0.23	0.40	0.36	0.29	0.06	0.33
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	6.3	5.9	5.7	5.8	6.3	6.3	6.5
SD	D.40	D.50	0.25	0.37	0.24	D.33	D.17
N	8	8	8	8	8	4	4

Table 6.7

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Albumin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALB

SEX: MALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	3.2	3.1	3.2	3.3	3.2	3.3	3.6
SD	0.18	0.14	0.12	0.09	0.14	0.13	0.13
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	3.2	3.2	3.2	3.2	3.2	3.2	3.5
SD	0.17	0.19	0.24	0.16	0.20	0.17	0.22
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	3.1	3.1	3.0	3.1	3.0	3.0	3.4
SD	0.17	0.15	0.19	0.12	0.21	0.25	0.29
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	3.2	3.2	2.8*	3.1	3.1	3.1	3.6
SD	0.17	0.12	0.19	0.12	0.20	0.17	0.25
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Albumin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALB

SEX: FEMALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	3.2	3.2	3.3	3.2	3.2	3.2	3.5
SD	0.19	0.11	0.15	0.16	0.13	0.19	0.05
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	3.3	3.2	3.3	3.3	3.3	3.3	3.4
SD	0.14	0.24	0.19	0.24	0.16	0.10	0.13
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	3.2	3.0	3.2	3.2	3.1	3.1	3.5
SD	0.20	0.19	0.15	0.16	0.16	0.18	0.08
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	3.3	3.2	2.9*	3.1	3.2	3.1	3.4
SD	0.20	0.18	0.16	0.11	0.10	0.14	0.05
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.9

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Globulin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLOB

SEX: MALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	3.2	2.6	2.7	3.0	2.9	3.1	3.0
SD	0.21	0.23	0.29	0.32	0.27	0.24	0.10
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	3.1	2.5	2.8	2.8	2.9	3.0	2.8
SD	0.12	0.13	0.29	0.14	0.20	0.40	0.10
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	3.1	2.5	2.8	3.1	3.0	3.2	3.1
SD	0.30	0.20	0.27	0.14	0.23	0.29	0.08
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	3.2	2.5	3.0	3.1	3.1	3.4	3.1
SD	0.24	0.14	0.30	0.30	0.23	0.14	0.15
N	8	8	8	8	8	4	4

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Globulin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLOB

SEX: FEMALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	2.9	2.5	2.7	2.7	3.0	3.1	3.1
SD	0.32	0.30	0.23	0.23	0.32	0.29	0.34
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	3.0	2.6	2.7	2.7	3.1	3.2	3.2
SD	0.26	0.24	0.33	0.23	0.16	0.13	0.37
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	3.0	2.7	2.7	2.7	3.2	3.1	3.0
SD	0.33	0.17	0.28	0.25	0.17	0.13	0.40
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	3.0	2.7	2.8	2.7	3.1	3.2	3.0
SD	0.28	0.37	0.25	0.31	0.30	0.39	0.17
N	8	8	8	8	8	4	4

Table 6.11

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: A/G Ratio

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: A/G

SEX: MALE

UNITS: -

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	1.00	1.22	1.21	1.10	1.11	1.07	1.23
SD	0.091	0.116	0.144	0.121	0.097	0.100	0.063
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	1.03	1.26	1.16	1.13	1.13	1.09	1.25
SD	0.052	0.074	0.090	0.049	0.071	0.186	0.102
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	1.04	1.24	1.09	1.02	1.02	0.93	1.10
SD	0.145	0.121	0.094	0.052	0.091	0.035	0.119
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	1.00	1.25	0.95*	1.01	1.00	0.91	1.17
SD	0.098	0.060	0.071	0.088	0.095	0.081	0.093
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: A/G Ratio

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: A/G

SEX: FEMALE

UNITS: -

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	1.10	1.25	1.21	1.20	1.07	1.04	1.12
SD	0.101	0.128	0.082	0.110	0.131	0.145	0.113
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	1.11	1.24	1.24	1.21	1.08	1.04	1.06
SD	0.077	0.159	0.123	0.086	0.056	0.062	0.119
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	1.09	1.10	1.18	1.21	0.98	1.02	1.20
SD	0.171	0.102	0.100	0.106	0.050	0.102	0.193
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	1.13	1.18	1.06*	1.15	1.03	1.00	1.14
SD	0.097	0.130	0.129	0.128	0.116	0.152	0.068
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.13

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Total Bilirubin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TBILI

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.18	0.13	0.14	0.14	0.15	0.16	0.18
SD	0.021	0.020	0.021	0.016	0.022	0.010	0.030
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.17	0.12	0.16	0.16	0.14	0.18	0.19
SD	0.026	0.015	0.025	0.029	0.019	0.019	0.010
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.19	0.14	0.21*	0.19*	0.17	0.17	0.22
SD	0.036	0.029	0.042	0.044	0.040	0.033	0.057
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.17	0.13	0.20*	0.15	0.15	0.16	0.15
SD	0.021	0.015	0.038	0.027	0.023	0.053	0.022
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.14

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Total Bilirubin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TBILI

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.16	0.15	0.19	0.20	0.18	0.15	0.21
SD	0.041	0.016	0.024	0.060	0.012	0.022	0.040
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.16	0.15	0.18	0.20	0.17	0.18	0.22
SD	0.024	0.016	0.031	0.029	0.015	0.039	0.025
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.14	0.13	0.20	0.17	0.16	0.15	0.18
SD	0.029	0.016	0.045	0.045	0.043	0.047	0.060
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.15	0.15	0.22	0.16	0.17	0.13	0.17
SD	0.017	0.027	0.065	0.037	0.034	0.022	0.029
N	8	8	8	8	8	4	4

Table 6.15

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Alkaline Phosphatase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALKP

SEX: MALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	138	120	123	114	92	86	82
SD	33.5	27.7	29.4	29.1	26.2	15.6	22.6
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	143	126	114	100	84	77	77
SD	58.9	48.7	39.0	32.5	24.5	31.7	30.0
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	108	96	90	93	78	84	89
SD	26.6	22.4	18.7	20.3	18.1	30.3	24.0
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	126	110	98	98	86	85	102
SD	43.0	39.4	21.7	27.5	28.4	25.9	47.8
N	8	8	8	8	8	4	4

Table 6.16

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Alkaline Phosphatase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALKP

SEX: FEMALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	120	107	108	103	93	83	77
SD	18.3	15.6	19.9	22.9	23.6	10.4	5.3
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	106	98	86	77*	72	77	77
SD	21.0	19.5	17.0	15.2	21.6	32.9	23.3
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	117	101	93	86	77	95	99
SD	52.0	39.6	28.2	21.3	14.1	33.0	19.4
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	93	84	90	77*	74	93	114
SD	19.4	18.4	24.3	11.6	15.0	35.5	36.2
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.17

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GGT

SEX: MALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	3	3	3	5	6	6	6
SD	1.6	1.7	1.7	1.3	0.7	0.6	1.7
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	3	3	3	4	6	6	5
SD	1.7	1.5	1.1	0.8	0.7	1.0	1.2
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	3	3	4	4	6	6	6
SD	1.9	1.6	1.6	1.2	0.9	0.5	1.4
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	3	4	4	3	7	5	4
SD	1.9	3.0	1.6	1.7	1.4	1.0	2.9
N	8	8	8	8	8	4	4

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GGT

SEX: FEMALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	2	3	3	4	6	3	6
SD	1.4	1.0	1.7	1.4	1.8	2.6	4.5
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	2	3	4	4	7	5	6
SD	1.4	1.0	0.9	1.5	1.3	1.3	0.5
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	3	3	4	4	7	6	6
SD	1.4	1.3	1.2	1.1	1.0	0.8	4.0
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	3	3	3	4	7	4	6
SD	1.7	1.4	1.5	0.9	1.5	1.7	1.0
N	8	8	8	8	8	4	4

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Cholesterol

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CHOL

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	215	160	169	174	154	173	162
SD	17.7	19.9	21.5	19.0	18.9	16.1	15.5
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	193	150	158	152	147	149	141
SD	34.4	21.0	29.5	30.9	26.3	28.9	15.2
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	198	151	165	174	155	156	149
SD	22.9	18.8	25.5	30.1	19.9	17.1	11.4
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	210	167	173	171	169	195	177
SD	31.3	25.6	30.0	28.1	31.5	64.6	53.9
N	8	8	8	8	8	4	4

Table 6.20

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Cholesterol

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CHOL

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	193	168	185	171	189	188	192
SD	25.1	31.3	34.6	30.1	35.7	40.2	79.9
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	202	164	173	167	185	222	184
SD	26.7	14.8	19.8	26.0	14.5	34.3	18.7
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	198	167	177	175	183	194	141
SD	28.9	23.6	34.4	29.4	17.6	37.6	27.7
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	186	159	162	158	177	185	213
SD	24.8	19.2	27.2	43.7	50.7	29.8	51.2
N	8	8	8	8	8	4	4

Table 6.21

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Triglycerides

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TRIG

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	43	44	33	38	37	32	34
SD	6.9	9.8	7.5	6.6	4.4	4.1	2.6
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	36	38	36	33	34	28	29
SD	6.4	5.4	7.1	6.2	6.1	5.0	7.5
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	39	39	37	38	36	39	38
SD	7.2	8.8	9.0	12.4	8.5	17.3	4.5
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	39	38	41	50*	48*	36	30
SD	5.6	5.9	5.3	11.7	15.4	3.7	3.6
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Triglycerides

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TRIG

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	43	40	45	43	44	40	34
SD	6.0	11.0	8.9	9.4	6.9	13.0	5.3
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	39	37	40	33	39	38	30
SD	10.8	12.5	9.4	9.8	8.5	12.5	6.1
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	39	34	40	41	45	47	26
SD	7.8	6.6	8.1	7.4	8.9	11.2	8.6
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	41	39	57	49	54	37	37
SD	4.7	8.1	12.8	15.8	11.1	12.3	13.7
N	8	8	8	8	8	4	4

Table 6.23

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: LDH

SEX: MALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	36	44	47	39	39	53	50
SD	14.1	14.1	16.1	10.8	15.5	10.3	12.3
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	35	44	37	36	36	45	51
SD	12.8	23.3	8.8	16.4	18.7	9.9	18.7
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	40	39	42	42	32	47	57
SD	10.1	8.9	14.3	13.9	10.9	9.1	20.6
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	39	44	71*	66*	43	46	56
SD	14.9	16.7	25.4	31.1	12.0	6.8	19.4
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.24

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: LDH

SEX: FEMALE
UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	48	47	72	53	43	52	40
SD	14.5	13.4	35.8	32.6	20.6	13.1	14.0
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	46	38	39	41	45	53	47
SD	11.7	12.5	7.4	13.4	28.1	37.1	20.7
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	48	49	47	37	40	51	42
SD	28.7	30.7	18.7	9.6	16.9	36.1	12.0
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	44	64	128*	50	72	75	51
SD	17.2	46.7	57.1	18.4	31.6	40.7	10.6
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.25

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Creatine Kinase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CK

SEX: MALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	225	233	269	211	155	145	149
SD	65.8	90.7	272.5	70.1	45.0	24.2	30.5
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	199	300	178	181	282	125	199
SD	50.5	265.3	66.8	59.9	322.5	32.3	94.6
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	231	181	187	236	149	134	253
SD	54.0	52.4	71.0	87.1	35.4	21.6	35.6
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	224	249	260	217	169	218	232
SD	73.2	105.3	154.0	74.2	40.0	121.4	88.1
N	8	8	8	8	8	4	4

Table 6.26

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Creatine Kinase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CK

SEX: FEMALE

UNITS: IU/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	265	153	183	147	183	134	189
SD	221.3	34.8	44.8	64.9	140.6	61.3	21.0
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	230	163	151	163	236	119	164
SD	152.2	49.4	66.4	77.6	189.1	37.9	61.6
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	181	178	146	146	116	148	209
SD	64.7	80.9	67.0	41.5	25.8	66.6	102.1
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	171	175	209	140	167	169	200
SD	36.1	51.2	119.6	27.1	69.0	56.6	82.6
N	8	8	8	8	8	4	4

Table 6.27

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: BUN

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	10.8	12.3	13.2	13.5	14.1	16.0	13.8
SD	2.83	2.55	2.29	2.90	2.02	3.05	1.91
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	11.7	11.5	13.0	13.3	17.2	16.0	15.6
SD	1.55	2.91	1.62	2.86	3.39	1.75	2.57
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	12.5	12.0	14.2	15.4	16.0	15.3	13.9
SD	2.48	4.01	3.17	3.76	2.57	1.84	2.02
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	11.7	12.2	13.5	15.0	16.3	17.5	14.8
SD	2.32	1.31	2.76	1.49	2.50	2.74	1.53
N	8	8	8	8	8	4	4

Table 6.28

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: BUN

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	12.9	11.6	15.4	15.9	18.3	15.2	16.9
SD	2.30	3.89	4.06	3.50	3.78	4.25	4.26
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	13.2	12.0	14.7	14.1	16.2	15.7	15.8
SD	2.33	3.67	2.36	2.83	3.64	4.80	3.51
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	10.7	10.7	13.1	14.9	17.5	12.6	12.5
SD	1.30	2.07	2.76	3.50	5.53	2.09	1.59
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	12.4	11.6	13.6	15.3	16.6	14.0	17.5
SD	2.85	3.34	2.97	2.79	2.55	1.90	4.62
N	8	8	8	8	8	4	4

Table 6.29

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Creatinine

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CREAT

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.76	0.72	0.75	0.78	0.79	0.84	0.85
SD	0.066	0.029	0.054	0.055	0.043	0.044	0.075
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.70	0.72	0.74	0.78	0.80	0.83	0.81
SD	0.085	0.090	0.072	0.075	0.068	0.090	0.088
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.77	0.72	0.76	0.75	0.77	0.76	0.81
SD	0.045	0.062	0.072	0.057	0.093	0.114	0.125
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.72	0.70	0.74	0.80	0.79	0.85	0.80
SD	0.090	0.039	0.060	0.085	0.067	0.085	0.133
N	8	8	8	8	8	4	4

Table 6.30

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Creatinine

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CREAT

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.77	0.78	0.81	0.78	0.83	0.79	0.83
SD	0.057	0.049	0.072	0.087	0.059	0.058	0.088
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.82	0.80	0.80	0.80	0.87	0.81	0.87
SD	0.078	0.099	0.098	0.085	0.060	0.054	0.045
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.68	0.70	0.74	0.71	0.75	0.63*	0.73
SD	0.090	0.076	0.100	0.083	0.101	0.022	0.111
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.76	0.74	0.76	0.75	0.90	0.69	0.71
SD	0.110	0.073	0.069	0.085	0.070	0.096	0.059
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.31

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Sodium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: NA

SEX: MALE

UNITS: mEq/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	147	145	146	146	147	147	148
SD	1.4	1.7	1.0	0.9	1.2	1.0	1.7
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	146	146	144	144	146	147	147
SD	0.8	1.4	1.6	1.8	1.3	2.1	1.3
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	147	146	146	147	146	147	147
SD	1.7	1.3	1.3	1.4	2.2	3.6	2.2
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	146	146	145	146	146	148	148
SD	1.9	1.6	2.0	1.8	2.5	1.5	1.4
N	8	8	8	8	8	4	4

Table 6.32

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Sodium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: NA

SEX: FEMALE

UNITS: mEq/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	146	147	146	145	147	145	145
SD	0.9	2.0	1.4	1.0	1.2	0.0	0.0
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	147	148	146	145	147	146	145
SD	1.3	1.4	1.5	0.9	1.1	1.3	1.8
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	146	147	145	145	147	146	145
SD	1.0	0.6	1.0	0.7	2.2	1.7	1.0
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	146	147	146	145	147	145	144
SD	1.1	1.6	1.1	1.6	1.2	1.6	1.4
N	8	8	8	8	8	4	4

Table 6.33

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Potassium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: K

SEX: MALE

UNITS: mEq/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	4.55	4.50	4.44	4.49	4.44	4.55	4.40
SD	0.165	0.237	0.272	0.283	0.106	0.103	0.115
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	4.50	4.54	4.28	4.43	4.43	4.36	4.34
SD	0.262	0.452	0.169	0.110	0.149	0.345	0.147
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	4.45	4.39	4.17	4.35	4.26	4.59	4.22
SD	0.262	0.244	0.155	0.208	0.242	0.121	0.121
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	4.51	4.42	4.33	4.48	4.46	4.74	4.40
SD	0.208	0.182	0.090	0.147	0.193	0.355	0.186
N	8	8	8	8	8	4	4

Table 6.34

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Potassium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: K

SEX: FEMALE

UNITS: mEq/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	4.36	4.35	4.60	4.42	4.50	4.50	4.28
SD	0.188	0.253	0.256	0.217	0.206	0.146	0.196
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	4.55	4.24	4.56	4.39	4.52	4.50	4.43
SD	0.163	0.145	0.149	0.147	0.217	0.242	0.111
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	4.42	4.32	4.40	4.31	4.25	4.42	4.11
SD	0.347	0.259	0.151	0.183	0.253	0.229	0.192
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	4.37	4.39	4.51	4.28	4.46	4.37	4.07
SD	0.173	0.237	0.183	0.120	0.207	0.163	0.297
N	8	8	8	8	8	4	4

Table 6.35

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Chloride

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CL

SEX: MALE

UNITS: mEq/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	114	109	112	111	113	113	114
SD	1.2	2.1	2.8	1.4	2.1	1.6	2.0
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	114	109	111	110	113	114	116
SD	1.6	2.4	2.3	1.6	1.5	1.0	1.7
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	114	109	111	112	114	114	116
SD	3.2	2.1	2.5	1.7	2.4	1.8	1.3
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	112	106	112	111	113	115	116
SD	1.9	2.4	2.5	1.4	1.7	1.3	4.3
N	8	8	8	8	8	4	4

Table 6.36

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Chloride

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CL

SEX: FEMALE

UNITS: mEq/L

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	112	108	109	111	113	109	114
SD	1.9	1.5	2.4	2.1	1.8	1.3	3.0
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	109	109	108	109	113	110	113
SD	2.8	2.1	2.0	2.0	1.9	1.3	1.4
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	108*	108	109	111	114	112	114
SD	3.1	1.6	3.9	2.3	1.9	1.9	1.2
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	111	108	110	109	114	110	114
SD	3.5	1.6	2.6	1.9	1.8	0.8	1.4
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.37

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Calcium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CA

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	10.3	10.2	10.1	10.1	10.4	10.7	9.9
SD	0.34	0.23	0.23	0.23	0.23	0.21	0.24
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	10.3	10.4	10.1	9.8	10.4	10.4	9.7
SD	0.26	0.27	0.20	0.32	0.27	0.29	0.21
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	10.3	10.2	10.1	9.9	10.1	10.3	9.5
SD	0.32	0.26	0.31	0.36	0.41	0.71	0.52
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	10.3	10.3	10.0	10.1	10.4	10.5	9.9
SD	0.22	0.16	0.21	0.21	0.27	0.43	0.34
N	8	8	8	8	8	4	4

Table 6.38

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Calcium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CA

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	11.2	10.3	10.4	10.0	10.6	9.9	10.1
SD	0.57	0.31	0.19	0.23	0.32	0.33	0.17
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	10.8	10.3	10.2	10.0	10.8	9.9	10.0
SD	0.21	0.23	0.31	0.23	0.26	0.14	0.26
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	10.8	10.2	10.1	9.8	10.7	9.3*	9.8
SD	0.24	0.31	0.24	0.42	0.33	0.25	0.17
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	11.2	10.3	9.8*	9.8	10.6	9.5	9.9
SD	0.57	0.37	0.16	0.27	0.17	0.15	0.14
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.39

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Inorganic Phosphorus

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: IP

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	5.7	5.9	6.0	5.8	5.3	4.9	4.1
SD	0.38	0.50	0.47	0.58	0.65	0.41	0.39
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	5.7	6.1	5.9	5.3	5.2	4.9	4.2
SD	0.29	0.73	0.72	0.74	0.55	0.48	0.33
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	5.3	5.6	5.3	5.1	4.6	4.8	3.5
SD	0.40	0.33	0.44	0.56	0.71	0.50	0.95
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	5.5	5.8	5.4	5.3	5.5	4.9	4.0
SD	0.52	0.24	0.41	0.76	0.36	0.79	0.13
N	8	8	8	8	8	4	4

Table 6.40

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Inorganic Phosphorus

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: IP

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	6.0	5.3	5.6	5.0	5.7	4.2	4.1
SD	1.04	0.49	0.88	0.78	0.78	0.69	0.51
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	5.7	4.7	5.5	4.6	5.4	4.5	3.6
SD	0.66	0.61	0.56	0.48	0.64	0.82	0.40
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	6.3	5.1	5.1	4.9	5.5	4.1	3.8
SD	0.67	0.42	0.45	0.44	0.52	0.56	0.78
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	6.2	5.2	5.1	5.1	5.7	4.1	4.3
SD	0.41	0.78	0.39	0.55	0.36	0.61	0.42
N	8	8	8	8	8	4	4

Table 6.41

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Glucose

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLU

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	107	108	105	102	106	108	101
SD	9.3	8.7	8.1	5.8	12.5	8.5	8.2
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	107	114	111	106	115	107	99
SD	10.0	6.7	5.8	6.4	8.0	4.1	1.3
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	105	107	106	102	109	107	111
SD	9.3	6.5	6.1	6.6	7.4	5.1	13.3
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	104	102	104	101	103	111	102
SD	7.1	7.8	10.4	10.6	6.7	16.3	9.4
N	8	8	8	8	8	4	4

Table 6.42

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Glucose

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLU

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	112	106	102	102	112	100	101
SD	6.1	7.8	9.0	3.2	7.8	4.0	7.5
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	117	106	102	100	110	99	101
SD	13.7	10.2	7.0	6.1	9.4	4.3	3.5
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	113	104	101	100	106	108*	111
SD	9.3	8.9	9.9	11.5	8.8	4.1	8.1
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	118	104	96	99	104	101	116*
SD	12.8	9.9	7.7	9.0	6.2	5.3	5.3
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 6.43

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Haptoglobin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: HAPT

SEX: MALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day							
MEAN	50.8	80.8	60.6	65.8	57.9	103.6	65.9
SD	27.65	29.97	43.32	42.13	39.61	27.40	53.61
N	7	7	7	5	4	3	3
Group: 2-M : 0.1 mg base/kg/day							
MEAN	42.0	69.7	66.1	66.1	50.1	55.5	68.7
SD	39.18	32.24	50.55	41.42	32.43	40.83	10.61
N	8	7	8	5	7	3	2
Group: 3-M : 0.3 mg base/kg/day							
MEAN	44.1	86.1	83.1	78.5	64.6	73.6	41.5
SD	21.17	22.34	43.10	37.88	19.09	31.29	21.62
N	7	6	8	7	5	4	3
Group: 4-M : 1.0 mg base/kg/day							
MEAN	40.2	70.1	183.6*	60.1	68.8	97.8	87.2
SD	28.85	30.68	71.58	38.91	31.06	8.64	45.86
N	8	7	8	8	8	3	3

*-Significant Difference from Control P < .05

Table 6.44

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF CLINICAL CHEMISTRY TESTS
TEST: Haptoglobin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: HAPT

SEX: FEMALE

UNITS: mg/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day							
MEAN	39.0	46.7	46.0	76.5	36.5	48.1	36.2
SD	3.82	37.48	38.77	48.88	8.70	28.99	6.01
N	2	4	3	3	4	2	2
Group: 2-F : 0.1 mg base/kg/day							
MEAN	32.8	45.2	71.8	40.0	43.8	62.1	25.5
SD	21.71	39.75	84.64	31.04	25.09	4.17	NA
N	5	6	3	2	3	2	1
Group: 3-F : 0.3 mg base/kg/day							
MEAN	48.8	52.6	74.3	44.7	52.8	55.7	41.3
SD	22.29	17.41	35.43	32.04	32.16	38.29	NA
N	7	6	6	5	6	3	1
Group: 4-F : 1.0 mg base/kg/day							
MEAN	28.1	31.7	182.4*	57.1	63.0	105.5	18.6
SD	8.43	16.64	77.86	23.03	36.74	NA	NA
N	6	7	8	7	5	1	1

*-Significant Difference from Control P < .05 NA-Not Applicable

Table 7.1

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: Erythrocytes

STUDY ID: UIC-18 SEX: MALE
STUDY NO: 193
ABBR: RBC UNITS: 10^6/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	6.85	6.50	6.49	6.92	6.62	6.73	6.96
SD	0.452	0.360	0.383	0.177	0.262	0.470	0.359
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	6.63	6.50	6.69	6.79	6.79	6.93	7.02
SD	0.299	0.241	0.518	0.353	0.405	0.349	0.192
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	6.72	6.33	6.42	6.30*	6.51	6.82	7.04
SD	0.498	0.278	0.534	0.595	0.735	1.122	0.812
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	6.44	6.48	5.89	6.77	6.47	6.91	6.95
SD	0.605	0.458	0.514	0.359	0.469	0.354	0.628
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.2

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Erythrocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: RBC

SEX: FEMALE

UNITS: 10^6/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	6.57	6.23	6.84	6.56	6.50	6.65	6.49
SD	0.387	0.343	0.600	0.690	0.300	0.270	0.353
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	6.87	6.76	6.67	6.51	7.01	7.12	7.22
SD	0.255	0.485	0.445	0.543	0.646	0.414	0.313
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	6.52	6.37	6.30	6.33	6.44	6.33	6.98
SD	0.354	0.482	0.634	0.401	0.599	0.794	0.596
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	6.70	6.78	6.11*	6.61	6.94	6.37	6.56
SD	0.395	0.543	0.200	0.399	0.318	0.601	0.540
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.3

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Hemoglobin

STUDY ID: UIC-18
STUDY NO: 193
ABBR: HGB

SEX: MALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	16.5	15.7	15.6	16.7	16.2	16.3	16.5
SD	0.98	0.75	0.78	0.53	0.90	1.15	0.82
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	16.0	15.7	15.9	16.4	16.6	16.6	16.9
SD	1.03	0.73	1.32	1.25	1.19	1.10	0.68
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	16.2	15.3	15.6	15.3*	15.7	15.7	16.4
SD	1.25	0.71	1.08	1.05	1.66	2.36	1.69
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	15.8	15.8	14.7	16.6	16.0	16.8	16.8
SD	1.00	0.61	1.07	0.68	1.11	0.74	1.41
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.4

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Hemoglobin

STUDY ID: UIC-18
STUDY NO: 193
ABBR: HGB

SEX: FEMALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	16.3	15.4	16.9	16.3	16.0	16.3	16.0
SD	1.06	0.79	1.37	1.64	0.91	0.57	1.09
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	16.7	16.3	16.2	16.1	16.9	17.0	17.3
SD	0.73	1.04	1.08	1.34	1.57	0.76	0.62
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	15.6	15.2	15.3*	15.4	15.4	14.7	16.4
SD	0.64	0.80	1.21	1.01	1.40	1.58	1.27
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	16.4	16.5	15.2*	15.8	16.6	15.3	15.5
SD	0.85	1.28	0.67	1.00	1.18	1.43	1.55
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.5

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: Hematocrit

STUDY ID: UIC-18 SEX: MALE
STUDY NO: 193
ABBR: HCT UNITS: %

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	47.8	45.3	45.2	48.0	46.3	47.0	48.3
SD	3.10	2.27	2.64	1.84	2.29	3.41	2.97
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	45.7	44.7	45.9	48.1	47.0	47.6	48.4
SD	2.89	2.37	3.99	6.43	3.60	3.25	2.06
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	46.9	44.3	45.3	44.9	45.0	45.9	47.3
SD	3.49	2.66	3.38	3.04	4.70	6.77	4.82
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	45.6	46.0	43.5	48.8	46.0	49.8	48.7
SD	3.11	1.94	3.06	1.31	3.37	2.38	3.76
N	8	8	8	8	8	4	4

Table 7.6

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Hematocrit

STUDY ID: UIC-18 SEX: FEMALE
STUDY NO: 193
ABBR: HCT UNITS: %

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	46.6	43.9	48.2	46.0	46.6	47.8	46.5
SD	3.21	2.10	3.97	4.60	2.62	1.88	2.95
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	47.9	46.9	46.6	45.6	49.5	49.4	50.4
SD	1.36	3.31	3.08	3.72	4.48	1.78	1.39
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	45.2	43.9	44.4	44.6	45.3	42.9	47.4
SD	1.78	2.48	3.35	2.82	4.49	4.48	3.41
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	47.2	47.5	44.7	45.9	49.1	45.3	45.2
SD	2.56	3.85	1.92	3.54	3.28	4.15	4.13
N	8	8	8	8	8	4	4

Table 7.7

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: Mean Corpuscular Volume

STUDY ID: UIC-18
STUDY NO: 193
ABBR: MCV

SEX: MALE

UNITS: fL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	69.8	69.8	69.6	69.3	69.9	69.9	69.5
SD	1.75	1.57	1.36	1.51	1.79	2.34	2.12
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	69.0	68.8	68.6	70.7	69.1	68.7	69.0
SD	2.09	2.41	2.20	6.11	2.12	1.96	1.86
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	69.8	69.9	70.7	71.6	69.2	67.3	67.3
SD	2.38	2.37	2.34	5.37	2.22	1.77	1.54
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	71.0	71.2	73.9*	72.1	71.1	72.1	70.2
SD	2.10	2.28	2.29	2.29	2.19	0.54	0.96
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.8

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Mean Corpuscular Volume

STUDY ID: UIC-18
STUDY NO: 193
ABBR: MCV

SEX: FEMALE

UNITS: fL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	70.8	70.5	70.6	70.1	71.6	71.9	71.6
SD	1.49	1.54	1.47	1.53	1.39	1.96	1.90
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	69.7	69.4	70.0	70.1	70.6	69.4	69.9
SD	1.41	1.19	1.55	1.52	1.43	2.12	2.17
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	69.3	68.9	70.6	70.4	70.3	68.0	68.0
SD	1.26	1.31	2.04	1.89	2.36	2.34	2.21
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	70.6	70.1	73.1*	69.5	70.6	71.1	69.0
SD	1.35	1.34	1.79	2.44	2.51	1.48	1.70
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.9

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Mean Corpuscular Hemo.

STUDY ID: UIC-18
STUDY NO: 193
ABBR: MCH

SEX: MALE

UNITS: pg

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	24.1	24.2	24.0	24.2	24.5	24.2	23.8
SD	0.65	0.45	0.64	0.39	0.74	0.70	0.13
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	24.2	24.2	23.8	24.1	24.4	24.0	24.0
SD	0.64	0.86	0.78	0.79	0.72	0.77	0.58
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	24.1	24.2	24.3	24.4	24.2	23.1*	23.4
SD	0.73	0.47	0.56	0.88	0.43	0.44	0.35
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	24.6	24.5	25.0*	24.5	24.7	24.4	24.2
SD	0.86	0.93	0.73	0.68	0.67	0.24	0.19
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.10

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Mean Corpuscular Hemo.

STUDY ID: UIC-18
STUDY NO: 193
ABBR: MCH

SEX: FEMALE

UNITS: pg

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	24.8	24.9	24.7	24.8	24.5	24.5	24.6
SD	0.36	0.57	0.50	0.33	0.54	0.43	0.54
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	24.4	24.1*	24.3	24.6	24.2	23.9	24.0
SD	0.64	0.45	0.36	0.35	0.49	0.54	0.56
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	24.0	23.8**	24.4	24.3	23.9	23.3	23.5
SD	0.51	0.59	0.61	0.69	0.67	0.68	0.66
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	24.6	24.4	24.9	23.9*	23.9	24.0	23.6
SD	0.81	0.57	0.74	0.86	0.93	0.70	0.87
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05 **-Significant Difference from Control P < .01

Table 7.11

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Mean Corpus. Hemo. Conc.

STUDY ID: UIC-18
STUDY NO: 193
ABBR: MCHC

SEX: MALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	34.5	34.7	34.5	34.9	35.0	34.6	34.2
SD	0.29	0.44	0.52	0.33	0.59	0.18	0.92
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	35.0	35.1	34.7	34.3	35.4	34.9	34.8
SD	0.53	0.53	0.44	2.05	0.30	0.44	0.28
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	34.5	34.6	34.5	34.2	34.9	34.2	34.8
SD	0.41	0.72	0.70	1.35	0.78	0.25	0.49
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	34.6	34.4	33.8*	34.0	34.7	33.8*	34.4
SD	0.45	0.35	0.31	0.68	0.38	0.47	0.30
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.12

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Mean Corpus. Hemo. Conc.

STUDY ID: UIC-18
STUDY NO: 193
ABBR: MCHC

SEX: FEMALE

UNITS: g/dL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	35.0	35.1	35.0	35.4	34.3	34.2	34.4
SD	0.43	0.37	0.46	0.59	0.51	0.33	0.46
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	34.9	34.8	34.8	35.2	34.2	34.5	34.3
SD	0.85	0.65	0.47	0.60	0.52	0.55	0.49
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	34.6	34.6	34.5*	34.6*	34.0	34.3	34.6
SD	0.58	0.43	0.39	0.40	0.50	0.37	0.35
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	34.8	34.7	34.0*	34.4*	33.9	33.7	34.3
SD	0.71	0.49	0.32	0.78	0.46	0.70	0.45
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.13

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Reticulocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: RETICS

SEX: MALE

UNITS: % RBCs

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.3	0.3	0.4	0.6	0.4	0.4	0.6
SD	0.13	0.13	0.21	0.42	0.15	0.22	0.40
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.3	0.4	0.5	0.5	0.6	0.2	0.2
SD	0.24	0.18	0.25	0.35	0.38	0.13	0.13
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.3	0.3	0.9*	0.8	0.6	0.5	0.4
SD	0.25	0.23	0.38	0.32	0.19	0.31	0.28
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.3	0.5	1.3*	1.3*	0.8	0.4	0.3
SD	0.18	0.24	0.36	0.31	0.43	0.16	0.10
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.14

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: Reticulocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: RETICS

SEX: FEMALE

UNITS: % RBCs

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.2	0.4	0.4	0.4	0.4	0.3	0.2
SD	0.13	0.28	0.16	0.20	0.30	0.10	0.10
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.3	0.2	0.4	0.4	0.3	0.4	0.6
SD	0.27	0.17	0.21	0.21	0.20	0.10	0.33
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.2	0.4	0.6	0.7	0.5	0.4	0.4
SD	0.18	0.22	0.18	0.34	0.19	0.45	0.13
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.2	0.3	1.6*	1.1*	1.3*	0.5	0.4
SD	0.10	0.19	0.63	0.52	0.54	0.25	0.39
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.15

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Nucleated Red Cells

STUDY ID: UIC-18
STUDY NO: 193
ABBR: NRBC

SEX: MALE

UNITS: COUNT

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0	0	0	0	0	0	0
SD	0.4	0.4	0.0	0.0	0.0	0.0	0.0
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0	0	0	0	0	0	0
SD	0.7	0.0	0.0	0.0	0.0	0.0	0.0
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0	0	0	0	0	0	0
SD	0.0	0.0	0.4	0.0	0.4	0.0	0.0
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0	0	1*	0	0	0	0
SD	0.0	0.4	0.9	0.4	0.0	0.0	0.0
N	8	7	8	8	8	4	4

WBC corrected for NRBC = or > 10

*-Significant Difference from Control P < .05

Table 7.16

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Nucleated Red Cells

STUDY ID: UIC-18 SEX: FEMALE
STUDY NO: 193
ABBR: NRBC UNITS: COUNT

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0	0	0	0	0	0	0
SD	0.0	0.0	0.0	0.0	0.0	0.0	0.0
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0	0	0	0	0	0	0
SD	0.0	0.0	0.0	0.0	0.4	0.0	0.0
N	8	8	7	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0	0	0	0	0	0	0
SD	0.0	0.0	0.0	0.0	0.0	0.0	0.5
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0	0	7*	0	1	0	0
SD	0.0	0.0	9.6	0.0	0.9	0.0	0.0
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

*-Significant Difference from Control P < .05

Table 7.17

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Heinz Bodies

STUDY ID: UIC-18
STUDY NO: 193
ABBR: HEINZ BOD.

SEX: MALE

UNITS: % RBCs

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.04	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.05	0.05
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.04	0.04	0.00	0.00
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4

Table 7.18

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Heinz Bodies

STUDY ID: UIC-18
STUDY NO: 193
ABBR: HEINZ BOD.

SEX: FEMALE

UNITS: % RBCs

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.1	0.1
SD	0.00	0.00	0.04	0.04	0.07	0.06	0.10
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.05	0.00	0.00	0.05
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	D.0	0.8
SD	0.00	0.00	0.00	0.04	0.04	0.00	1.55
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.DO	0.00	0.05	0.07	0.DO	0.00
N	8	8	8	8	8	4	4

Table 7.19

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: % Methemoglobin

STUDY ID: UIC-18
STUDY NO: 193
ABBR: % METHGB

SEX: MALE

UNITS: % HGBs

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	1.4	1.3	1.4	0.9	0.5	0.6	0.7
SD	1.12	0.98	1.03	0.41	0.17	0.17	0.12
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	1.6	1.5	2.9	1.8	1.7	0.5	0.7
SD	0.85	1.04	0.95	0.26	0.51	0.14	0.06
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	1.3	1.2	9.5*	6.2*	6.3*	0.6	0.8
SD	0.68	0.62	1.54	1.29	1.37	0.14	0.17
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.9	1.1	27.5*	21.5*	20.1*	1.1	0.7
SD	0.66	0.82	4.03	5.26	5.02	0.56	0.08
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: % Methemoglobin

STUDY ID: UIC-18
STUDY NO: 193
ABBR: % METHGB

SEX: FEMALE

UNITS: % HGBs

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	1.2	0.9	0.7	0.7	0.6	0.7	0.7
SD	1.12	0.58	0.33	0.10	0.18	0.17	0.13
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.7	0.9	2.5	1.9	2.6	0.7	0.6
SD	0.51	0.81	0.57	0.37	1.21	0.10	0.10
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	1.1	1.0	8.5*	6.8*	7.0*	0.6	0.7
SD	0.73	0.70	1.79	1.71	1.73	0.00	0.10
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.9	1.0	26.3*	21.2*	21.9*	0.8	0.8
SD	0.73	0.39	4.68	4.27	4.07	0.10	0.10
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.21

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: Platelets

STUDY ID: UIC-18 SEX: MALE
STUDY NO: 193
ABBR: PLT UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	277	213	217	217	200	227	215
SD	35.8	26.9	28.4	40.4	46.5	26.2	33.4
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	352*	272*	219	188	203	237	231
SD	63.4	46.5	51.0	59.4	44.2	27.7	34.4
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	255	202	95*	135*	134*	230	221
SD	92.7	39.6	14.6	27.5	40.7	17.5	38.8
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	323	249	73*	143*	160	286	210
SD	26.1	24.2	20.2	27.4	34.4	58.0	41.2
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.22

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Platelets

STUDY ID: UIC-18 - SEX: FEMALE
STUDY NO: 193
ABBR: PLT UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	276	261	233	234	223	227	229
SD	43.5	57.5	16.7	44.3	45.8	30.6	48.6
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	298	260	187	227	223	282	321
SD	28.1	27.9	53.3	32.5	53.8	18.4	48.0
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	260	232	114*	158*	151	276	257
SD	60.8	64.0	62.4	59.4	61.4	85.5	84.3
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	282	267	106*	162	226	289	253
SD	51.9	53.5	31.0	90.8	117.8	67.7	64.9
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.23

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Prothrombin Time

STUDY ID: UIC-18 - SEX: MALE
STUDY NO: 193
ABBR: PT UNITS: sec

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	8.4	8.4	8.5	8.5	9.3	8.5	8.3
SD	0.59	0.53	0.53	0.60	0.98	0.56	0.49
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	8.3	8.2	8.3	8.5	8.3*	8.3	8.0
SD	0.24	0.26	0.29	0.19	0.21	0.10	0.13
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	8.3	8.1	8.4	8.2	8.7	8.2	7.9
SD	0.28	0.24	0.61	0.33	0.91	0.10	0.12
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	8.4	8.3	8.2	8.3	8.1*	8.6	8.1
SD	0.26	0.39	0.73	0.38	0.34	0.55	0.54
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.24

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Prothrombin Time

STUDY ID: UIC-18
STUDY NO: 193
ABBR: PT

SEX: FEMALE

UNITS: sec

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	8.2	8.2	8.2	8.3	8.2	8.3	8.0
SD	0.21	0.27	0.21	0.30	0.20	0.24	0.39
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	8.2	8.3	8.3	8.5	8.3	8.2	8.1
SD	0.14	0.32	0.23	0.14	0.20	0.26	0.19
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	8.2	8.2	8.1	8.2	8.2	8.3	8.0
SD	0.23	0.28	0.14	0.18	0.13	0.13	0.28
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	8.2	8.2	8.0*	8.2	8.1	8.2	7.8
SD	0.20	0.21	0.21	0.22	0.23	0.35	0.17
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.25

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Act. Partial Thrombo. Time

STUDY ID: UIC-18 SEX: MALE
STUDY NO: 193
ABBR: APTT UNITS: sec

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	10.8	10.3	9.8	10.2	9.1	9.8	9.7
SD	0.94	0.70	0.65	0.79	0.80	0.44	0.68
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	10.4	10.0	9.7	10.2	9.9	9.4	9.6
SD	0.95	0.80	0.73	0.74	0.87	0.30	0.29
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	10.4	10.3	9.6	10.2	9.5	9.5	9.7
SD	0.26	0.49	0.77	0.49	0.93	0.80	0.41
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	11.5	11.2	10.5	11.1	10.6*	10.3	11.1*
SD	1.16	1.48	1.07	1.24	0.82	0.79	0.84
N	8	8	8	8	8	4	4

*-Significant Difference from Control P < .05

Table 7.26

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Act. Partial Thrombo. Time

STUDY ID: UIC-18
STUDY NO: 193
ABBR: APTT

SEX: FEMALE

UNITS: sec

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	10.7	10.0	9.9	10.2	9.6	9.9	10.2
SD	0.83	0.60	0.21	0.59	0.79	0.93	0.54
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	10.5	10.0	10.0	10.0	9.8	9.5	10.0
SD	0.43	0.72	0.63	0.51	0.49	0.53	0.31
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	10.5	9.8	9.8	9.9	9.7	10.4	10.2
SD	0.55	0.72	0.36	0.37	0.65	0.38	0.32
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	10.5	10.0	10.0	9.6	9.5	9.9	10.0
SD	0.43	0.41	0.45	0.27	0.47	0.28	0.22
N	8	8	8	8	8	4	4

Table 7.27

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Leukocytes

STUDY ID: UIC-18 SEX: MALE
STUDY NO: 193
ABBR: WBC UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	7.1	9.3	8.9	8.4	8.9	7.9	7.7
SD	1.11	2.31	1.54	2.09	2.38	1.40	1.00
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	6.8	9.1	8.2	7.5	8.1	7.8	8.2
SD	0.67	1.87	0.84	1.24	1.06	1.19	0.51
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	7.0	9.5	10.1	8.8	8.7	6.4	6.2
SD	1.35	2.50	3.02	2.28	1.66	1.02	1.63
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	7.6	9.7	10.8	12.2	12.5	7.9	9.0
SD	1.49	2.52	2.61	6.22	5.15	2.79	3.20
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

Table 7.28

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Leukocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: WBC

SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	8.1	8.4	8.7	8.9	8.7	8.8	7.5
SD	2.49	2.15	2.02	1.04	1.55	0.38	1.51
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	6.3	8.0	8.2	8.2	8.3	6.5*	7.8
SD	1.14	1.52	1.63	1.52	2.76	1.06	1.44
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	7.7	8.9	8.8	8.4	8.4	6.9	7.1
SD	2.40	1.51	1.60	1.02	1.15	0.40	0.45
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	6.7	8.6	11.2	12.0*	13.8*	8.3	8.1
SD	1.42	1.35	2.92	3.19	3.79	1.98	1.97
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10
*-Significant Difference from Control P < .05

Table 7.29

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: M. Neutrophils

STUDY ID: UIC-18
STUDY NO: 193
ABBR: M. Neutrop

SEX: MALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	4.0	6.0	6.2	5.9	6.1	5.4	5.3
SD	0.87	1.72	1.29	1.84	2.35	0.76	0.41
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	3.7	6.5	5.2	4.8	5.3	5.4	5.5
SD	0.46	2.10	0.68	1.04	0.89	1.11	0.08
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	3.5	6.5	6.7	6.1	6.0	4.4	4.1
SD	0.67	1.86	2.42	1.75	1.48	0.88	0.96
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	4.0	6.3	6.6	8.6	8.9	5.2	6.0
SD	0.94	2.15	1.81	4.65	3.96	2.48	2.24
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

Table 7.30

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: M. Neutrophils

STUDY ID: UIC-18
STUDY NO: 193
ABBR: M. Neutrop

SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	5.2	4.7	5.9	6.3	5.6	5.6	4.6
SD	2.26	2.46	1.23	1.22	1.17	0.48	1.21
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	3.7	5.0	5.0	5.5	5.1	3.9	4.8
SD	0.97	1.69	1.54	1.47	2.09	0.69	0.77
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	4.3	5.4	5.7	5.4	5.0	4.0	4.8
SD	1.96	1.30	1.24	1.31	1.51	0.79	0.45
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	3.8	5.4	8.0*	9.0*	9.9*	5.6	5.2
SD	0.45	1.29	2.47	2.67	2.86	2.01	1.80
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10
*-Significant Difference from Control P < .05

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: I. Neutrophils

STUDY IO: UIC-18
STUDY NO: 193
ABBR: I. Neutrop

SEX: MALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.5
SD	0.00	0.04	0.04	0.00	0.00	0.00	0.95
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.04	0.00	0.00
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.0	0.0	0.1	0.0	0.0	0.0	0.0
SD	0.04	0.00	0.09	0.04	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.07	0.04	0.07	0.00	0.00	0.00
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

Table 7.32

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: I. Neutrophils

STUDY ID: UIC-18
STUDY NO: 193
ABBR: I. Neutrop

SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.0	0.0	0.5	0.0	0.0	0.0	0.0
SD	0.00	0.00	1.52	0.00	0.04	0.00	0.00
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.1	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.14	0.00	0.04	0.00	0.04	0.00	0.00
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.05	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.1	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.11	0.04	0.00	0.07	0.00	0.00	0.00
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

Table 7.33

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Lymphocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Lymphocyte

SEX: MALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	2.3	2.6	2.1	2.0	2.2	2.0	1.5
SD	0.81	1.03	0.83	0.61	0.60	0.42	1.06
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	2.3	2.1	2.2	2.2	2.2	1.8	2.0
SD	0.35	0.65	0.63	0.38	0.35	0.21	0.39
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	2.5	2.2	2.5	2.0	2.1	1.4	1.9
SD	0.90	0.89	0.49	0.63	0.64	0.68	0.71
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	2.9	2.7	3.0	2.5	2.5	2.1	2.4
SD	0.99	1.15	1.24	0.79	0.97	0.95	0.53
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Lymphocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Lymphocyte

SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	2.2	2.2	2.1	2.2	2.5	2.5	2.3
SD	1.05	0.37	1.01	0.87	0.54	0.52	0.36
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	2.4	2.1	2.3	2.2	2.7	2.3	2.6
SD	0.75	0.58	0.62	0.50	0.69	0.50	0.76
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	2.6	2.5	3.0	2.5	2.7	2.5	2.1
SD	0.50	0.89	0.83	0.62	0.52	0.53	0.26
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	2.4	2.2	2.4	2.3	3.0	2.2	2.5
SD	0.79	1.01	0.91	0.86	1.34	0.29	0.38
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

Table 7.35

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Monocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Monocytes

SEX: MALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.5	0.5	0.5	0.2	0.3	0.3	0.3
SD	0.19	0.30	0.21	0.13	0.16	0.22	0.06
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.4	0.4	0.5	0.3	0.3	0.2	0.4
SD	0.16	0.30	0.27	0.20	0.19	0.13	0.16
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.4	0.4	0.5	0.2	0.4	0.3	0.1
SD	0.24	0.18	0.35	0.12	0.22	0.15	0.08
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.4	0.4	1.0*	0.5	0.6*	0.3	0.2
SD	0.11	0.14	0.42	0.42	0.28	0.08	0.22
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10
*-Significant Difference from Control P < .05

Table 7.36

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Monocytes

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Monocytes

SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.3	0.6	0.8	0.2	0.3	0.3	0.2
SD	0.14	0.31	0.68	0.12	0.14	0.17	0.10
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.3	0.4	0.5	0.3	0.3	0.1	0.2
SD	0.08	0.15	0.23	0.18	0.15	0.05	0.06
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.3	0.7	0.4	0.3	0.3	0.1	0.1
SD	0.18	0.18	0.24	0.18	0.15	0.15	0.10
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.6	0.5	0.5	0.4	0.6	0.3	0.2
SD	0.37	0.14	0.31	0.24	0.50	0.13	0.08
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

Table 7.37

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: Eosinophils

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Eosinophil

SEX: MALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.3	0.2	0.2	0.2	0.3	0.2	0.2
SD	0.19	0.18	0.23	0.21	0.16	0.13	0.23
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.4	0.2	0.3	0.3	0.2	0.5	0.3
SD	0.32	0.16	0.20	0.18	0.15	0.13	0.22
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.5	0.3	0.3	0.5	0.3	0.3	0.2
SD	0.24	0.17	0.28	0.52	0.21	0.22	0.05
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.4	0.3	0.2	0.6	0.4	0.4	0.4
SD	0.21	0.17	0.11	0.75	0.46	0.42	0.25
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Eosinophils

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Eosinophil

SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.3	0.2	0.3	0.2	D.3	0.5	0.4
SD	0.34	0.15	0.23	0.16	0.18	0.29	0.28
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.4	0.2	0.2	0.2	0.2	0.3	0.3
SD	0.36	0.10	0.20	0.13	0.14	0.22	0.29
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.2	0.3	0.2	0.3	0.3	0.3	0.2
SD	0.14	0.17	0.15	0.19	0.22	0.17	0.15
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.2	0.2	0.2	0.3	0.3	0.3	0.2
SD	D.20	0.12	0.18	0.18	0.15	0.14	0.06
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

Table 7.39

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF HEMATOLOGY TESTS
TEST: Basophils

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Basophils

SEX: MALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	WEEK -3	WEEK -1	WEEK 4	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-M : 0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day							
MEAN	0.1	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.18	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

SUMMARY OF HEMATOLOGY TESTS
TEST: Basophils

STUDY ID: UIC-18
STUDY NO: 193
ABBR: Basophils

SEX: FEMALE

UNITS: 10^3/mm^3

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(S):	WEEK 4	WEEK -3	WEEK -1	WEEK 8	WEEK 13	WEEK 18	WEEK 26
Group: 1-F : 0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day							
MEAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SD	0.00	0.00	0.00	0.00	0.00	0.00	0.00
N	8	8	8	8	8	4	4

WBC corrected for NRBC = or > 10

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF URINALYSIS TESTS
TEST: pH

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: PH

SEX: MALE

UNITS: -

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day						
MEAN	7.5	6.8	6.4	6.4	5.8	5.0
SD	1.07	1.16	0.52	1.30	0.96	0.00
N	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day						
MEAN	7.5	6.4	6.4	6.1	5.8	6.0
SD	1.07	0.52	0.52	0.83	0.50	2.00
N	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day						
MEAN	7.3	6.9	6.4	6.1	5.8	5.5
SD	1.16	0.83	0.92	0.99	0.50	0.58
N	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day						
MEAN	7.0	7.6	6.6	6.0	5.0	6.0
SD	0.93	1.51	1.19	0.53	0.00	0.82
N	8	8	8	8	4	4

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF URINALYSIS TESTS
TEST: pH

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: PH

SEX: FEMALE

UNITS: -

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day						
MEAN	6.6	6.4	6.6	6.1	6.3	5.5
SD	0.92	0.52	1.19	0.64	0.50	0.58
N	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day						
MEAN	6.5	6.8	6.6	6.3	6.0	6.3
SD	0.93	1.04	0.74	1.04	0.82	0.96
N	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day						
MEAN	6.5	6.4	6.0	5.9	5.5	5.0
SD	0.76	0.52	0.76	0.64	0.58	0.00
N	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day						
MEAN	6.8	6.3	6.6	5.9	6.0	6.3
SD	0.71	0.46	0.52	0.64	0.82	1.89
N	8	8	8	8	4	4

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF URINALYSIS TESTS
TEST: Specific Gravity

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: SG

SEX: MALE

UNITS: g/mL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-M : 0 mg base/kg/day						
MEAN	1.047	1.048	1.058	1.054	1.076	1.057
SD	0.0283	0.0211	0.0275	0.0264	0.0502	0.0378
N	8	8	8	8	4	4
Group: 2-M : 0.1 mg base/kg/day						
MEAN	1.055	1.058	1.072	1.050	1.056	1.069
SD	0.0295	0.0279	0.0381	0.0283	0.0325	0.0104
N	8	8	8	8	4	4
Group: 3-M : 0.3 mg base/kg/day						
MEAN	1.056	1.044	1.074	1.073	1.053	1.050
SD	0.0258	0.0226	0.0243	0.0253	0.0319	0.0174
N	8	8	8	8	4	4
Group: 4-M : 1.0 mg base/kg/day						
MEAN	1.061	1.046	1.069	1.069	1.058	1.042
SD	0.0446	0.0300	0.0305	0.0451	0.0161	0.0171
N	8	8	8	8	4	4

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

SUMMARY OF URINALYSIS TESTS
TEST: Specific Gravity

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: SG

SEX: FEMALE

UNITS: g/mL

ANALYSIS OF VARIANCE FOLLOWED BY DUNNETT'S PROCEDURE

PERIOD(s):	Week -3	Week 4	Week 8	Week 13	Week 18	Week 26
Group: 1-F : 0 mg base/kg/day						
MEAN	1.045	1.060	1.075	1.060	1.050	1.058
SD	0.0283	0.0252	0.0179	0.0225	0.0120	0.0170
N	8	8	8	8	4	4
Group: 2-F : 0.1 mg base/kg/day						
MEAN	1.055	1.054	1.075	1.069	1.053	1.051
SD	0.0195	0.0207	0.0402	0.0277	0.0145	0.0178
N	8	8	8	8	4	4
Group: 3-F : 0.3 mg base/kg/day						
MEAN	1.057	1.074	1.072	1.079	1.059	1.088
SD	0.0134	0.0167	0.0142	0.0261	0.0182	0.0660
N	8	8	8	8	4	4
Group: 4-F : 1.0 mg base/kg/day						
MEAN	1.050	1.072	1.064	1.084	1.043	1.082
SD	0.0109	0.0157	0.0256	0.0370	0.0197	0.0635
N	8	8	8	8	4	4

Table 9.1

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511
WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT)

STUDY: 193
SEX: MALE

TREATMENT PERIOD

ALL FATES DAYS: 92-93 ALL BALANCES
ANALYSIS OF VARIANCE USING DUNNETT'S PROCEDURE

	GROUP:	(1) 1-M	(2) 2-M	(3) 3-M	(4) 4-M
Adrenal Glands (% BRAIN WEIGHT)					
	MEAN	1.94	1.73	1.74	1.54
	SD	0.279	0.277	0.111	0.265
	N	4	4	4	4
Heart (% BRAIN WEIGHT)					
	MEAN	125.23	113.55	113.71	108.58
	SD	15.934	11.660	6.450	2.658
	N	4	4	4	4
Kidneys (% BRAIN WEIGHT)					
	MEAN	66.15	69.22	58.04	61.20
	SD	7.190	9.965	6.300	6.782
	N	4	4	4	4
Liver (% BRAIN WEIGHT)					
	MEAN	361.45	387.69	375.70	405.65
	SD	34.309	51.317	60.111	28.348
	N	4	4	4	4
Spleen (% BRAIN WEIGHT)					
	MEAN	54.14	40.62	48.25	45.55
	SD	10.480	4.397	12.569	15.641
	N	4	4	4	4
Testes (% BRAIN WEIGHT)					
	MEAN	20.37	18.67	17.47	15.95
	SD	1.634	2.541	2.234	2.384
	N	4	4	4	4
Thyroid + Parathyroids (% BRAIN WEIGHT)					
	MEAN	1.36	1.46	1.32	1.31
	SD	0.128	0.242	0.282	0.199
	N	4	4	4	4

(1)-0 mg base/kg/day
(2)-0.1 mg base/kg/day
(3)-0.3 mg base/kg/day
(4)-1.0 mg base/kg/day

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511
WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT)

STUDY: 193
SEX: FEMALE

TREATMENT PERIOD

ALL FATES DAYS: 92-93 ALL BALANCES
ANALYSIS OF VARIANCE USING DUNNETT'S PROCEDURE

	GROUP:	(5) 1-F	(6) 2-F	(7) 3-F	(8) 4-F
Adrenal Glands (% BRAIN WEIGHT)					
	MEAN	1.98	2.30	1.81	1.55
	SD	0.581	0.416	0.456	0.469
	N	4	4	4	4
Heart (% BRAIN WEIGHT)					
	MEAN	113.56	113.53	110.07	102.30
	SD	9.329	11.964	10.226	18.261
	N	4	4	4	4
Kidneys (% BRAIN WEIGHT)					
	MEAN	52.08	58.01	55.94	55.00
	SD	3.736	6.424	6.266	6.453
	N	4	4	4	4
Liver (% BRAIN WEIGHT)					
	MEAN	331.56	367.84	373.09	373.61
	SD	47.774	46.803	72.917	58.715
	N	4	4	4	4
Ovaries (% BRAIN WEIGHT)					
	MEAN	1.50	2.23	2.05	1.39
	SD	0.544	1.470	0.835	0.363
	N	4	4	4	4
Spleen (% BRAIN WEIGHT)					
	MEAN	41.11	52.77	59.57	67.34
	SD	11.833	9.496	14.809	33.161
	N	4	4	4	4
Thyroid + Parathyroids (% BRAIN WEIGHT)					
	MEAN	1.28	1.23	1.34	1.12
	SD	0.150	0.160	0.200	0.198
	N	4	4	4	4

(5)-0 mg base/kg/day
(6)-0.1 mg base/kg/day
(7)-0.3 mg base/kg/day
(8)-1.0 mg base/kg/day

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511
WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT)

STUDY: 193
SEX: MALE

RECOVERY PERIOD

ALL FATES DAYS: 183-184 ALL BALANCES
ANALYSIS OF VARIANCE USING DUNNETT'S PROCEDURE

GROUP:		(1) 1-M	(2) 2-M	(3) 3-M	(4) 4-M
Adrenal Glands(% BRAIN WEIGHT)					
	MEAN	1.94	1.94	1.60	1.81
	SD	0.729	0.421	0.160	0.275
	N	4	4	4	4
Heart(% BRAIN WEIGHT)					
	MEAN	116.15	123.15	116.30	116.94
	SD	20.316	4.935	9.465	12.542
	N	4	4	4	4
Kidneys(% BRAIN WEIGHT)					
	MEAN	69.07	68.71	64.73	65.96
	SD	13.991	5.968	7.183	8.422
	N	4	4	4	4
Liver(% BRAIN WEIGHT)					
	MEAN	311.12	324.41	347.09	377.92**
	SD	21.994	22.995	20.580	24.554
	N	4	4	4	4
Spleen(% BRAIN WEIGHT)					
	MEAN	43.83	46.30	50.20	49.12
	SD	11.209	4.684	30.482	5.816
	N	4	4	4	4
Testes(% BRAIN WEIGHT)					
	MEAN	20.76	16.38	18.19	17.38
	SD	4.239	4.112	0.985	5.269
	N	4	4	4	4
Thyroid + Parathyroids(% BRAIN WEIGHT)					
	MEAN	1.47	1.39	1.25	1.41
	SD	0.569	0.270	0.253	0.082
	N	4	4	4	4

(1)-0 mg base/kg/day
(2)-0.1 mg base/kg/day
(3)-0.3 mg base/kg/day
(4)-1.0 mg base/kg/day
** - Significant difference P<.01

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511
WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

ORGAN WEIGHT SUMMARY (% BRAIN WEIGHT)

STUDY: 193
SEX: FEMALE

RECOVERY PERIOD

ALL FATES DAYS: 183-184 ALL BALANCES
ANALYSIS OF VARIANCE USING DUNNETT'S PROCEDURE

GROUP:	(5) 1-F	(6) 2-F	(7) 3-F	(8) 4-F
Adrenal Glands(% BRAIN WEIGHT)				
MEAN	2.05	2.05	2.14	2.08
SD	0.056	0.615	0.746	0.489
N	4	4	4	4
Heart(% BRAIN WEIGHT)				
MEAN	102.20	115.65	106.76	105.27
SD	5.438	16.590	14.573	12.325
N	4	4	4	4
Kidneys(% BRAIN WEIGHT)				
MEAN	49.81	48.33	59.51	54.01
SD	6.964	5.348	3.004	4.958
N	4	4	4	4
Liver(% BRAIN WEIGHT)				
MEAN	312.86	308.59	303.42	378.92
SD	51.415	50.676	29.472	61.883
N	4	4	4	4
Ovaries(% BRAIN WEIGHT)				
MEAN	1.91	1.44	1.61	2.19
SD	0.666	0.300	0.173	0.589
N	4	4	4	4
Spleen(% BRAIN WEIGHT)				
MEAN	44.97	43.35	40.56	45.67
SD	3.771	12.380	5.530	14.047
N	4	4	4	4
Thyroid + Parathyroids(% BRAIN WEIGHT)				
MEAN	1.28	1.19	1.08	1.09
SD	0.187	0.147	0.240	0.169
N	4	4	4	4

(5)-0 mg base/kg/day
(6)-0.1 mg base/kg/day
(7)-0.3 mg base/kg/day
(8)-1.0 mg base/kg/day

DRAFT

Table 10

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511
WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

Summary of Microscopic Lesions


		Week 14				Week 27			
		Dose (mg base/kg/day)							
ORGAN - lesion	Sex	0	0.1	0.3	1.0	0	0.1	0.3	1.0
LUNG									
- Accumulation,	M	0/4 (0.00)*	0/4 (0.00)	1/4 (0.38)	4/4 (2.25)	0/4 (0.00)	0/4 (0.00)	1/4 (0.06)	1/4 (0.13)
alveolar macrophage	F	2/4 (0.19)	2/4 (0.13)	2/4 (0.75)	4/4 (2.25)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
- Inflammation	M	0/4 (0.00)	0/4 (0.00)	1/4 (0.38)	4/4 (0.50)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	1/4 (0.13)
chronic, perivascular	F	1/4 (0.06)	2/4 (0.25)	2/4 (0.50)	4/4 (0.75)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
- Inflammation	M	0/4 (0.00)	0/4 (0.00)	1/4 (0.13)	3/4 (0.63)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	2/4 (0.19)
chronic, interstitium	F	1/4 (0.13)	0/4 (0.00)	1/4 (0.38)	4/4 (1.50)	0/4 (0.00)	0/4 (0.00)	1/4 (0.13)	2/4 (0.44)
- Basophilic granular	M	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	1/4 (0.63)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
material	F	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	3/4 (0.94)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
- Inflammation	M	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
chronic, peribronchial	F	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	1/4 (0.06)
LYMPH NODE, BRONCHIAL									
- Accumulation,	M	-	-	-	2/2 (3.00)	-	-	-	-
macrophage	F	-	-	1/1 (2.00)	3/3 (3.00)	-	-	-	-
BONE MARROW (RIB)									
- Hyperplasia	M	0/4 (0.00)	1/4 (0.25)	4/4 (1.75)	4/4 (2.75)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
	F	0/4 (0.00)	0/4 (0.00)	2/4 (0.50)	4/4 (1.50)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
SPLEEN									
- Erythropoiesis	M	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)
	F	0/4 (0.00)	0/4 (0.00)	2/4 (0.50)	2/4 (0.75)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)	0/4 (0.00)

* Incidence (mean group severity score)
- None examined

Figure 1

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

Summary of Male Body Weights




DRAFT

Figure 2

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

Summary of Female Body Weights



DRAFT

DRAFT

APPENDIX A

Analytical Chemistry Report

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

UIC/TRL STUDY NUMBER 193

Identity, Purity and Stability Study of WR242511

Analysts: Adam Negrusz
A. Karl Larsen, Jr.

Study Site: Drug Disposition Research Laboratory
College of Pharmacy
University of Illinois at Chicago
Chicago, Illinois 60612

Sponsor: Toxicology Research Laboratory
University of Illinois at Chicago
Chicago, Illinois 60612

Report Prepared by: Dr. Adam Negrusz

Report Prepared: March 12, 1996

Approved: March 12, 1996
Dr. Eugene F. Woods, Ph.D.
Laboratory Director

Part I: Identity, Purity and Stability Study of WR242511

Objective

The objective of this study was to confirm the identity, establish the purity and stability of WR242511.

Identification

GC-MS System

Gas Chromatograph:	Hewlett-Packard Series II
Mass Selective Detector:	Hewlett-Packard Model 5970
Analytical Column:	30 m x 0.25 mm ID, DB-5 with a 3 micron film thickness.
GC Parameters:	Injector temp. 250°C, oven temp. 70°C initial, 280°C final, 15°C/minute ramp, carrier gas - helium, flow rate 2 ml/minute, split ratio 10:1

Procedure

Subject sample (WR242511 tartrate) was submitted by the Toxicology Research Laboratory. The sample was dissolved in methanol to a concentration of 0.71 μg base/ml and a 2 μl aliquot was injected on the column. The MSD scanned from 40 amu to 400 amu at a rate of 1 scan per second.

Results - GC-MS

The mass spectrum indicates a molecular ion m/e 373 which is in agreement with the WR242511 free base molecular weight. Major fragments of WR242511 sample are m/e 84, 175, 203, 288.

Figure 1 shows the mass spectrum of the WR242511 sample.

Purity

Experimental

The subject sample (WR242511 tartrate) was supplied by the Toxicology Research Laboratory and stored at -20°C when it was not analyzed.

Description

A fine yellow powder, no obvious odor.

Spectrum

An ultraviolet spectrum (Figure 2) recorded on a Shimadzu Spectronic 200 UV spectrometer (dual beam) was obtained from a 14.2 μg base/ml solution of WR242511 prepared in mobile phase. The sample was found with maximal absorptivity observed at 212 nm and 264 nm.

HPLC System

Solvent Delivery System:	Waters 510 Pump
Injector:	Rheodyne 7125 with 50 μl sample loop
Analytical Column:	Spherisorb CN 5 μ, 250 mm x 4.6 mm (Alltech)
Detector:	Perkin-Elmer LC-55B UV Detector, 225 nm, 264 nm
Integrator:	Spectra-Physics SP4270 Integrator
Mobile Phase:	20% methanol, 50% acetonitrile, 30% 0.01 M ammonium formate (in water), pH 3.0 (adjusted with 88% formic acid), flow 1.5 ml/minute

Procedure

Six solutions of WR242511 were prepared as follows. Twenty five mg of a WR242511 tartrate sample was weighed into a 25 ml volumetric flask. The sample was dissolved in and the volume brought to mark with mobile phase. A 25 μl aliquot of each solution was immediately chromatographed at 225 nm and next at 264 nm.

Calculation of Results

Quantitations were based on the assumption of equal detector response per unit weight of all UV-absorbing components. Areas of WR242511 and other detectable components in the subject sample chromatograms were employed in the following equation to calculate the percentage of WR242511 present in the sample:

$$\%\text{PURITY} = (\text{area of WR242511/total area}) \times 100$$

Results


DRAFT

Typical chromatograms are shown in Figure 3. The subject samples were found to contain less than 1% of one UV-absorbing impurity (225 nm). At 264 nm, no visible impurities were observed. Percent purity of initial WR242511 sample was found to be 99.32%, standard deviation - 0.03%; terminal purity was 99.20% $\pm$ 0.10%. The assay results are presented in Tables 1 and 2.

DRAFT

FIGURE 1


MASS SPECTRUM OF WR242511 SAMPLE



DRAFT

FIGURE 2


ULTRAVIOLET SPECTRUM OF WR242511



DRAFT

FIGURE 3

CHROMATOGRAMS OF WR242511 SAMPLE, CONC. 0.71 MG BASE/ML, 225 NM, A - INITIAL SAMPLE, B - TERMINAL SAMPLE



A B

DRAFT

Table 1

Purity Data for WR242511
Initial Sample

Solutions

Peak Identity	1	2	3	4	5	6
A	1740	1918	1908	1776	1724	1795
B	2105	1899	2317	1987	1726	1981
WR242511	563320	583535	596616	567607	560299	562946
% Purity	99.32	99.32	99.30	99.31	99.39	99.29

Mean ± S.D. - 99.32 ± 0.03

DRAFT

Table 2

Purity Data for WR242511
Terminal Sample

Solutions

Peak Identity	1	2	3	4	5	6
A	5892	5472	5547	5704	6207	5438
B	22291	21109	21573	22443	21327	18050
WR242511	3649259	3535752	3474495	3565767	3620320	3492032
% Purity	99.063	99.114	99.226	99.215	99.245	99.332

Mean ± S.D. - 99.20 ± 0.10

DRAFT

APPENDIX B

CLINICAL PATHOLOGY METHODOLOGY

DRAFT

Alanine Aminotransferase (ALT/GPT)
Modified Wroblewski & La Due procedure
Ciba-Corning 550 Express Clinical Chemistry System
Henry, R.J., Chiamori, N., Golub, O.J. and Berkman, S.
Am. J. Clin. Path., 34, 381, 1960.

Aspartate Aminotransferase
Modified Karmen procedure
Ciba-Corning 550 Clinical Chemistry Stystem
Bergmeyer, H.V., Scheibe, P., and Wahlefeld, A.W.
Clin. Chem., 24, 68, 1978.

Total Protein
Biuret technique
Ciba-Corning 550 Express Clinical Chemistry System
Kingsley, G.R.
J. Biol. Chem. 131, 197, 1939.

Albumin
Bromocresol green method
Ciba-Corning 550 Express Clinical Chemistry System
Doumas, B.T. and Biggs, H.G.
Standard Methods of Clinical Chemistry, 7, 175, 1972.

Total Bilirubin
Modified Walters and Gerard method
Ciba-Corning 550 Express Clinical Chemistry System
Ertinghausen, G., Fabiny-Byrd, D.L., Tiffany, T.O., and Carey, S.J.
Clin. Chem. 19, 1366, 1973.

Alkaline Phosphatase
Modified Bessey-Lowry procedure
Ciba-Corning 550 Express Clinical Chemistry System
Neumann, H. and Von Vreedendaal
M. Clin. Chem. Acta., 17, 183, 1967.

Gamma Glutamyl Transferase (GGT)
JFCC Methods for Gamma Glutamyl Transferase
Shaw, L.M., Stromme, J.H., London, J.L., Theodorsen, L.
J. Clin. Chem. Clin. Biochem. 21, 633-646, 1983.

Cholesterol
Cholesterol esterase-oxidase method
Ciba-Corning 550 Express Clinical Chemistry System
Rosechlow, P., et. al
Z.F. Klin. Chem. V. Klin. Biochem. 12, 226, 1974.

Triglycerides
Tetrazolium salt reduction method
Ciba-Corning 550 Express Clinical Chemistry System
Klotzsch, S., *et. al.*
Advances Automated Analysis, Vol. 1, Mediad Inc., Tarrytown, N.Y., p. 111, 1973.

DRAFT

Lactate Dehydrogenase
L → P technique
Ciba-Corning 550 Express Clinical Chemistry System
Wacker, W.E.C., Ulmer, D.D., Valle, B.L.
New England J Med. 225, 449, 1956.

Creatine Kinase (CK)
Modification of Szasz *et al.* procedure
Ciba-Corning 550 Express Clinical Chemistry System
Clin. Chem. 22, 650-656, 1976.

Urea Nitrogen (BUN)
Modified urease technique
Ciba-Corning 550 Express Clinical Chemistry System
Talke, H. and Schubert, G.E.
Klin. Wchnschr. 43, 174, 1965.

Creatinine
Jaffe method
Ciba-Corning 550 Express Clinical Chemistry System
Larsen. K.
Clin. Chem. Acta, 41, 209, 1972

Na+, K+
Ion specific electrodes
Model 614 ISE Na+/K+ Analyzer (Ciba Corning)

Chloride
Mecuric thiocyanate procedure
Ciba-Corning 550 Express Clinical Chemistry System
Zall, O.M., Fisher, D. and Garner, M.Q.
Anal. Chem, 28, 1065, 1956.

Calcium
Modified alizarin procedure
Ciba-Corning 550 Express Clinical Chemistry System
Frings, C.S., et. al.
Clin. Chem., 16, 816, 1970.

Phosphorus, Inorganic
Ammonium molybdate method
Ciba-Corning 550 Express Clinical Chemistry System
Fiske, C.H. and Subbarow, Y.
J. Biol. Chem. 66, 325, 1925.

Glucose
Hexokinase method
Ciba-Corning 550 Express Clinical Chemistry System
Bondar, J.L. and Mead, D.C.
Clin. Chem. 20, 586, 1974.

Haptoglobin
Antigen-antibody method
Ciba-Corning 550 Express Clinical Chemistry System
Atlantic Antibodies Test Kit

DRAFT

Erythrocyte Count
Electronic counting procedure
Sysmex K1000 Hematology Analyzer

Hemoglobin
Cyanomethemoglobin method
Sysmex K1000 Hematology Analyzer

Hematocrit
Indirect method; calculated value based on volume of red cells and volume of blood

Mean Corpuscular Volume (MCV)
Indirect method; calculated value based on hematocrit and red blood cell count

Mean Corpuscular Hemoglobin (MCH)
Indirect method; calculated value based on erythrocyte count and hemoglobin

Mean Corpuscular Hemoglobin Concentration (MCHC)
Indirect method; calculated value based on hematocrit and hemoglobin

Reticulocyte Count
New methylene blue staining procedure
Brecher, G., Am. J. Clin. Path., 19, 895, 1949.

Platelet Count
Electronic counting procedure
Sysmex K1000 Hematology Analyzer

Prothrombin Time (PT)
Electra 700 coagulation machine

Activated Partial Thromboplastin Time (APTT)
Electra 700 coagulation machine

Fibrinogen
Electra 700 coagulation machine

Leukocyte Count
Electronic counting procedure
Sysmex K1000 Hematology Analyzer

Leukocyte Differential Count
Neutrophils - Immature (bands)
Neutrophils - Mature (segs)
Monocytes
Basophils
Lymphocytes
Eosinophils
Wright stain procedure
Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

DRAFT

Nucleated RBCs

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

RBC Morphology

Wright stain procedure

Schalm, O.W., Jain, N.C. and Carroll, E.J. Veterinary Hematology, Color Plates Chapter, 3rd Edition, Lee and Febiger, 1975.

Heinz Bodies

Methyl violet staining technique

Methemoglobin

Co-oximeter (Instrumentation Laboratory Model 282)

URINALYSIS

DRAFT

Qualitative Measurements

Ketones, Protein, Glucose, Blood, Bilirubin, Urobilinogen, Nitrite, Leukocytes, pH
Boehringer Mannheim Chemstrip 9 Reagent Strips

Specific Gravity

Optical temperature compensated refractometer

Microscopic Evaluation

Urinary sediment stained with kova-stain and evaluated using the Ames Atlas of Urine Sediment, Ames Co., Division Miles Laboratories, Elkhart, Indiana.

DRAFT

APPENDIX C

Individual Observations (Clinical Signs)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 1-M SEX: MALE
DAY 1-DAY 184 DOSE: 0(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8656	Normal			DAY 1-DAY 91
	Scheduled Sacrifice			DAY 92
8687	Normal			DAY 1-DAY 91
	Scheduled Sacrifice			DAY 92
8669	Normal			DAY 1-DAY 91
	Scheduled Sacrifice			DAY 92
8673	Normal			DAY 1-DAY 91
	Scheduled Sacrifice			DAY 92
8667	Normal			DAY 1-DAY 182
	Scheduled Sacrifice			DAY 183
8654	Normal			DAY 1-DAY 182
	Scheduled Sacrifice			DAY 183
8680	Normal			DAY 1-DAY 182
	Scheduled Sacrifice			DAY 183
8676	Normal			DAY 1-DAY 182
	Scheduled Sacrifice			DAY 183

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 1-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 0(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8721	Normal			DAY 1-DAY 92
	Scheduled Sacrifice			DAY 93
8712	Normal			DAY 1-DAY 92
	Scheduled Sacrifice			DAY 93
8710	Normal			DAY 1-DAY 92
	Scheduled Sacrifice			DAY 93
8723	Normal			DAY 1-DAY 92
	Scheduled Sacrifice			DAY 93
8705	Normal			DAY 1-DAY 183
	Scheduled Sacrifice			DAY 184
8700	Normal			DAY 1-DAY 183
	Scheduled Sacrifice			DAY 184
8699	Normal			DAY 1-DAY 57
	Normal			DAY 59-DAY 183
	Scheduled Sacrifice			DAY 184
	Vomit Seen In Run			DAY 58
8690	Normal			DAY 1-DAY 183
	Scheduled Sacrifice			DAY 184

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 2-M SEX: MALE
DAY 1-DAY 184 DOSE: 0.1(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8685	Normal			DAY 1-DAY 91
	Scheduled Sacrifice			DAY 92
8663	Normal			DAY 1-DAY 91
	Scheduled Sacrifice			DAY 92
8686	Blue Tongue	1		DAY 38-DAY 45
	Blue Tongue	1		DAY 50
	Blue Tongue	1		DAY 55-DAY 57
	Blue Tongue	1		DAY 59
	Blue Tongue	1		DAY 61
	Normal			DAY 1-DAY 37
	Normal			DAY 46-DAY 49
	Normal			DAY 51-DAY 54
	Normal			DAY 58
	Normal			DAY 60
	Normal			DAY 62-DAY 91
	Scheduled Sacrifice			DAY 92
8665	Normal			DAY 1-DAY 9
	Normal			DAY 11-DAY 182
	Scheduled Sacrifice			DAY 183
	Vomit Seen In Run			DAY 10
8666	Normal			DAY 1-DAY 32
	Normal			DAY 34-DAY 182
	Scheduled Sacrifice			DAY 183
	Vomit Seen In Run			DAY 33
8655	Normal			DAY 1-DAY 182
	Scheduled Sacrifice			DAY 183
8659	Blue Tongue	1		DAY 45-DAY 46
	Normal			DAY 1-DAY 44
	Normal			DAY 47-DAY 83
	Normal			DAY 85-DAY 182
	Scheduled Sacrifice			DAY 183
	Vomit Seen In Run			DAY 84
8677	Normal			DAY 1-DAY 91
	Scheduled Sacrifice			DAY 92

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 2-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 0.1(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8717	Normal			DAY 1-DAY 92
	Scheduled Sacrifice			DAY 93
8703	Blue Tongue	1		DAY 39
	Normal			DAY 1-DAY 92
	Scheduled Sacrifice			DAY 93
8713	Normal			DAY 1-DAY 50
	Normal			DAY 52-DAY 92
	Scheduled Sacrifice			DAY 93
	Vomit Seen In Run			DAY 51
8693	Normal			DAY 1-DAY 92
	Scheduled Sacrifice			DAY 93
8695	Normal			DAY 1-DAY 183
	Scheduled Sacrifice			DAY 184
8709	Normal			DAY 1-DAY 183
	Scheduled Sacrifice			DAY 184
8715	Blue Tongue	1		DAY 41
	Normal			DAY 1-DAY 40
	Normal			DAY 42-DAY 183
	Scheduled Sacrifice			DAY 184
8697	Normal			DAY 1-DAY 183
	Scheduled Sacrifice			DAY 184

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 3-M SEX: MALE
DAY 1-DAY 184 DOSE: 0.3 (mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8674	Blue Tongue	1		DAY 24-DAY 28
	Blue Tongue	1		DAY 34-DAY 50
	Blue Tongue	1		DAY 60-DAY 62
	Blue Tongue	1		DAY 74-DAY 75
	Blue Tongue	1		DAY 82-DAY 84
	Blue Tongue	1		DAY 92
	Normal			DAY 1-DAY 23
	Normal			DAY 29-DAY 33
	Normal			DAY 51-DAY 59
	Normal			DAY 63-DAY 73
	Normal			DAY 76-DAY 81
	Normal			DAY 85-DAY 91
	Normal			DAY 93-DAY 182
	Scheduled Sacrifice			DAY 183
8653	Blue Tongue	1		DAY 30
	Blue Tongue	1		DAY 39
	Normal			DAY 1-DAY 29
	Normal			DAY 31-DAY 38
	Normal			DAY 40-DAY 91
	Scheduled Sacrifice			DAY 92
8660	Blue Tongue	1		DAY 42-DAY 43
	Blue Tongue	1		DAY 89
	Normal			DAY 1-DAY 41
	Normal			DAY 44-DAY 88
	Normal			DAY 90-DAY 91
	Scheduled Sacrifice			DAY 92
8668	Blue Tongue	1		DAY 15-DAY 17
	Blue Tongue	1		DAY 19-DAY 25
	Blue Tongue	1		DAY 27-DAY 44
	Blue Tongue	1		DAY 46-DAY 53
	Blue Tongue	1		DAY 55-DAY 62
	Blue Tongue	1		DAY 65
	Blue Tongue	1		DAY 75
	Blue Tongue	1		DAY 80-DAY 84

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 3-M SEX: MALE
DAY 1-DAY 184 DOSE: 0.3(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8668 (contd.)	Blue Tongue	1		DAY 90
	Normal			DAY 1-DAY 14
	Normal			DAY 18
	Normal			DAY 26
	Normal			DAY 45
	Normal			DAY 54
	Normal			DAY 63-DAY 64
	Normal			DAY 66-DAY 74
	Normal			DAY 76-DAY 79
	Normal			DAY 85-DAY 89
	Normal			DAY 91
	Scheduled Sacrifice			DAY 92
8682	Normal			DAY 1-DAY 182
	Scheduled Sacrifice			DAY 183
8684	Blue Tongue	1		DAY 46-DAY 47
	Normal			DAY 1-DAY 45
	Normal			DAY 48-DAY 91
	Scheduled Sacrifice			DAY 92
8662	Blue Tongue	1		DAY 30
	Blue Tongue	1		DAY 60-DAY 61
	Normal			DAY 1-DAY 29
	Normal			DAY 31-DAY 59
	Normal			DAY 62-DAY 182
	Scheduled Sacrifice			DAY 183
8688	Blue Tongue	1		DAY 35-DAY 37
	Blue Tongue	1		DAY 50
	Blue Tongue	1		DAY 96-DAY 97
	Diarrhea	1		DAY 74
	Normal			DAY 1-DAY 34
	Normal			DAY 38-DAY 49
	Normal			DAY 51-DAY 73
	Normal			DAY 75-DAY 95
	Normal			DAY 98-DAY 182
	Scheduled Sacrifice			DAY 183

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 3-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 0.3(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8692	Blue Tongue	1		DAY 28
	Blue Tongue	1		DAY 34
	Blue Tongue	1		DAY 44-DAY 49
	Blue Tongue	1		DAY 58-DAY 60
	Blue Tongue	1		DAY 73-DAY 75
	Blue Tongue	1		DAY 81-DAY 82
	Normal			DAY 1-DAY 27
	Normal			DAY 29-DAY 33
	Normal			DAY 35-DAY 43
	Normal			DAY 50-DAY 57
	Normal			DAY 61-DAY 72
	Normal			DAY 76-DAY 80
	Normal			DAY 83-DAY 92
	Scheduled Sacrifice			DAY 93
8718	Blue Tongue	1		DAY 22
	Blue Tongue	1		DAY 31-DAY 36
	Blue Tongue	1		DAY 38-DAY 44
	Blue Tongue	1		DAY 50
	Blue Tongue	1		DAY 54-DAY 57
	Blue Tongue	1		DAY 59-DAY 63
	Blue Tongue	1		DAY 66-DAY 73
	Blue Tongue	1		DAY 75-DAY 79
	Blue Tongue	1		DAY 82
	Blue Tongue	1		DAY 92
	Normal			DAY 1-DAY 21
	Normal			DAY 23-DAY 30
	Normal			DAY 37
	Normal			DAY 45-DAY 49
	Normal			DAY 51-DAY 53
	Normal			DAY 58
	Normal			DAY 64-DAY 65
	Normal			DAY 74
	Normal			DAY 80-DAY 81
	Normal			DAY 83-DAY 91
	Scheduled Sacrifice			DAY 93

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 3-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 0.3(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8706	Blue Tongue	1		DAY 30
	Blue Tongue	1		DAY 38
	Blue Tongue	1		DAY 40-DAY 41
	Blue Tongue	1		DAY 51-DAY 53
	Blue Tongue	1		DAY 65-DAY 71
	Normal			DAY 1-DAY 29
	Normal			DAY 31-DAY 37
	Normal			DAY 39
	Normal			DAY 42-DAY 50
	Normal			DAY 54-DAY 64
	Normal			DAY 72-DAY 92
	Scheduled Sacrifice			DAY 93
8714	Blue Tongue	1		DAY 54-DAY 56
	Blue Tongue	1		DAY 74-DAY 75
	Normal			DAY 1-DAY 53
	Normal			DAY 57-DAY 73
	Normal			DAY 76-DAY 92
	Scheduled Sacrifice			DAY 93
8701	Blue Tongue	1		DAY 18
	Blue Tongue	1		DAY 24-DAY 26
	Blue Tongue	1		DAY 29-DAY 40
	Blue Tongue	1		DAY 49-DAY 50
	Blue Tongue	1		DAY 52-DAY 53
	Blue Tongue	1		DAY 55-DAY 56
	Blue Tongue	1		DAY 59-DAY 62
	Blue Tongue	1		DAY 65
	Blue Tongue	1		DAY 70-DAY 72
	Normal			DAY 1-DAY 17
	Normal			DAY 19-DAY 23
	Normal			DAY 27-DAY 28
	Normal			DAY 41-DAY 48
	Normal			DAY 51
	Normal			DAY 54
	Normal			DAY 57-DAY 58
	Normal			DAY 63-DAY 64
	Normal			DAY 66-DAY 69
	Normal			DAY 73-DAY 183
	Scheduled Sacrifice			DAY 184

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 3-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 0.3 (mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8702	Blue Tongue	1		DAY 28-DAY 30
	Blue Tongue	1		DAY 52-DAY 53
	Blue Tongue	1		DAY 73-DAY 75
	Normal			DAY 1-DAY 27
	Normal			DAY 31-DAY 51
	Normal			DAY 54-DAY 72
	Normal			DAY 76-DAY 183
	Scheduled Sacrifice			DAY 184
8720	Blue Tongue	1		DAY 35-DAY 36
	Blue Tongue	1		DAY 52-DAY 53
	Normal			DAY 1-DAY 34
	Normal			DAY 37-DAY 51
	Normal			DAY 54-DAY 183
	Scheduled Sacrifice			DAY 184
8704	Blue Tongue	1		DAY 28-DAY 29
	Blue Tongue	1		DAY 31-DAY 32
	Blue Tongue	1		DAY 35-DAY 36
	Blue Tongue	1		DAY 38
	Blue Tongue	1		DAY 41-DAY 45
	Blue Tongue	1		DAY 48-DAY 53
	Blue Tongue	1		DAY 57
	Blue Tongue	1		DAY 59-DAY 62
	Normal			DAY 1-DAY 27
	Normal			DAY 30
	Normal			DAY 33-DAY 34
	Normal			DAY 37
	Normal			DAY 39-DAY 40
	Normal			DAY 46-DAY 47
	Normal			DAY 54-DAY 56
	Normal			DAY 58
	Normal			DAY 63-DAY 183
	Scheduled Sacrifice			DAY 184

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-M SEX: MALE
DAY 1-DAY 184 DOSE: 1.0(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8661	Blue Sclera	1		DAY 87
	Blue Tongue	1		DAY 7-DAY 59
	Blue Tongue	1		DAY 63-DAY 64
	Blue Tongue	1		DAY 66-DAY 91
	Blue Tongue	2		DAY 60-DAY 62
	Blue Tongue	2		DAY 65
	Normal			DAY 1-DAY 6
	Scheduled Sacrifice			DAY 92
8670	Blue Gums	1		DAY 34
	Blue Gums	1		DAY 38-DAY 39
	Blue Tongue	1		DAY 10-DAY 36
	Blue Tongue	1		DAY 40-DAY 56
	Blue Tongue	1		DAY 58-DAY 67
	Blue Tongue	1		DAY 69-DAY 73
	Blue Tongue	1		DAY 76-DAY 79
	Blue Tongue	1		DAY 84-DAY 90
	Blue Tongue	2		DAY 37-DAY 39
	Blue Tongue	2		DAY 57
	Blue Tongue	2		DAY 68
	Blue Tongue	2		DAY 74-DAY 75
	Blue Tongue	2		DAY 80-DAY 83
	Blue Tongue	2		DAY 91
	Normal			DAY 1-DAY 9
	Scheduled Sacrifice			DAY 92
8681	Blue Gums	1		DAY 36-DAY 38
	Blue Gums	1		DAY 85-DAY 86
	Blue Sclera	1		DAY 51
	Blue Sclera	1		DAY 83-DAY 85
	Blue Sclera	1		DAY 89
	Blue Tongue	1		DAY 10-DAY 22
	Blue Tongue	1		DAY 24-DAY 36
	Blue Tongue	1		DAY 40-DAY 50
	Blue Tongue	1		DAY 54-DAY 59
	Blue Tongue	1		DAY 63-DAY 64
	Blue Tongue	1		DAY 68-DAY 74

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-M SEX: MALE
DAY 1-DAY 184 DOSE: 1.0(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8681 (contd.)	Blue Tongue	1		DAY 78-DAY 83
	Blue Tongue	1		DAY 85
	Blue Tongue	2		DAY 37-DAY 39
	Blue Tongue	2		DAY 51-DAY 53
	Blue Tongue	2		DAY 60-DAY 62
	Blue Tongue	2		DAY 65-DAY 67
	Blue Tongue	2		DAY 75-DAY 77
	Blue Tongue	2		DAY 84
	Blue Tongue	2		DAY 86-DAY 91
	Normal			DAY 1-DAY 9
	Normal			DAY 23
	Scheduled Sacrifice			DAY 92
8664	Blue Gums	1		DAY 41
	Blue Tongue	1		DAY 12-DAY 26
	Blue Tongue	1		DAY 28-DAY 89
	Blue Tongue	1		DAY 91
	Blue Tongue	2		DAY 90
	Diarrhea	1		DAY 25
	Normal			DAY 1-DAY 11
	Normal			DAY 27
	Scheduled Sacrifice			DAY 92
8675	Blue Gums	1		DAY 26
	Blue Gums	1		DAY 36
	Blue Gums	1		DAY 63
	Blue Gums	1		DAY 94
	Blue Sclera	1		DAY 94
	Blue Tongue	1		DAY 4-DAY 18
	Blue Tongue	1		DAY 20-DAY 35
	Blue Tongue	1		DAY 37-DAY 38
	Blue Tongue	1		DAY 41-DAY 42
	Blue Tongue	1		DAY 44
	Blue Tongue	1		DAY 58
	Blue Tongue	1		DAY 63-DAY 64
	Blue Tongue	1		DAY 74-DAY 77
	Blue Tongue	1		DAY 85
	Blue Tongue	1		DAY 94-DAY 99

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-M SEX: MALE
DAY 1-DAY 184 DOSE: 1.0 (mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8675 (contd.)	Blue Tongue	1		DAY 102-DAY 104
	Blue Tongue	2		DAY 36
	Blue Tongue	2		DAY 39-DAY 40
	Blue Tongue	2		DAY 43
	Blue Tongue	2		DAY 45-DAY 57
	Blue Tongue	2		DAY 59-DAY 62
	Blue Tongue	2		DAY 65-DAY 73
	Blue Tongue	2		DAY 78-DAY 84
	Blue Tongue	2		DAY 86-DAY 93
	Normal			DAY 1-DAY 3
	Normal			DAY 19
	Normal			DAY 100-DAY 101
	Normal			DAY 105-DAY 182
	Scheduled Sacrifice			DAY 183
8683	Blue Tongue	1		DAY 13
	Blue Tongue	1		DAY 27-DAY 35
	Blue Tongue	1		DAY 39-DAY 91
	Blue Tongue	1		DAY 93
	Blue Tongue	1		DAY 96-DAY 98
	Normal			DAY 1-DAY 12
	Normal			DAY 14-DAY 26
	Normal			DAY 36-DAY 38
	Normal			DAY 92
	Normal			DAY 94-DAY 95
	Normal			DAY 99-DAY 182
	Scheduled Sacrifice			DAY 183
8658	Blue Tongue	1		DAY 7-DAY 9
	Blue Tongue	1		DAY 12-DAY 35
	Blue Tongue	1		DAY 39-DAY 44
	Blue Tongue	1		DAY 50
	Blue Tongue	1		DAY 52-DAY 58
	Blue Tongue	1		DAY 60-DAY 67
	Blue Tongue	1		DAY 69
	Blue Tongue	1		DAY 73
	Blue Tongue	1		DAY 75
	Blue Tongue	1		DAY 85-DAY 90

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-M SEX: MALE
DAY 1-DAY 184 DOSE: 1.0 (mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8658 (contd.)	Blue Tongue	1		DAY 94-DAY 113
	Blue Tongue	1		DAY 118
	Blue Tongue	1		DAY 124
	Blue Tongue	1		DAY 129
	Blue Tongue	1		DAY 131
	Blue Tongue	2		DAY 36-DAY 38
	Blue Tongue	2		DAY 45-DAY 49
	Blue Tongue	2		DAY 51
	Blue Tongue	2		DAY 59
	Blue Tongue	2		DAY 68
	Blue Tongue	2		DAY 70-DAY 72
	Blue Tongue	2		DAY 74
	Blue Tongue	2		DAY 76-DAY 84
	Blue Tongue	2		DAY 91-DAY 93
	Normal			DAY 1-DAY 6
	Normal			DAY 10-DAY 11
	Normal			DAY 114-DAY 117
	Normal			DAY 119-DAY 123
	Normal			DAY 125-DAY 128
	Normal			DAY 130
	Normal			DAY 132-DAY 182
	Scheduled Sacrifice			DAY 183
8652	Blue Gums	1		DAY 22
	Blue Gums	1		DAY 27-DAY 28
	Blue Gums	1		DAY 31-DAY 36
	Blue Gums	1		DAY 55
	Blue Gums	1		DAY 58-DAY 59
	Blue Gums	1		DAY 63-DAY 64
	Blue Gums	1		DAY 94
	Blue Tongue	1		DAY 9-DAY 44
	Blue Tongue	1		DAY 50-DAY 63
	Blue Tongue	1		DAY 66-DAY 71
	Blue Tongue	1		DAY 76-DAY 77
	Blue Tongue	1		DAY 82-DAY 89
	Blue Tongue	1		DAY 91
	Blue Tongue	1		DAY 94-DAY 103
	Blue Tongue	2		DAY 45-DAY 49

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-M SEX: MALE
DAY 1-DAY 184 DOSE: 1.0 (mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8652 (contd.)	Blue Tongue	2		DAY 59
	Blue Tongue	2		DAY 64-DAY 65
	Blue Tongue	2		DAY 72-DAY 75
	Blue Tongue	2		DAY 78-DAY 81
	Blue Tongue	2		DAY 90
	Blue Tongue	2		DAY 92-DAY 93
	Normal			DAY 1-DAY 8
	Normal			DAY 104-DAY 182
	Scheduled Sacrifice			DAY 183
	Vomit Seen In Run			DAY 78

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 1.0(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8696	Blue Gums	1		DAY 36
	Blue Sclera	1		DAY 50-DAY 57
	Blue Sclera	1		DAY 59-DAY 62
	Blue Sclera	1		DAY 70-DAY 72
	Blue Sclera	1		DAY 83-DAY 84
	Blue Sclera	1		DAY 86-DAY 91
	Blue Tongue	1		DAY 16
	Blue Tongue	1		DAY 19-DAY 20
	Blue Tongue	1		DAY 22-DAY 23
	Blue Tongue	1		DAY 28-DAY 92
	Normal			DAY 1-DAY 15
	Normal			DAY 17-DAY 18
	Normal			DAY 21
	Normal			DAY 24-DAY 27
	Scheduled Sacrifice			DAY 93
8719	Blue Gums	1		DAY 41
	Blue Tongue	1		DAY 7-DAY 61
	Blue Tongue	1		DAY 63-DAY 71
	Blue Tongue	1		DAY 73
	Blue Tongue	1		DAY 75-DAY 78
	Blue Tongue	1		DAY 80-DAY 92
	Blue Tongue	2		DAY 72
	Blue Tongue	2		DAY 74
	Blue Tongue	2		DAY 79
	Normal			DAY 1-DAY 6
	Normal			DAY 62
	Scheduled Sacrifice			DAY 93
8711	Blue Tongue	1		DAY 7-DAY 22
	Blue Tongue	1		DAY 24-DAY 92
	Normal			DAY 1-DAY 6
	Normal			DAY 23
	Scheduled Sacrifice			DAY 93
8716	Blue Gums	1		DAY 34
	Blue Tongue	1		DAY 10-DAY 13

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 1.0(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8716 (contd.)	Blue Tongue	1		DAY 16-DAY 17
	Blue Tongue	1		DAY 19-DAY 21
	Blue Tongue	1		DAY 24-DAY 85
	Blue Tongue	1		DAY 87-DAY 92
	Normal			DAY 1-DAY 9
	Normal			DAY 14-DAY 15
	Normal			DAY 18
	Normal			DAY 22-DAY 23
	Normal			DAY 86
	Scheduled Sacrifice			DAY 93
8725	Blue Gums	1		DAY 67-DAY 68
	Blue Tongue	1		DAY 9
	Blue Tongue	1		DAY 29
	Blue Tongue	1		DAY 31-DAY 94
	Blue Tongue	1		DAY 96
	Normal			DAY 1-DAY 8
	Normal			DAY 10-DAY 28
	Normal			DAY 30
	Normal			DAY 95
	Normal			DAY 97-DAY 183
	Scheduled Sacrifice			DAY 184
8707	Blue Tongue	1		DAY 9-DAY 68
	Blue Tongue	1		DAY 73-DAY 74
	Blue Tongue	1		DAY 76-DAY 82
	Blue Tongue	1		DAY 85
	Blue Tongue	1		DAY 87
	Blue Tongue	1		DAY 89-DAY 93
	Blue Tongue	1		DAY 95-DAY 97
	Blue Tongue	1		DAY 99
	Blue Tongue	2		DAY 69-DAY 72
	Blue Tongue	2		DAY 75
	Blue Tongue	2		DAY 83-DAY 84
	Blue Tongue	2		DAY 86
	Blue Tongue	2		DAY 88
	Normal			DAY 1-DAY 8
	Normal			DAY 94
	Normal			DAY 98
	Normal			DAY 100-DAY 183
	Scheduled Sacrifice			DAY 184

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 1.0(mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8689	Blue Gums	1		DAY 68
	Blue Gums	1		DAY 94
	Blue Sclera	1		DAY 37
	Blue Sclera	1		DAY 58
	Blue Sclera	1		DAY 63
	Blue Sclera	1		DAY 86
	Blue Tongue	1		DAY 6-DAY 33
	Blue Tongue	1		DAY 78-DAY 80
	Blue Tongue	1		DAY 85-DAY 86
	Blue Tongue	1		DAY 90-DAY 91
	Blue Tongue	1		DAY 95-DAY 98
	Blue Tongue	1		DAY 101
	Blue Tongue	1		DAY 103
	Blue Tongue	1		DAY 105-DAY 116
	Blue Tongue	1		DAY 118
	Blue Tongue	2		DAY 34-DAY 77
	Blue Tongue	2		DAY 81-DAY 84
	Blue Tongue	2		DAY 87-DAY 89
	Blue Tongue	2		DAY 92-DAY 94
	Normal			DAY 1-DAY 5
	Normal			DAY 99-DAY 100
	Normal			DAY 102
	Normal			DAY 104
	Normal			DAY 117
	Normal			DAY 119-DAY 183
	Scheduled Sacrifice			DAY 184
8722	Blue Gums	1		DAY 16-DAY 36
	Blue Gums	1		DAY 38-DAY 42
	Blue Gums	1		DAY 44-DAY 45
	Blue Gums	1		DAY 48
	Blue Gums	1		DAY 50-DAY 68
	Blue Gums	1		DAY 70-DAY 72
	Blue Gums	1		DAY 76-DAY 90
	Blue Gums	1		DAY 93-DAY 94
	Blue Sclera	1		DAY 37
	Blue Sclera	1		DAY 56-DAY 57
	Blue Sclera	1		DAY 63-DAY 64

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

INDIVIDUAL CLINICAL SIGNS

STUDY: 193 GROUP: 4-F SEX: FEMALE
DAY 1-DAY 184 DOSE: 1.0 (mg/kg)

ANIMAL #	OBSERVATIONS	SEVERITY	LOC	TIME OCCURRED
8722 (contd.)	Blue Sclera	1		DAY 90
	Blue Tongue	1		DAY 7-DAY 9
	Blue Tongue	1		DAY 12-DAY 36
	Blue Tongue	1		DAY 39-DAY 63
	Blue Tongue	1		DAY 65-DAY 67
	Blue Tongue	1		DAY 69-DAY 71
	Blue Tongue	1		DAY 73-DAY 81
	Blue Tongue	1		DAY 85-DAY 89
	Blue Tongue	1		DAY 91-DAY 98
	Blue Tongue	1		DAY 113-DAY 115
	Blue Tongue	2		DAY 37-DAY 38
	Blue Tongue	2		DAY 64
	Blue Tongue	2		DAY 68
	Blue Tongue	2		DAY 72
	Blue Tongue	2		DAY 82-DAY 84
	Blue Tongue	2		DAY 90
	Normal			DAY 1-DAY 6
	Normal			DAY 10-DAY 11
	Normal			DAY 99-DAY 112
	Normal			DAY 116-DAY 183
	Scheduled Sacrifice			DAY 184

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (Intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 1					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 2					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 3					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 4					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	7 88%
Blue Tongue					
SEV					
1		0	0	0	1 12%
DAY 5					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	7 88%
Blue Tongue					
SEV					
1		0	0	0	1 12%
DAY 6					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	7 88%
Blue Tongue					
SEV					
1		0	0	0	1 12%
DAY 7					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	5 62%
Blue Tongue					
SEV					
1		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 8					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	5 62%
Blue Tongue					
SEV					
1		0	0	0	3 38%
DAY 9					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	4 50%
Blue Tongue					
SEV					
1		0	0	0	4 50%
DAY 10					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	8 100%	3 38%
Blue Tongue					
SEV					
1		0	0	0	5 62%
Vomit Seen In Run		0	1 12%	0	0
DAY 11					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	3 38%
Blue Tongue					
SEV					
1		0	0	0	5 62%
DAY 12					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	1 12%
Blue Tongue					
SEV					
1		0	0	0	7 88%
DAY 13					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	8 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193

SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 14					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	1 12%
Blue Tongue SEV					
1		0	0	0	7 88%
DAY 15					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	1 12%
Blue Tongue SEV					
1		0	0	1 12%	7 88%
DAY 16					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	1 12%
Blue Tongue SEV					
1		0	0	1 12%	7 88%
DAY 17					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	1 12%
Blue Tongue SEV					
1		0	0	1 12%	7 88%
DAY 18					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	1 12%
Blue Tongue SEV					
1		0	0	0	7 88%
DAY 19					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	2 25%
Blue Tongue SEV					
1		0	0	1 12%	6 75%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 20					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
DAY 21					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
DAY 22					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
DAY 23					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	2 25%
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
DAY 24					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DDSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 25					
No. Dbserved		8	8	8	8
Normal		8 100%	8 100%	6 75%	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
Diarrhea					
SEV					
1		0	0	0	1 12%
DAY 26					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
DAY 27					
No. Dbserved		8	8	8	8
Normal		8 100%	8 100%	6 75%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
DAY 28					
No. Dbserved		8	8	8	8
Normal		8 10D%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	8 100%
DAY 29					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	8 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 30					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Tongue					
SEV					
1		0	0	3 38%	8 100%
DAY 31					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	8 100%
DAY 32					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	8 100%
DAY 33					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	8 100%
Vomit Seen In Run		0	1 12%	0	0

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 34					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	2 25%	8 100%
DAY 35					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	8 100%
DAY 36					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	1 12%
Blue Gums					
SEV					
1		0	0	0	3 38%
Blue Tongue					
SEV					
1		0	0	3 38%	5 62%
2		0	0	0	2 25%
DAY 37					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	4 50%
2		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 38					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	6 75%	1 12%
Blue Gums					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	1 12%	2 25%	4 50%
2		0	0	0	3 38%
DAY 39					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	1 12%	3 38%	5 62%
2		0	0	0	3 38%
DAY 40					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	6 75%	0
Blue Tongue					
SEV					
1		0	1 12%	2 25%	7 88%
2		0	0	0	1 12%
DAY 41					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	1 12%	2 25%	8 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 42					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	5 62%	0
Blue Tongue					
SEV					
1		0	1 12%	3 38%	8 100%
DAY 43					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	5 62%	0
Blue Tongue					
SEV					
1		0	1 12%	3 38%	7 88%
2		0	0	0	1 12%
DAY 44					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	6 75%	0
Blue Tongue					
SEV					
1		0	1 12%	2 25%	8 100%
DAY 45					
No. Observed		8	8	8	8
Normal		8 100%	6 75%	7 88%	0
Blue Tongue					
SEV					
1		0	2 25%	1 12%	5 62%
2		0	0	0	3 38%
DAY 46					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	5 62%	0
Blue Tongue					
SEV					
1		0	1 12%	3 38%	5 62%
2		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 47					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Tongue					
SEV					
1		0	0	3 38%	5 62%
2		0	0	0	3 38%
DAY 48					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	2 25%	5 62%
2		0	0	0	3 38%
DAY 49					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	2 25%	5 62%
2		0	0	0	3 38%
DAY 50					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	5 62%	0
Blue Tongue					
SEV					
1		0	1 12%	3 38%	7 88%
2		0	0	0	1 12%
DAY 51					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	5 62%
2		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 52					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
2		0	0	0	2 25%
DAY 53					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
2		0	0	0	2 25%
DAY 54					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	7 88%
2		0	0	0	1 12%
DAY 55					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	1 12%	1 12%	7 88%
2		0	0	0	1 12%
DAY 56					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	7 88%	0
Blue Tongue					
SEV					
1		0	1 12%	1 12%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 57					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	7 88%	0
Blue Tongue					
SEV					
1		0	1 12%	1 12%	6 75%
2		0	0	0	2 25%
DAY 58					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	8 100%
DAY 59					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	1 12%	1 12%	6 75%
2		0	0	0	3 38%
DAY 60					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Tongue					
SEV					
1		0	0	3 38%	5 62%
2		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 61					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	5 62%	0
Blue Tongue					
SEV					
1		0	1 12%	3 38%	5 62%
2		0	0	0	3 38%
DAY 62					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	2 25%	5 62%
2		0	0	0	3 38%
DAY 63					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	0	8 100%
DAY 64					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	7 88%
2		0	0	0	1 12%
DAY 65					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	4 50%
2		0	0	0	4 50%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193

SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 66					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 67					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 68					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	5 62%
2		0	0	0	3 38%
DAY 69					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	7 88%
2		0	0	0	1 12%
DAY 70					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 71					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 72					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	5 62%
2		0	0	0	3 38%
DAY 73					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 74					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	1 12%	5 62%
2		0	0	0	3 38%
Diarrhea					
SEV					
1		0	0	1 12%	0
DAY 75					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	2 25%	5 62%
2		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 76					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 77					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 78					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	5 62%
2		0	0	0	3 38%
Vomit Seen In Run		0	0	0	1 12%
DAY 79					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	5 62%
2		0	0	0	3 38%
DAY 80					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	4 50%
2		0	0	0	4 50%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 81					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	4 50%
2		0	0	0	4 50%
DAY 82					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	2 25%	5 62%
2		0	0	0	3 38%
DAY 83					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	5 62%
2		0	0	0	3 38%
DAY 84					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	6 75%	0
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	5 62%
2		0	0	0	3 38%
Vomit Seen In Run		0	1 12%	0	0

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 85					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	8 100%
DAY 86					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 87					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 88					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 89					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
2		0	0	0	2 25%
DAY 90					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	4 50%
2		0	0	0	4 50%
DAY 91					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Tongue					
SEV					
1		0	0	0	4 50%
2		0	0	0	4 50%
DAY 92					
No. Observed		8	8	8	8
Scheduled Sacrifice		4 50%	4 50%	4 50%	4 50%
Normal		4 50%	4 50%	3 38%	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	0
2		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 93					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	0
Blue Tongue					
SEV					
1		0	0	0	1 25%
2		0	0	0	3 75%
DAY 94					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Gums					
SEV					
1		0	0	0	2 50%
Blue Sclera					
SEV					
1		0	0	0	1 25%
Blue Tongue					
SEV					
1		0	0	0	3 75%
DAY 95					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Tongue					
SEV					
1		0	0	0	3 75%
DAY 96					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	3 75%	0
Blue Tongue					
SEV					
1		0	0	1 25%	4 100%
DAY 97					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	3 75%	0
Blue Tongue					
SEV					
1		0	0	1 25%	4 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 98					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	0
Blue Tongue					
SEV					
1		0	0	0	4 100%
DAY 99					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Tongue					
SEV					
1		0	0	0	3 75%
DAY 100					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	2 50%
Blue Tongue					
SEV					
1		0	0	0	2 50%
DAY 101					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	2 50%
Blue Tongue					
SEV					
1		0	0	0	2 50%
DAY 102					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Tongue					
SEV					
1		0	0	0	3 75%
DAY 103					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Tongue					
SEV					
1		0	0	0	3 75%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 104					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	2 50%
Blue Tongue					
SEV					
1		0	0	0	2 50%
DAY 105					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 106					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 107					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 108					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 109					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 110					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV					
1		0	0	0	1 25%
DAY 111					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV					
1		0	0	0	1 25%
DAY 112					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV					
1		0	0	0	1 25%
DAY 113					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV					
1		0	0	0	1 25%
DAY 114					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 115					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 116					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 117					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 118					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 119					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 120					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 121					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 122					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 123					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 124					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 125					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 126					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 127					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 128					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 129					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 130					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 131					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 132					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 133					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 134					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 135					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 136					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 137					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 138					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 139					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 140					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 141					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 142					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 143					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 144					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 145					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 146					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 147					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 148					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 149					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 150					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 151					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 152					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 153					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 154					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 155					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 156					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 157					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 158					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 159					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 160					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 161					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 162					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 163					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 164					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 - 0.3 2-M	0.3 3-M	1.0 4-M
DAY 165					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 166					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 167					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 168					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 169					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 170					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 171					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 172					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 173					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 174					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: MALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-M	0.1 2-M	0.3 3-M	1.0 4-M
DAY 175					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 176					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 177					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 178					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 179					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 180					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 181					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 182					
	No. Observed	4	4	4	4
	Normal	4 100%	4 100%	4 100%	4 100%
DAY 183					
	No. Observed	4	4	4	4
	Scheduled Sacrifice	4 100%	4 100%	4 100%	4 100%
DAY 184					
	No. Observed	0	0	0	0

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 - 0.3 2-F	0.3 3-F	1.0 4-F
DAY 1					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 2					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 3					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 4					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 5					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	8 100%
DAY 6					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	7 88%
Blue Tongue					
SEV					
1		0	0	0	1 12%
DAY 7					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	4 50%
Blue Tongue					
SEV					
1		0	0	0	4 50%
DAY 8					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	4 50%
Blue Tongue					
SEV					
1		0	0	0	4 50%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 9					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	2 25%
Blue Tongue					
SEV					
1		0	0	0	6 75%
DAY 10					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	3 38%
Blue Tongue					
SEV					
1		0	0	0	5 62%
DAY 11					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	3 38%
Blue Tongue					
SEV					
1		0	0	0	5 62%
DAY 12					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	2 25%
Blue Tongue					
SEV					
1		0	0	0	6 75%
DAY 13					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	2 25%
Blue Tongue					
SEV					
1		0	0	0	6 75%
DAY 14					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	3 38%
Blue Tongue					
SEV					
1		0	0	0	5 62%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 15					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	3 38%
Blue Tongue					
SEV					
1		0	0	0	5 62%
DAY 16					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	7 88%
DAY 17					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	2 25%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	6 75%
DAY 18					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	3 38%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	5 62%
DAY 19					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	7 88%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 20					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	7 88%
DAY 21					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	2 25%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	6 75%
DAY 22					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	2 25%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
DAY 23					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	3 38%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	5 62%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 24					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	2 25%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
DAY 25					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	2 25%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
DAY 26					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	2 25%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
DAY 27					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	2 25%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	6 75%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 28					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
DAY 29					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	8 100%
DAY 30					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
DAY 31					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	8 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 32					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	8 100%
DAY 33					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	8 100%
DAY 34					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 35					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	4 50%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	4 50%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 36					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	4 50%	0
Blue Gums					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	4 50%	7 88%
2		0	0	0	1 12%
DAY 37					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Sclera					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	1 12%	6 75%
2		0	0	0	2 25%
DAY 38					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	4 50%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	4 50%	6 75%
2		0	0	0	2 25%
DAY 39					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	1 12%	2 25%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 40					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 41					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	1 12%	3 38%	7 88%
2		0	0	0	1 12%
DAY 42					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 43					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%
DAY 44					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 45					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%
DAY 46					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%
DAY 47					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 48					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	D	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%
DAY 49					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 50					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 51					
No. Observed		8	8	8	8
Normal		8 100%	7 88%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%
Vomit Seen In Run		D	1 12%	D	0

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 52					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	3 38%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	5 62%	7 88%
2		0	0	0	1 12%
DAY 53					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	3 38%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	5 62%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 54					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%
DAY 55					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 56					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 57					
	No. Observed	8	8	8	8
	Normal	8 100%	8 100%	6 75%	0
	Blue Gums				
	SEV				
	1	0	0	0	1 12%
	Blue Sclera				
	SEV				
	1	0	0	0	2 25%
	Blue Tongue				
	SEV				
	1	0	0	2 25%	7 88%
	2	0	0	0	1 12%
DAY 58					
	No. Observed	8	8	8	8
	Normal	7 88%	8 100%	7 88%	0
	Blue Gums				
	SEV				
	1	0	0	0	1 12%
	Blue Sclera				
	SEV				
	1	0	0	0	1 12%
	Blue Tongue				
	SEV				
	1	0	0	1 12%	7 88%
	2	0	0	0	1 12%
	Vomit Seen In Run	1 12%	0	0	0
DAY 59					
	No. Observed	8	8	8	8
	Normal	8 100%	8 100%	4 50%	0
	Blue Gums				
	SEV				
	1	0	0	0	1 12%
	Blue Sclera				
	SEV				
	1	0	0	0	1 12%
	Blue Tongue				
	SEV				
	1	0	0	4 50%	7 88%
	2	0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 60					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	4 50%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	4 50%	7 88%
2		0	0	0	1 12%
DAY 61					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 62					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	6 75%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 63					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%
DAY 64					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 65					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193

SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 66					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%
DAY 67					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	2 25%	7 88%
2		0	0	0	1 12%
DAY 68					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	3 38%
Blue Tongue					
SEV					
1		0	0	2 25%	6 75%
2		0	0	0	2 25%
DAY 69					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Tongue					
SEV					
1		0	0	2 25%	6 75%
2		0	0	0	2 25%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 - 0.3 2-F	0.3 3-F	1.0 4-F
DAY 70					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	6 75%
2		0	0	0	2 25%
DAY 71					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	3 38%	6 75%
2		0	0	0	2 25%
DAY 72					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	4 50%
2		0	0	0	4 50%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 73					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Tongue					
SEV					
1		0	0	3 38%	7 88%
2		0	0	0	1 12%
DAY 74					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	5 62%	0
Blue Tongue					
SEV					
1		0	0	3 38%	6 75%
2		0	0	0	2 25%
DAY 75					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	4 50%	0
Blue Tongue					
SEV					
1		0	0	4 50%	6 75%
2		0	0	0	2 25%
DAY 76					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%
DAY 77					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 78					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	8 100%
DAY 79					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%
DAY 80					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	8 100%
DAY 81					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 82					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	6 75%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	2 25%	6 75%
2		0	0	0	2 25%
DAY 83					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	5 62%
2		0	0	0	3 38%
DAY 84					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	5 62%
2		0	0	0	3 38%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 85					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	8 100%
DAY 86					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	1 12%
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	1 12%
DAY 87					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 88					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	6 75%
2		0	0	0	2 25%
DAY 89					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	7 88%
2		0	0	0	1 12%
DAY 90					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Sclera					
SEV					
1		0	0	0	2 25%
Blue Tongue					
SEV					
1		0	0	0	7 88%
2		0	0	0	1 12%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 - 0.3 2-F	0.1 - 0.3 3-F	1.0 4-F
DAY 91					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	8 100%	0
Blue Sclera					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	8 100%
DAY 92					
No. Observed		8	8	8	8
Normal		8 100%	8 100%	7 88%	0
Blue Tongue					
SEV					
1		0	0	1 12%	7 88%
2		0	0	0	1 12%
DAY 93					
No. Observed		8	8	8	8
Scheduled Sacrifice		4 50%	4 50%	4 50%	4 50%
Normal		4 50%	4 50%	4 50%	0
Blue Gums					
SEV					
1		0	0	0	1 12%
Blue Tongue					
SEV					
1		0	0	0	3 38%
2		0	0	0	1 12%
DAY 94					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Gums					
SEV					
1		0	0	0	2 50%
Blue Tongue					
SEV					
1		0	0	0	2 50%
2		0	0	0	1 25%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 95					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Tongue					
SEV					
1		0	0	0	3 75%
DAY 96					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	0
Blue Tongue					
SEV					
1		0	0	0	4 100%
DAY 97					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	1 25%
Blue Tongue					
SEV					
1		0	0	0	3 75%
DAY 98					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	2 50%
Blue Tongue					
SEV					
1		0	0	0	2 50%
DAY 99					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue					
SEV					
1		0	0	0	1 25%
DAY 100					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 101					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 102					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 103					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 104					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 105					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 106					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
OAY 107					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 108					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 109					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 110					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 111					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 112					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 113					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	2 50%
Blue Tongue SEV 1		0	0	0	2 50%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 114					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	2 50%
Blue Tongue SEV 1		0	0	0	2 50%
DAY 115					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	2 50%
Blue Tongue SEV 1		0	0	0	2 50%
DAY 116					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 117					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 118					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	3 75%
Blue Tongue SEV 1		0	0	0	1 25%
DAY 119					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

SEVERITY CODES

Observation	Severity No.	Description
Blue Gums/ Blue Tongue/ Blue Sclera	1	Mild (easily seen, blue color)
	2	Severe (intense, harsh, blue-purple color)

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 120					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 121					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 122					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 123					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 124					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 125					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 126					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 127					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 128					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 129					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 130					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 131					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 132					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 133					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 134					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 135					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 136					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 137					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 138					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 139					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 140					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 141					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 142					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 143					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 144					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 145					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 146					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 147					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 148					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 149					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 150					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 151					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 152					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 153					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 154					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 155					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 156					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 157					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 158					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 159					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 160					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 161					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 162					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 163					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 164					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 165					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 166					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 167					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 168					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 169					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 170					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 171					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 172					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 173					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 174					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 175					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 176					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 177					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 178					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 179					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 180					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 181					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%

DRAFT

INCIDENCE OF OBSERVATIONS

STUDY: 193 SEX: FEMALE

PERIOD	DOSE:(mg/kg) GROUP:	0 1-F	0.1 2-F	0.3 3-F	1.0 4-F
DAY 182					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 183					
No. Observed		4	4	4	4
Normal		4 100%	4 100%	4 100%	4 100%
DAY 184					
No. Observed		4	4	4	4
Scheduled Sacrifice		4 100%	4 100%	4 100%	4 100%

DRAFT

APPENDIX D

Individual Body Weights and Body Weight Gains

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8656	10.3	10.1	10.3	10.5	10.4	10.1	10.4	10.3	10.4	10.4	10.2	10.6
8687	10.8	10.9	11.0	11.7	11.4	11.5	11.7	11.5	11.8	11.6	11.6	11.8
8669	11.8	11.8	12.1	12.1	11.5	12.2	12.4	12.3	12.4	12.5	12.3	12.9
8673	11.8	12.1	12.1	12.5	12.2	12.3	12.0	12.1	12.3	11.9	12.0	12.1
8667	10.0	10.4	10.5	10.5	10.5	10.6	10.7	10.5	10.5	10.5	10.6	10.6
8654	10.9	10.7	10.7	10.8	10.6	10.9	10.5	10.4	10.6	10.5	10.3	10.4
8680	11.6	12.0	12.1	12.1	12.2	12.4	12.4	12.3	12.5	12.4	12.2	12.7
8676	13.6	13.6	13.6	13.5	13.5	13.7	13.8	13.8	14.1	13.8	13.7	14.0
MEAN	11.4	11.5	11.6	11.7	11.5	11.7	11.7	11.7	11.8	11.7	11.6	11.9
S.D.	1.13	1.15	1.12	1.06	1.07	1.17	1.17	1.22	1.28	1.20	1.20	1.29
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8656	10.9	10.7	10.6	10.7	10.9	10.8
8687	11.5	11.6	11.6	11.6	11.3	11.3
8669	12.4	12.3	12.4	12.3	12.6	12.7
8673	12.3	12.3	12.4	12.4	12.4	12.0
8667	11.1	11.0	11.3	11.1	11.2	11.2
8654	10.5	10.4	10.6	10.3	10.2	10.1
8680	12.7	12.9	13.1	13.4	13.1	13.2
8676	14.0	14.2	14.4	14.5	14.4	14.5
MEAN	11.9	11.9	12.1	12.0	12.0	12.0
S.D.	1.15	1.26	1.30	1.41	1.37	1.43
N	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8685	10.4	10.5	10.5	10.6	10.7	10.4	10.6	10.5	10.6	10.1	10.2	10.5
8679	--	--	--	--	--	--	--	--	--	--	--	--
8663	11.5	11.7	11.9	12.0	11.8	12.0	12.1	12.0	12.0	12.1	12.0	12.2
8686	11.9	11.7	11.4	11.8	11.5	11.7	11.5	11.2	11.8	11.5	11.2	10.1
8665	10.7	10.8	10.8	10.8	10.7	10.9	10.9	10.9	10.9	10.9	11.0	11.2
8666	11.6	11.5	11.7	11.6	11.6	11.7	11.7	11.6	11.8	11.4	11.5	11.7
8655	11.8	11.8	11.7	11.8	11.8	11.7	11.9	11.7	11.7	11.9	11.9	12.1
8659	12.0	11.7	11.9	11.8	11.9	12.0	12.2	12.0	11.8	11.9	11.7	12.1
8677	12.0	12.2	12.6	12.5	12.7	12.7	12.7	12.5	12.8	12.9	12.7	13.2
MEAN	11.5	11.5	11.6	11.6	11.6	11.6	11.7	11.6	11.7	11.6	11.5	11.6
S.D.	0.61	0.56	0.66	0.62	0.66	0.70	0.69	0.65	0.67	0.84	0.75	1.00
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8685	10.4	10.1	10.3	10.3	10.4	10.4
8679	--	--	--	--	--	--
8663	12.5	12.4	12.6	12.5	12.6	12.6
8686	10.3	11.0	11.1	11.3	11.3	11.2
8665	11.1	11.1	11.3	10.7	11.3	11.4
8666	11.8	11.6	12.0	11.7	11.7	11.8
8655	12.0	11.7	12.4	12.2	12.2	12.0
8659	12.4	12.4	12.5	12.4	12.5	12.2
8677	13.4	13.2	13.4	13.4	13.6	13.6
MEAN	11.7	11.7	12.0	11.8	12.0	11.9
S.D.	1.08	0.97	0.99	1.02	0.99	0.96
N	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8674	10.3	9.8	9.7	9.9	10.1	10.2	10.4	10.5	10.8	10.7	10.7	10.8
8653	11.6	11.8	11.5	11.6	11.4	11.3	11.2	11.0	10.9	10.6	10.6	10.4
8660	11.7	11.8	11.8	11.9	11.9	11.9	11.9	12.0	11.9	12.0	12.0	12.0
8668	12.3	12.5	12.6	12.7	12.8	12.9	13.0	12.8	12.7	12.7	12.4	12.5
8682	10.8	10.4	10.4	10.6	10.2	9.8	10.1	9.8	10.0	9.4	9.3	9.2
8684	10.6	10.9	11.1	11.1	10.9	11.1	11.2	11.2	11.1	11.0	11.1	11.3
8662	11.6	11.8	11.7	12.1	11.5	11.5	11.5	11.4	11.5	11.1	10.8	10.6
8688	12.2	12.4	12.5	12.5	12.6	12.9	13.1	12.9	13.1	13.1	12.7	13.1
MEAN	11.4	11.4	11.4	11.6	11.4	11.5	11.6	11.5	11.5	11.3	11.2	11.2
S.D.	0.74	0.96	0.99	0.96	1.00	1.12	1.09	1.08	1.03	1.21	1.12	1.26
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8674	10.8	10.7	10.8	10.8	11.0	10.6
8653	10.3	10.0	9.6	9.2	8.9	8.8
8660	12.1	11.9	12.2	12.1	12.1	12.0
8668	12.4	12.3	12.5	12.1	12.1	10.2
8682	9.2	9.2	9.3	9.1	9.0	9.0
8684	11.2	11.1	11.2	11.3	11.4	11.3
8662	10.9	10.4	10.6	10.3	10.4	10.4
8688	13.4	13.5	13.5	13.4	13.6	13.4
MEAN	11.3	11.1	11.2	11.0	11.1	10.7
S.D.	1.31	1.38	1.45	1.49	1.61	1.52
N	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8661	11.0	10.6	10.9	10.8	10.7	10.8	10.8	10.6	10.6	10.3	10.2	10.3
8670	10.6	10.6	10.5	10.7	10.3	10.3	10.3	10.3	10.3	10.1	10.1	10.2
8681	11.6	12.0	12.0	12.2	11.8	12.0	11.8	11.8	12.1	11.8	11.8	12.0
8664	12.0	12.2	12.2	12.3	11.9	11.9	11.7	11.5	11.3	10.9	10.7	11.2
8675	10.3	10.5	10.4	10.6	10.4	10.4	10.5	10.3	10.5	10.2	10.3	10.6
8683	10.9	11.3	11.4	11.0	10.9	10.8	10.9	10.9	10.9	10.9	11.0	11.5
8658	11.5	11.3	11.4	11.3	10.9	10.8	10.8	10.6	10.6	10.4	10.3	10.3
8652	12.5	12.5	12.5	12.3	12.3	12.2	12.3	12.0	11.9	12.0	11.9	11.6
MEAN	11.3	11.4	11.4	11.4	11.2	11.2	11.1	11.0	11.0	10.8	10.8	11.0
S.D.	0.74	0.79	0.78	0.75	0.75	0.76	0.71	0.68	0.67	0.73	0.72	0.70
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8661	10.7	10.6	10.6	10.5	10.5	10.4
8670	10.3	10.3	10.3	10.2	9.8	9.8
8681	12.0	12.1	12.4	12.1	12.0	12.0
8664	11.2	11.3	11.2	11.1	11.2	11.3
8675	10.1	10.0	10.0	9.9	10.0	10.0
8683	11.4	11.3	11.5	11.5	11.7	11.3
8658	10.7	10.7	10.8	10.6	10.5	10.6
8652	11.9	11.8	12.0	11.9	12.0	11.9
MEAN	11.0	11.0	11.1	11.0	11.0	10.9
S.D.	0.70	0.73	0.83	0.80	0.88	0.84
N	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8721	8.5	8.7	8.7	8.8	8.8	8.7	9.0	8.9	8.7	8.5	8.6	8.7
8712	9.6	9.4	9.5	9.3	9.5	9.8	9.9	9.5	9.3	9.4	9.3	9.7
8710	10.0	10.0	10.3	10.5	10.6	10.4	10.6	10.4	10.6	10.6	10.7	10.9
8723	10.8	10.9	10.8	10.7	10.6	10.8	11.0	10.7	10.7	10.7	11.1	11.1
8705	8.6	8.7	8.9	8.8	8.9	8.7	9.0	9.0	8.9	9.2	9.3	9.5
8700	10.1	10.0	10.2	10.2	10.1	9.9	10.2	9.8	10.3	10.2	10.1	10.2
8699	10.4	10.5	10.5	10.7	10.4	10.7	10.9	10.8	10.6	10.6	10.6	10.8
8690	10.3	10.9	11.0	11.0	10.8	10.7	10.6	10.5	10.5	10.4	10.6	10.5
MEAN	9.8	9.9	10.0	10.0	10.0	10.0	10.2	10.0	10.0	10.0	10.0	10.2
S.D.	0.84	0.89	0.86	0.90	0.79	0.86	0.79	0.76	0.84	0.81	0.87	0.82
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8721	8.7	8.5	8.4	8.8	8.8	8.9
8712	10.2	9.9	10.2	10.3	10.3	10.2
8710	11.3	11.0	11.2	11.1	11.3	11.2
8723	10.7	10.9	10.5	10.6	10.7	11.2
8705	9.3	8.8	9.0	9.0	9.1	8.8
8700	10.0	9.9	10.0	9.9	9.9	9.7
8699	10.9	10.8	10.7	10.9	10.8	11.0
8690	10.9	10.7	10.9	10.9	11.0	11.0
MEAN	10.3	10.1	10.1	10.2	10.2	10.3
S.D.	0.89	0.97	0.96	0.88	0.90	1.01
N	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8717	7.4	7.3	7.4	7.4	7.4	7.1	7.5	6.9	6.6	7.1	7.1	7.9
8703	9.6	9.7	9.7	10.0	9.8	9.8	10.1	9.5	9.8	9.4	9.5	9.5
8713	10.5	10.4	10.3	10.7	10.5	10.7	10.7	10.7	10.9	10.6	10.4	10.6
8693	11.3	11.0	11.0	11.2	11.1	11.3	11.4	11.1	11.4	11.1	11.3	11.7
8695	8.3	8.3	8.2	8.4	8.3	8.6	8.2	8.5	8.5	8.6	8.7	8.8
8709	9.5	9.4	9.3	9.5	9.1	9.2	9.3	9.4	9.2	9.2	9.2	9.4
8715	10.3	10.1	10.3	10.6	10.6	10.4	10.6	10.3	10.3	10.2	10.4	10.9
8697	10.9	11.2	11.5	11.4	11.4	11.3	11.6	11.6	11.6	11.6	11.8	11.8
MEAN	9.7	9.7	9.7	9.9	9.8	9.8	9.9	9.8	9.8	9.7	9.8	10.1
S.D.	1.33	1.33	1.38	1.40	1.41	1.45	1.48	1.53	1.67	1.46	1.51	1.40
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8717	7.6	7.9	8.2	8.3	8.3	8.7
8703	9.6	9.4	9.3	9.2	9.3	8.9
8713	11.0	11.0	11.2	11.2	10.8	11.2
8693	11.7	12.0	12.2	11.8	11.9	11.9
8695	8.7	8.6	8.7	8.8	8.7	8.9
8709	9.7	9.3	9.3	9.3	9.6	9.7
8715	10.8	10.8	11.0	10.7	10.8	10.8
8697	12.0	12.4	12.3	12.5	12.6	12.5
MEAN	10.1	10.2	10.3	10.2	10.3	10.3
S.D.	1.52	1.62	1.60	1.53	1.53	1.48
N	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3(mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8692	8.7	8.6	8.5	8.5	8.3	7.9	8.1	8.0	8.1	7.9	7.9	8.0
8718	9.3	9.2	9.2	9.4	9.5	9.8	9.9	9.9	10.2	9.7	9.7	9.9
8706	10.4	10.7	10.7	10.7	10.5	10.5	10.6	10.6	10.8	10.6	10.6	10.6
8714	11.1	11.2	11.2	11.8	11.5	11.5	11.7	11.2	11.2	11.3	11.3	11.6
8701	9.0	8.9	8.9	9.1	9.0	9.0	9.1	8.8	8.9	8.8	8.6	8.9
8702	9.2	9.0	8.9	8.9	8.7	8.5	8.5	8.5	8.4	7.9	7.9	7.8
8720	10.3	10.3	10.3	10.1	10.4	10.3	10.3	10.4	10.3	10.4	10.0	10.4
8704	10.7	10.8	10.5	10.9	10.7	10.9	10.5	10.4	10.7	10.6	10.6	10.5
MEAN	9.8	9.8	9.8	9.9	9.8	9.8	9.8	9.7	9.8	9.7	9.6	9.7
S.D.	0.89	1.02	1.01	1.14	1.12	1.24	1.20	1.15	1.19	1.31	1.30	1.35
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3(mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8692	8.1	8.0	8.1	8.3	8.2	8.3
8718	10.2	10.1	10.0	9.9	9.6	9.7
8706	10.7	10.3	10.5	10.2	10.3	10.2
8714	11.8	11.7	11.7	12.0	12.0	12.2
8701	9.1	9.0	9.1	9.0	9.1	8.9
8702	8.0	7.8	7.9	7.9	7.8	7.6
8720	10.4	10.4	10.6	10.4	10.3	10.4
8704	10.4	10.3	10.7	10.7	10.8	10.9
MEAN	9.8	9.7	9.8	9.8	9.8	9.8
S.D.	1.33	1.33	1.34	1.35	1.38	1.48
N	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY -5	DAY 3	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8696	8.6	8.5	8.4	8.3	8.3	8.3	8.4	8.4	8.2	8.2	8.2	8.3
8719	9.3	9.4	9.4	9.5	9.4	9.3	9.5	8.9	9.3	9.3	9.2	9.2
8711	10.4	10.1	9.8	10.0	9.7	10.6	9.6	9.6	9.5	9.1	9.1	9.3
8716	10.4	10.3	10.2	10.3	10.1	9.8	10.0	9.9	9.8	9.6	9.8	10.0
8725	8.5	8.3	8.3	8.0	7.5	7.4	7.5	7.5	7.6	7.8	7.8	7.8
8707	9.7	9.7	9.4	9.5	9.1	9.3	9.2	9.2	9.3	9.1	9.1	9.4
8689	10.3	10.0	9.9	10.0	9.9	9.7	9.6	9.6	9.6	9.6	9.6	9.6
8722	10.9	10.4	10.1	9.8	9.7	9.4	9.5	9.4	9.3	9.4	9.5	9.4
MEAN	9.8	9.6	9.4	9.4	9.2	9.2	9.2	9.1	9.1	9.0	9.0	9.1
S.D.	0.89	0.80	0.73	0.83	0.89	0.98	0.82	0.79	0.76	0.66	0.69	0.72
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0(mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90
8696	8.3	8.3	8.1	8.4	8.4	8.3
8719	9.7	9.4	9.1	8.9	9.2	9.1
8711	9.6	9.4	9.6	9.8	9.8	9.7
8716	10.0	10.1	10.3	10.1	10.2	10.3
8725	7.9	8.0	7.9	7.8	7.8	7.8
8707	9.4	9.0	8.7	9.0	9.2	9.2
8689	9.7	9.6	9.7	9.9	9.6	9.5
8722	9.4	9.2	9.2	9.0	8.8	8.8
MEAN	9.3	9.1	9.1	9.1	9.1	9.1
S.D.	0.74	0.69	0.82	0.79	0.78	0.79
N	8	8	8	8	8	8

--: Data Unavailable

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8656	b	b	b	b	b	b	b	b	b	b	b	b
8687	b	b	b	b	b	b	b	b	b	b	b	b
8669	b	b	b	b	b	b	b	b	b	b	b	b
8673	b	b	b	b	b	b	b	b	b	b	b	b
8667	11.2	11.4	11.3	11.5	11.3	11.5	11.5	11.2	11.1	11.1	11.1	11.3
8654	10.3	10.5	10.3	10.0	9.8	10.1	10.2	9.8	10.1	9.7	9.8	10.8
8680	12.9	13.2	12.7	13.2	13.4	13.4	13.4	13.3	13.2	13.4	13.6	13.9
8676	14.3	14.6	14.4	15.1	14.9	15.2	15.4	15.3	15.7	16.0	16.0	16.3
MEAN	12.2	12.4	12.2	12.5	12.4	12.6	12.6	12.4	12.5	12.6	12.6	13.1
S.D.	1.78	1.83	1.78	2.20	2.25	2.22	2.27	2.41	2.48	2.76	2.75	2.54
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1 (mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8685	b	b	b	b	b	b	b	b	b	b	b	b
8679	--	--	--	--	--	--	--	--	--	--	--	--
8663	b	b	b	b	b	b	b	b	b	b	b	b
8686	b	b	b	b	b	b	b	b	b	b	b	b
8665	11.4	11.6	11.3	11.8	11.6	11.9	11.9	11.8	11.8	11.7	11.9	12.2
8666	11.7	12.4	11.7	11.9	11.9	12.0	12.0	11.8	11.8	11.8	11.6	12.0
8655	11.8	12.0	11.7	12.2	12.0	12.1	12.2	11.9	11.7	12.0	12.2	12.6
8659	12.3	12.4	12.2	12.3	12.3	12.3	12.2	12.2	11.6	11.9	11.7	11.7
8677	b	b	b	b	b	b	b	b	b	b	b	b
MEAN	11.8	12.1	11.7	12.1	12.0	12.1	12.1	11.9	11.7	11.9	11.9	12.1
S.D.	0.37	0.38	0.37	0.24	0.29	0.17	0.15	0.19	0.10	0.13	0.26	0.38
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8674	10.7	10.9	10.7	10.8	10.8	10.7	10.5	10.3	10.4	10.4	10.5	10.8
8653	b	b	b	b	b	b	b	b	b	b	b	b
8660	b	b	b	b	b	b	b	b	b	b	b	b
8668	b	b	b	b	b	b	b	b	b	b	b	b
8682	8.8	9.1	8.7	8.5	8.9	9.1	9.1	9.0	9.2	9.3	9.3	9.6
8684	b	b	b	b	b	b	b	b	b	b	b	b
8662	10.5	10.7	10.8	10.9	10.8	10.9	11.0	10.8	11.0	11.1	10.7	11.1
8688	13.4	13.8	13.1	14.2	13.8	14.1	14.1	14.1	13.9	14.4	14.3	14.4
MEAN	10.9	11.1	10.8	11.1	11.1	11.2	11.2	11.1	11.1	11.3	11.2	11.5
S.D.	1.90	1.96	1.80	2.35	2.03	2.09	2.11	2.17	2.00	2.20	2.16	2.05
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8661	b	b	b	b	b	b	b	b	b	b	b	b
8670	b	b	b	b	b	b	b	b	b	b	b	b
8681	b	b	b	b	b	b	b	b	b	b	b	b
8664	b	b	b	b	b	b	b	b	b	b	b	b
8675	10.1	10.4	10.4	10.4	10.8	11.0	11.2	11.0	11.2	11.3	11.5	11.8
8683	11.3	11.8	11.5	11.9	11.9	12.2	12.0	11.9	12.0	12.4	12.5	12.4
8658	10.1	10.1	9.7	9.8	9.7	9.6	9.3	9.0	9.3	9.2	9.3	9.9
8652	11.8	12.1	11.7	12.4	12.3	12.5	12.3	12.3	12.4	12.6	12.7	13.4
MEAN	10.8	11.1	10.8	11.1	11.2	11.3	11.2	11.1	11.2	11.4	11.5	11.9
S.D.	0.86	1.00	0.94	1.23	1.17	1.32	1.35	1.47	1.38	1.56	1.56	1.47
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8721	b	b	b	b	b	b	b	b	b	b	b	b
8712	b	b	b	b	b	b	b	b	b	b	b	b
8710	b	b	b	b	b	b	b	b	b	b	b	b
8723	b	b	b	b	b	b	b	b	b	b	b	b
8705	8.9	9.1	8.9	9.1	8.8	8.9	9.0	9.0	9.3	9.5	9.8	9.4
8700	9.4	9.9	9.7	10.0	9.8	10.0	10.1	9.9	10.0	10.2	10.2	10.4
8699	10.9	10.9	11.0	11.0	11.2	11.5	11.0	10.7	10.8	11.1	11.4	11.0
8690	11.1	11.3	11.7	11.9	11.9	12.2	12.2	12.2	12.4	12.7	13.0	13.0
MEAN	10.1	10.3	10.3	10.5	10.4	10.7	10.6	10.5	10.6	10.9	11.1	11.0
S.D.	1.09	0.99	1.26	1.21	1.39	1.48	1.36	1.36	1.33	1.38	1.44	1.52
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8717	b	b	b	b	b	b	b	b	b	b	b	b
8703	b	b	b	b	b	b	b	b	b	b	b	b
8713	b	b	b	b	b	b	b	b	b	b	b	b
8693	b	b	b	b	b	b	b	b	b	b	b	b
8695	8.9	8.9	8.4	8.8	8.8	9.0	9.1	9.1	9.0	9.3	9.4	9.4
8709	9.5	9.7	9.7	9.6	9.6	9.9	10.1	9.8	9.8	9.8	9.8	10.1
8715	10.5	10.7	10.5	10.8	10.8	11.1	10.9	11.0	11.2	11.2	11.2	11.5
8697	12.4	12.5	12.4	12.5	12.4	12.3	12.6	12.6	12.5	13.0	13.0	12.9
MEAN	10.3	10.5	10.3	10.4	10.4	10.6	10.7	10.6	10.6	10.8	10.9	11.0
S.D.	1.53	1.55	1.67	1.61	1.57	1.44	1.48	1.53	1.55	1.66	1.63	1.55
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8692	b	b	b	b	b	b	b	b	b	b	b	b
8718	b	b	b	b	b	b	b	b	b	b	b	b
8706	b	b	b	b	b	b	b	b	b	b	b	b
8714	b	b	b	b	b	b	b	b	b	b	b	b
8701	8.8	8.9	8.4	8.9	8.7	8.7	8.3	8.5	8.5	8.6	8.8	9.1
8702	7.5	7.9	7.6	8.0	7.9	8.1	8.0	7.7	7.7	7.7	8.0	8.2
8720	10.3	10.5	10.4	10.7	10.5	10.7-	10.5	10.3	10.5	10.5	10.6	10.5
8704	10.7	10.8	10.7	10.9	10.8	11.2	11.4	11.2	11.1	11.4	11.4	11.7
MEAN	9.3	9.5	9.3	9.6	9.5	9.7	9.6	9.4	9.5	9.6	9.7	9.9
S.D.	1.47	1.37	1.51	1.41	1.40	1.51	1.66	1.61	1.61	1.70	1.57	1.54
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL BODY WEIGHTS (Kilograms)

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 97	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146	DAY 153	DAY 160	DAY 167	DAY 181
8696	b	b	b	b	b	b	b	b	b	b	b	b
8719	b	b	b	b	b	b	b	b	b	b	b	b
8711	b	b	b	b	b	b	b	b	b	b	b	b
8716	b	b	b	b	b	b	b	b	b	b	b	b
8725	7.9	8.3	8.0	8.0	7.9	8.1	8.0	7.9	8.0	7.9	7.9	8.2
8707	9.2	9.6	9.5	10.0	9.8	10.1	10.3	9.9	10.1	10.4	10.8	11.0
8689	9.3	9.7	9.6	9.8	9.7	9.4	9.5	9.6	9.3	9.5	9.6	10.1
8722	8.7	8.9	8.8	9.2	9.1	9.4	9.5	9.4	9.4	9.7	10.0	10.3
MEAN	8.8	9.1	9.0	9.3	9.1	9.3	9.3	9.2	9.2	9.4	9.6	9.9
S.D.	0.64	0.66	0.74	0.90	0.87	0.83	0.96	0.89	0.88	1.06	1.22	1.20
N	4	4	4	4	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8656	-0.2	0.2	0.2	-0.1	-0.3	0.3	-0.1	0.1	0.0	-0.2	0.4
8687	0.1	0.1	0.7	-0.3	0.1	0.2	-0.2	0.3	-0.2	0.0	0.2
8669	0.0	0.3	0.0	-0.6	0.7	0.2	-0.1	0.1	0.1	-0.2	0.6
8673	0.3	0.0	0.4	-0.3	0.1	-0.3	0.1	0.2	-0.4	0.1	0.1
8667	0.4	0.1	0.0	0.0	0.1	0.1	-0.2	0.0	0.0	0.1	0.0
8654	-0.2	0.0	0.1	-0.2	0.3	-0.4	-0.1	0.2	-0.1	-0.2	0.1
8680	0.4	0.1	0.0	0.1	0.2	0.0	-0.1	0.2	-0.1	-0.2	0.5
8676	0.0	0.0	-0.1	0.0	0.2	0.1	0.0	0.3	-0.3	-0.1	0.3
MEAN	0.1	0.1	0.2	-0.2	0.2	0.0	-0.1	0.2	-0.1	-0.1	0.3
S.D.	0.24	0.11	0.27	0.23	0.28	0.25	0.10	0.10	0.17	0.14	0.21
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period
[b]Baseline is day -5

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90 -	TOTAL GAIN
8656	0.3	-0.2	-0.1	0.1	0.2	-0.1	0.5
8687	-0.3	0.1	0.0	0.0	-0.3	0.0	0.5
8669	-0.5	-0.1	0.1	-0.1	0.3	0.1	0.9
8673	0.2	0.0	0.1	0.0	0.0	-0.4	0.2
8667	0.5	-0.1	0.3	-0.2	0.1	0.0	1.2
8654	0.1	-0.1	0.2	-0.3	-0.1	-0.1	-0.8
8680	0.0	0.2	0.2	0.3	-0.3	0.1	1.6
8676	0.0	0.2	0.2	0.1	-0.1	0.1	0.9
MEAN	0.0	0.0	0.1	0.0	0.0	0.0	0.6
S.D.	0.32	0.15	0.13	0.19	0.22	0.17	0.72
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8685	0.1	0.0	0.1	0.1	-0.3	0.2	-0.1	0.1	-0.5	0.1	0.3
8679	--	--	--	--	--	--	--	--	--	--	--
8663	0.2	0.2	0.1	-0.2	0.2	0.1	-0.1	0.0	0.1	-0.1	0.2
8686	-0.2	-0.3	0.4	-0.3	0.2	-0.2	-0.3	0.6	-0.3	-0.3	-1.1
8665	0.1	0.0	0.0	-0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.2
8666	-0.1	0.2	-0.1	0.0	0.1	0.0	-0.1	0.2	-0.4	0.1	0.2
8655	0.0	-0.1	0.1	0.0	-0.1	0.2	-0.2	0.0	0.2	0.0	0.2
8659	-0.3	0.2	-0.1	0.1	0.1	0.2	-0.2	-0.2	0.1	-0.2	0.4
8677	0.2	0.4	-0.1	0.2	0.0	0.0	-0.2	0.3	0.1	-0.2	0.5
MEAN	0.0	0.1	0.1	0.0	0.1	0.1	-0.2	0.1	-0.1	-0.1	0.1
S.D.	0.19	0.22	0.17	0.17	0.18	0.14	0.09	0.24	0.27	0.16	0.50
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a] Weight gains compared to the previous period
[b] Baseline is day -5

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN
8685	-0.1	-0.3	0.2	0.0	0.1	0.0	0.0
8679	--	--	--	--	--	--	--
8663	0.3	-0.1	0.2	-0.1	0.1	0.0	1.1
8686	0.2	0.7	0.1	0.2	0.0	-0.1	-0.7
8665	-0.1	0.0	0.2	-0.6	0.6	0.1	0.7
8666	0.1	-0.2	0.4	-0.3	0.0	0.1	0.2
8655	-0.1	-0.3	0.7	-0.2	0.0	-0.2	0.2
8659	0.3	0.0	0.1	-0.1	0.1	-0.3	0.2
8677	0.2	-0.2	0.2	0.0	0.2	0.0	1.6
MEAN	0.1	-0.1	0.3	-0.1	0.1	-0.1	0.4
S.D.	0.18	0.33	0.20	0.24	0.20	0.14	0.71
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8674	-0.5	-0.1	0.2	0.2	0.1	0.2	0.1	0.3	-0.1	0.0	0.1
8653	0.2	-0.3	0.1	-0.2	-0.1	-0.1	-0.2	-0.1	-0.3	0.0	-0.2
8660	0.1	0.0	0.1	0.0	0.0	0.0	0.1	-0.1	0.1	0.0	0.0
8668	0.2	0.1	0.1	0.1	0.1	0.1	-0.2	-0.1	0.0	-0.3	0.1
8682	-0.4	0.0	0.2	-0.4	-0.4	0.3	-0.3	0.2	-0.6	-0.1	-0.1
8684	0.3	0.2	0.0	-0.2	0.2	0.1	0.0	-0.1	-0.1	0.1	0.2
8662	0.2	-0.1	0.4	-0.6	0.0	0.0	-0.1	0.1	-0.4	-0.3	-0.2
8688	0.2	0.1	0.0	0.1	0.3	0.2	-0.2	0.2	0.0	-0.4	0.4
MEAN	0.0	0.0	0.1	-0.1	0.0	0.1	-0.1	0.1	-0.2	-0.1	0.0
S.D.	0.31	0.16	0.13	0.28	0.21	0.13	0.15	0.17	0.24	0.18	0.21
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a] Weight gains compared to the previous period
[b] Baseline is day -5

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN
8674	0.0	-0.1	0.1	0.0	0.2	-0.4	0.3
8653	-0.1	-0.3	-0.4	-0.4	-0.3	-0.1	-2.8
8660	0.1	-0.2	0.3	-0.1	0.0	-0.1	0.3
8668	-0.1	-0.1	0.2	-0.4	0.0	-1.9	-2.1
8682	0.0	0.0	0.1	-0.2	-0.1	0.0	-1.8
8684	-0.1	-0.1	0.1	0.1	0.1	-0.1	0.7
8662	0.3	-0.5	0.2	-0.3	0.1	0.0	-1.2
8688	0.3	0.1	0.0	-0.1	0.2	-0.2	1.2
MEAN	0.1	-0.2	0.1	-0.2	0.0	-0.4	-0.7
S.D.	0.17	0.19	0.21	0.18	0.17	0.64	1.48
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8661	-0.4	0.3	-0.1	-0.1	0.1	0.0	-0.2	0.0	-0.3	-0.1	0.1
8670	0.0	-0.1	0.2	-0.4	0.0	0.0	0.0	0.0	-0.2	0.0	0.1
8681	0.4	0.0	0.2	-0.4	0.2	-0.2	0.0	0.3	-0.3	0.0	0.2
8664	0.2	0.0	0.1	-0.4	0.0	-0.2	-0.2	-0.2	-0.4	-0.2	0.5
8675	0.2	-0.1	0.2	-0.2	0.0	0.1	-0.2	0.2	-0.3	0.1	0.3
8683	0.4	0.1	-0.4	-0.1	-0.1	0.1	0.0	0.0	0.0	0.1	0.5
8658	-0.2	0.1	-0.1	-0.4	-0.1	0.0	-0.2	0.0	-0.2	-0.1	0.0
8652	0.0	0.0	-0.2	0.0	-0.1	0.1	-0.3	-0.1	0.1	-0.1	-0.3
MEAN	0.1	0.0	0.0	-0.3	0.0	0.0	-0.1	0.0	-0.2	0.0	0.2
S.D.	0.28	0.13	0.22	0.17	0.11	0.12	0.12	0.16	0.17	0.11	0.27
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a] Weight gains compared to the previous period
[b] Baseline is day -5

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90 -	TOTAL GAIN
8661	0.4	-0.1	0.0	-0.1	0.0	-0.1	-0.6
8670	0.1	0.0	0.0	-0.1	-0.4	0.0	-0.8
8681	0.0	0.1	0.3	-0.3	-0.1	0.0	0.4
8664	0.0	0.1	-0.1	-0.1	0.1	0.1	-0.7
8675	-0.5	-0.1	0.0	-0.1	0.1	0.0	-0.3
8683	-0.1	-0.1	0.2	0.0	0.2	-0.4	0.4
8658	0.4	0.0	0.1	-0.2	-0.1	0.1	-0.9
8652	0.3	-0.1	0.2	-0.1	0.1	-0.1	-0.6
MEAN	0.1	0.0	0.1	-0.1	0.0	-0.1	-0.4
S.D.	0.30	0.09	0.14	0.09	0.19	0.16	0.52
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8721	0.2	0.0	0.1	0.0	-0.1	0.3	-0.1	-0.2	-0.2	0.1	0.1
8712	-0.2	0.1	-0.2	0.2	0.3	0.1	-0.4	-0.2	0.1	-0.1	0.4
8710	0.0	0.3	0.2	0.1	-0.2	0.2	-0.2	0.2	0.0	0.1	0.2
8723	0.1	-0.1	-0.1	-0.1	0.2	0.2	-0.3	0.0	0.0	0.4	0.0
8705	0.1	0.2	-0.1	0.1	-0.2	0.3	0.0	-0.1	0.3	0.1	0.2
8700	-0.1	0.2	0.0	-0.1	-0.2	0.3	-0.4	0.5	-0.1	-0.1	0.1
8699	0.1	0.0	0.2	-0.3	0.3	0.2	-0.1	-0.2	0.0	0.0	0.2
8690	0.6	0.1	0.0	-0.2	-0.1	-0.1	-0.1	0.0	-0.1	0.2	-0.1
MEAN	0.1	0.1	0.0	0.0	0.0	0.2	-0.2	0.0	0.0	0.1	0.1
S.D.	0.24	0.13	0.15	0.17	0.23	0.14	0.15	0.24	0.15	0.16	0.15
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period
[b]Baseline is day -5

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN
8721	0.0	-0.2	-0.1	0.4	0.0	0.1	0.4
8712	0.5	-0.3	0.3	0.1	0.0	-0.1	0.6
8710	0.4	-0.3	0.2	-0.1	0.2	-0.1	1.2
8723	-0.4	0.2	-0.4	0.1	0.1	0.5	0.4
8705	-0.2	-0.5	0.2	0.0	0.1	-0.3	0.2
8700	-0.2	-0.1	0.1	-0.1	0.0	-0.2	-0.4
8699	0.1	-0.1	-0.1	0.2	-0.1	0.2	0.6
8690	0.4	-0.2	0.2	0.0	0.1	0.0	0.7
MEAN	0.1	-0.2	0.1	0.1	0.1	0.0	0.5
S.D.	0.33	0.20	0.23	0.17	0.09	0.25	0.46
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1 (mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8717	-0.1	0.1	0.0	0.0	-0.3	0.4	-0.6	-0.3	0.5	0.0	0.8
8703	0.1	0.0	0.3	-0.2	0.0	0.3	-0.6	0.3	-0.4	0.1	0.0
8713	-0.1	-0.1	0.4	-0.2	0.2	0.0	0.0	0.2	-0.3	-0.2	0.2
8693	-0.3	0.0	0.2	-0.1	0.2	0.1	-0.3	0.3	-0.3	0.2	0.4
8695	0.0	-0.1	0.2	-0.1	0.3	-0.4	0.3	0.0	0.1	0.1	0.1
8709	-0.1	-0.1	0.2	-0.4	0.1	0.1	0.1	-0.2	0.0	0.0	0.2
8715	-0.2	0.2	0.3	0.0	-0.2	0.2	-0.3	0.0	-0.1	0.2	0.5
8697	0.3	0.3	-0.1	0.0	-0.1	0.3	0.0	0.0	0.0	0.2	0.0
MEAN	-0.1	0.0	0.2	-0.1	0.0	0.1	-0.2	0.0	-0.1	0.1	0.3
S.D.	0.19	0.15	0.16	0.14	0.21	0.25	0.33	0.22	0.29	0.14	0.28
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a] Weight gains compared to the previous period
[b] Baseline is day -5

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN
8717	-0.3	0.3	0.3	0.1	0.0	0.4	1.3
8703	0.1	-0.2	-0.1	-0.1	0.1	-0.4	-0.7
8713	0.4	0.0	0.2	0.0	-0.4	0.4	0.7
8693	0.0	0.3	0.2	-0.4	0.1	0.0	0.6
8695	-0.1	-0.1	0.1	0.1	-0.1	0.2	0.6
8709	0.3	-0.4	0.0	0.0	0.3	0.1	0.2
8715	-0.1	0.0	0.2	-0.3	0.1	0.0	0.5
8697	0.2	0.4	-0.1	0.2	0.1	-0.1	1.6
MEAN	0.1	0.0	0.1	-0.1	0.0	0.1	0.6
S.D.	0.23	0.28	0.15	0.21	0.21	0.27	0.69
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8692	-0.1	-0.1	0.0	-0.2	-0.4	0.2	-0.1	0.1	-0.2	0.0	0.1
8718	-0.1	0.0	0.2	0.1	0.3	0.1	0.0	0.3	-0.5	0.0	0.2
8706	0.3	0.0	0.0	-0.2	0.0	0.1	0.0	0.2	-0.2	0.0	0.0
8714	0.1	0.0	0.6	-0.3	0.0	-0.2	-0.5	0.0	0.1	0.0	0.3
8701	-0.1	0.0	0.2	-0.1	0.0	0.1	-0.3	0.1	-0.1	-0.2	0.3
8702	-0.2	-0.1	0.0	-0.2	-0.2	0.0	0.0	-0.1	-0.5	0.0	-0.1
8720	0.0	0.0	-0.2	0.3	-0.1	0.0	0.1	-0.1	0.1	-0.4	0.4
8704	0.1	-0.3	0.4	-0.2	0.2	-0.4	-0.1	0.3	-0.1	0.0	-0.1
MEAN	0.0	-0.1	0.2	-0.1	0.0	0.0	-0.1	0.1	-0.2	-0.1	0.1
S.D.	0.16	0.11	0.26	0.20	0.22	0.19	0.20	0.16	0.23	0.15	0.19
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period
[b]Baseline is day -5

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN
8692	0.1	-0.1	0.1	0.2	-0.1	0.1	-0.4
8718	0.3	-0.1	-0.1	-0.1	-0.3	0.1	0.4
8706	0.1	-0.4	0.2	-0.3	0.1	-0.1	-0.2
8714	0.2	-0.1	0.0	0.3	0.0	0.2	1.1
8701	0.2	-0.1	0.1	-0.1	0.1	-0.2	-0.1
8702	0.2	-0.2	0.1	0.0	-0.1	-0.2	-1.6
8720	0.0	0.0	0.2	-0.2	-0.1	0.1	0.1
8704	-0.1	-0.1	0.4	0.0	0.1	0.1	0.2
MEAN	0.1	-0.1	0.1	0.0	0.0	0.0	-0.1
S.D.	0.13	0.12	0.15	0.20	0.14	0.16	0.77
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 3[b]	DAY 7	DAY 10	DAY 14	DAY 17	DAY 21	DAY 24	DAY 28	DAY 34	DAY 41	DAY 48
8696	-0.1	-0.1	-0.1	0.0	0.0	0.1	0.0	-0.2	0.0	0.0	0.1
8719	0.1	0.0	0.1	-0.1	-0.1	0.2	-0.6	0.4	0.0	-0.1	0.0
8711	-0.3	-0.3	0.2	-0.3	0.9	-1.0	0.0	-0.1	-0.4	0.0	0.2
8716	-0.1	-0.1	0.1	-0.2	-0.3	0.2	-0.1	-0.1	-0.2	0.2	0.2
8725	-0.2	0.0	-0.3	-0.5	-0.1	0.1	0.0	0.1	0.2	0.0	0.0
8707	0.0	-0.3	0.1	-0.4	0.2	-0.1	0.0	0.1	-0.2	0.0	0.3
8689	-0.3	-0.1	0.1	-0.1	-0.2	-0.1	0.0	0.0	0.0	0.0	0.0
8722	-0.5	-0.3	-0.3	-0.1	-0.3	0.1	-0.1	-0.1	0.1	0.1	-0.1
MEAN	-0.2	-0.2	0.0	-0.2	0.0	-0.1	-0.1	0.0	-0.1	0.0	0.1
S.D.	0.19	0.13	0.20	0.17	0.39	0.40	0.21	0.19	0.19	0.09	0.14
N	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

[a] Weight gains compared to the previous period
[b] Baseline is day -5

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 54	DAY 62	DAY 69	DAY 76	DAY 83	DAY 90	TOTAL GAIN
8696	0.0	0.0	-0.2	0.3	0.0	-0.1	-0.3
8719	0.5	-0.3	-0.3	-0.2	0.3	-0.1	-0.2
8711	0.3	-0.2	0.2	0.2	0.0	-0.1	-0.7
8716	0.0	0.1	0.2	-0.2	0.1	0.1	-0.1
8725	0.1	0.1	-0.1	-0.1	0.0	0.0	-0.7
8707	0.0	-0.4	-0.3	0.3	0.2	0.0	-0.5
8689	0.1	-0.1	0.1	0.2	-0.3	-0.1	-0.8
8722	0.0	-0.2	0.0	-0.2	-0.2	0.0	-2.1
MEAN	0.1	-0.1	-0.1	0.0	0.0	0.0	-0.7
S.D.	0.18	0.18	0.21	0.23	0.20	0.07	0.63
N	8	8	8	8	8	8	8

--: Data Unavailable

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms) [a]

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 97 [c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8656	b	b	b	b	b	b	b	b
8687	b	b	b	b	b	b	b	b
8669	b	b	b	b	b	b	b	b
8673	b	b	b	b	b	b	b	b
8667	0.0	0.2	-0.1	0.2	-0.2	0.2	0.0	-0.3
8654	0.2	0.2	-0.2	-0.3	-0.2	0.3	0.1	-0.4
8680	-0.3	0.3	-0.5	0.5	0.2	0.0	0.0	-0.1
8676	-0.2	0.3	-0.2	0.7	-0.2	0.3	0.2	-0.1
MEAN	-0.1	0.3	-0.3	0.3	-0.1	0.2	0.1	-0.2
S.D.	0.22	0.06	0.17	0.43	0.20	0.14	0.10	0.15
N	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a] Weight gains compared to the previous period

[c] Baseline is day 90

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8656	b	b	b	b	--
8687	b	b	b	b	--
8669	b	b	b	b	--
8673	b	b	b	b	--
8667	-0.1	0.0	0.0	0.2	0.1
8654	0.3	-0.4	0.1	1.0	0.7
8680	-0.1	0.2	0.2	0.3	0.7
8676	0.4	0.3	0.0	0.3	1.8
MEAN	0.1	0.0	0.1	0.5	0.8
S.D.	0.26	0.31	0.10	0.37	0.71
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 97[c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8685	b	b	b	b	b	b	b	b
8679	--	--	--	--	--	--	--	--
8663	b	b	b	b	b	b	b	b
8686	b	b	b	b	b	b	b	b
8665	0.0	0.2	-0.3	0.5	-0.2	0.3	0.0	-0.1
8666	-0.1	0.7	-0.7	0.2	0.0	0.1	0.0	-0.2
8655	-0.2	0.2	-0.3	0.5	-0.2	0.1	0.1	-0.3
8659	0.1	0.1	-0.2	0.1	0.0	0.0	-0.1	0.0
8677	b	b	b	b	b	b	b	b
MEAN	-0.1	0.3	-0.4	0.3	-0.1	0.1	0.0	-0.2
S.D.	0.13	0.27	0.22	0.21	0.12	0.13	0.08	0.13
N	4	4	4	4	4	4	4	4

'--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

[c]Baseline is day 90

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms) [a]

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8685	b	b	b	b	--
8679	--	--	--	--	--
8663	b	b	b	b	--
8686	b	b	b	b	--
8665	0.0	-0.1	0.2	0.3	0.8
8666	0.0	0.0	-0.2	0.4	0.2
8655	-0.2	0.3	0.2	0.4	0.6
8659	-0.6	0.3	-0.2	0.0	-0.5
8677	b	b	b	b	--
MEAN	-0.2	0.1	0.0	0.3	0.3
S.D.	0.28	0.21	0.23	0.19	0.57
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 97[c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8674	0.1	0.2	-0.2	0.1	0.0	-0.1	-0.2	-0.2
8653	b	b	b	b	b	b	b	b
8660	b	b	b	b	b	b	b	b
8668	b	b	b	b	b	b	b	b
8682	-0.2	0.3	-0.4	-0.2	0.4	0.2	0.0	-0.1
8684	b	b	b	b	b	b	b	b
8662	0.1	0.2	0.1	0.1	-0.1	0.1	0.1	-0.2
8688	0.0	0.4	-0.7	1.1	-0.4	0.3	0.0	0.0
MEAN	0.0	0.3	-0.3	0.3	0.0	0.1	0.0	-0.1
S.D.	0.14	0.10	0.34	0.57	0.33	0.17	0.13	0.10
N	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

[c]Baseline is day 90

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8674	0.1	0.0	0.1	0.3	0.2
8653	b	b	b	b	--
8660	b	b	b	b	--
8668	b	b	b	b	--
8682	0.2	0.1	0.0	0.3	0.6
8684	b	b	b	b	--
8662	0.2	0.1	-0.4	0.4	0.7
8688	-0.2	0.5	-0.1	0.1	1.0
MEAN	0.1	0.2	-0.1	0.3	0.6
S.D.	0.19	0.22	0.22	0.13	0.33
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms) [a]

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 97 [c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8661	b	b	b	b	b	b	b	b
8670	b	b	b	b	b	b	b	b
8681	b	b	b	b	b	b	b	b
8664	b	b	b	b	b	b	b	b
8675	0.1	0.3	0.0	0.0	0.4	0.2	0.2	-0.2
8683	0.0	0.5	-0.3	0.4	0.0	0.3	-0.2	-0.1
8658	-0.5	0.0	-0.4	0.1	-0.1	-0.1	-0.3	-0.3
8652	-0.1	0.3	-0.4	0.7	-0.1	0.2	-0.2	0.0
MEAN	-0.1	0.3	-0.3	0.3	0.1	0.2	-0.1	-0.2
S.D.	0.26	0.21	0.19	0.32	0.24	0.17	0.22	0.13
N	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a] Weight gains compared to the previous period

[c] Baseline is day 90

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8661	b	b	b	b	--
8670	b	b	b	b	--
8681	b	b	b	b	--
8664	b	b	b	b	--
8675	0.2	0.1	0.2	0.3	1.8
8683	0.1	0.4	0.1	-0.1	1.1
8658	0.3	-0.1	0.1	0.6	-0.7
8652	0.1	0.2	0.1	0.7	1.5
MEAN	0.2	0.2	0.1	0.4	0.9
S.D.	0.10	0.21	0.05	0.36	1.12
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 97[c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8721	b	b	b	b	b	b	b	b
8712	b	b	b	b	b	b	b	b
8710	b	b	b	b	b	b	b	b
8723	b	b	b	b	b	b	b	b
8705	0.1	0.2	-0.2	0.2	-0.3	0.1	0.1	0.0
8700	-0.3	0.5	-0.2	0.3	-0.2	0.2	0.1	-0.2
8699	-0.1	0.0	0.1	0.0	0.2	0.3	-0.5	-0.3
8690	0.1	0.2	0.4	0.2	0.0	0.3	0.0	0.0
MEAN	-0.1	0.2	0.0	0.2	-0.1	0.2	-0.1	-0.1
S.D.	0.19	0.21	0.29	0.13	0.22	0.10	0.29	0.15
N	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

[c]Baseline is day 90

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8721	b	b	b	b	--
8712	b	b	b	b	--
8710	b	b	b	b	--
8723	b	b	b	b	--
8705	0.3	0.2	0.3	-0.4	0.6
8700	0.1	0.2	0.0	0.2	0.7
8699	0.1	0.3	0.3	-0.4	0.0
8690	0.2	0.3	0.3	0.0	2.0
MEAN	0.2	0.3	0.2	-0.2	0.8
S.D.	0.10	0.06	0.15	0.30	0.84
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 97[c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8717	b	b	b	b	b	b	b	b
8703	b	b	b	b	b	b	b	b
8713	b	b	b	b	b	b	b	b
8693	b	b	b	b	b	b	b	b
8695	0.0	0.0	-0.5	0.4	0.0	0.2	0.1	0.0
8709	-0.2	0.2	0.0	-0.1	0.0	0.3	0.2	-0.3
8715	-0.3	0.2	-0.2	0.3	0.0	0.3	-0.2	0.1
8697	-0.1	0.1	-0.1	0.1	-0.1	-0.1	0.3	0.0
MEAN	-0.2	0.1	-0.2	0.2	0.0	0.2	0.1	-0.1
S.D.	0.13	0.10	0.22	0.22	0.05	0.19	0.22	0.17
N	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

[c]Baseline is day 90

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8717	b	b	b	b	--
8703	b	b	b	b	--
8713	b	b	b	b	--
8693	b	b	b	b	--
8695	-0.1	0.3	0.1	0.0	0.5
8709	0.0	0.0	0.0	0.3	0.4
8715	0.2	0.0	0.0	0.3	0.7
8697	-0.1	0.5	0.0	-0.1	0.4
MEAN	0.0	0.2	0.0	0.1	0.5
S.D.	0.14	0.24	0.05	0.21	0.14
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms) [a]

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 97[c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8692	b	b	b	b	b	b	b	b
8718	b	b	b	b	b	b	b	b
8706	b	b	b	b	b	b	b	b
8714	b	b	b	b	b	b	b	b
8701	-0.1	0.1	-0.5	0.5	-0.2	0.0	-0.4	0.2
8702	-0.1	0.4	-0.3	0.4	-0.1	0.2	-0.1	-0.3
8720	-0.1	0.2	-0.1	0.3	-0.2	0.2	-0.2	-0.2
8704	-0.2	0.1	-0.1	0.2	-0.1	0.4	0.2	-0.2
MEAN	-0.1	0.2	-0.3	0.4	-0.2	0.2	-0.1	-0.1
S.D.	0.05	0.14	0.19	0.13	0.06	0.16	0.25	0.22
N	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

[c]Baseline is day 90

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8692	b	b	b	b	--
8718	b	b	b	b	--
8706	b	b	b	b	--
8714	b	b	b	b	--
8701	0.0	0.1	0.2	0.3	0.2
8702	0.0	0.0	0.3	0.2	0.6
8720	0.2	0.0	0.1	-0.1	0.1
8704	-0.1	0.3	0.0	0.3	0.8
MEAN	0.0	0.1	0.2	0.2	0.4
S.D.	0.13	0.14	0.13	0.19	0.33
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 97[c]	DAY 104	DAY 111	DAY 119	DAY 125	DAY 133	DAY 139	DAY 146
8696	b	b	b	b	b	b	b	b
8719	b	b	b	b	b	b	b	b
8711	b	b	b	b	b	b	b	b
8716	b	b	b	b	b	b	b	b
8725	0.1	0.4	-0.3	0.0	-0.1	0.2	-0.1	-0.1
8707	0.0	0.4	-0.1	0.5	-0.2	0.3	0.2	-0.4
8689	-0.2	0.4	-0.1	0.2	-0.1	-0.3	0.1	0.1
8722	-0.1	0.2	-0.1	0.4	-0.1	0.3	0.1	-0.1
MEAN	-0.1	0.4	-0.2	0.3	-0.1	0.1	0.1	-0.1
S.D.	0.13	0.10	0.10	0.22	0.05	0.29	0.13	0.21
N	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

[c]Baseline is day 90

DRAFT

INDIVIDUAL WEIGHT GAIN (Kilograms)[a]

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 153	DAY 160	DAY 167	DAY 181	TOTAL GAIN
8696	b	b	b	b	--
8719	b	b	b	b	--
8711	b	b	b	b	--
8716	b	b	b	b	--
8725	0.1	-0.1	0.0	0.3	0.4
8707	0.2	0.3	0.4	0.2	1.8
8689	-0.3	0.2	0.1	0.5	0.6
8722	0.0	0.3	0.3	0.3	1.5
MEAN	0.0	0.2	0.2	0.3	1.1
S.D.	0.22	0.19	0.18	0.13	0.68
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

[a]Weight gains compared to the previous period

DRAFT

APPENDIX E

Individual Food Consumption Data

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8656	242	329	395	326	387	321	380	400	361	400	360	304
8687	293	400	400	400	400	400	400	326	291	374	400	342
8669	289	309	372	263	400	229	367	400	200	292	265	233
8673	229	247	400	400	400	400	400	400	400	400	400	400
8667	316	355	306	329	391	372	400	400	400	400	400	400
8654	400	400	400	400	400	400	400	400	400	400	400	400
8680	366	400	400	400	400	400	400	400	400	400	341	400
8676	361	355	400	400	400	400	400	400	366	349	344	400
MEAN	312	349	384	365	397	365	393	391	352	377	364	360
S.D.	60.7	53.8	33.0	52.6	5.2	61.7	12.7	26.2	72.0	39.0	47.7	62.8
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8656	400	400	400	400	b	b	b	b	b	b	b	b
8687	232	391	400	400	b	b	b	b	b	b	b	b
8669	400	391	371	239	b	b	b	b	b	b	b	b
8673	400	400	400	400	b	b	b	b	b	b	b	b
8667	400	382	400	400	400	400	400	400	400	400	400	400
8654	400	400	400	400	400	400	400	400	400	400	400	400
8680	400	74	400	400	352	217	400	400	400	400	400	400
8676	400	400	400	400	400	400	400	400	400	400	400	400
MEAN	379	355	396	380	388	354	400	400	400	400	400	400
S.D.	59.4	113.6	10.3	56.9	24.0	91.5	0.0	0.0	0.0	0.0	0.0	0.0
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 1-M SEX: MALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8656	b	b	b	b	b
8687	b	b	b	b	b
8669	b	b	b	b	b
8673	b	b	b	b	b
8667	400	400	400	400	400
8654	400	400	400	400	400
8680	400	400	400	400	331
8676	400	400	400	400	285
MEAN	400	400	400	400	354
S.D.	0.0	0.0	0.0	0.0	56.3
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8685	400	400	340	360	400	385	400	400	400	400	400	381
8679	--	--	--	--	--	--	--	--	--	--	--	--
8663	222	357	400	400	400	400	400	400	400	400	400	400
8686	293	238	400	400	400	400	400	400	400	400	400	400
8665	315	321	310	386	398	331	400	400	400	400	291	400
8666	400	258	371	347	400	400	400	400	400	400	310	400
8655	270	264	218	248	400	256	400	361	400	244	290	400
8659	233	289	336	338	400	400	400	400	400	400	400	345
8677	210	210	400	369	400	324	400	400	400	268	400	400
MEAN	293	292	347	356	400	362	400	395	400	364	361	391
S.D.	75.1	63.6	62.3	49.3	0.7	53.4	0.0	13.8	0.0	67.0	53.6	19.6
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8685	400	400	400	400	b	b	b	b	b	b	b	b
8679	--	--	--	--	--	--	--	--	--	--	--	--
8663	259	400	400	400	b	b	b	b	b	b	b	b
8686	400	400	400	400	b	b	b	b	b	b	b	b
8665	400	400	400	400	400	400	400	400	400	400	400	400
8666	400	400	400	400	400	400	400	400	400	400	400	400
8655	400	400	325	400	400	400	400	400	400	400	400	400
8659	400	400	400	400	321	400	400	400	400	400	400	400
8677	400	400	400	400	b	b	b	b	b	b	b	b
MEAN	382	400	391	400	380	400	400	400	400	400	400	400
S.D.	49.9	0.0	26.5	0.0	39.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 2-M SEX: MALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8685	b	b	b	b	b
8679	--	--	--	--	--
8663	b	b	b	b	b
8686	b	b	b	b	b
8665	400	361	400	400	400
8666	400	400	400	400	400
8655	400	400	400	400	400
8659	400	400	400	400	400
8677	b	b	b	b	b
MEAN	400	390	400	400	400
S.D.	0.0	19.5	0.0	0.0	0.0
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8674	114	360	240	328	400	400	400	400	400	364	400	400
8653	295	390	263	227	360	305	400	400	400	400	400	356
8660	400	360	320	269	400	162	252	394	400	358	316	400
8668	234	319	400	400	400	382	400	400	400	400	400	400
8682	326	225	400	400	400	400	400	400	400	400	400	400
8684	233	352	309	247	400	373	400	400	218	299	400	400
8662	382	375	400	400	400	400	400	400	400	400	400	400
8688	372	400	286	210	288	390	369	400	400	330	372	139
MEAN	295	348	327	310	381	352	378	399	377	369	386	362
S.D.	97.0	55.4	65.1	82.1	40.1	82.8	51.9	2.1	64.3	38.6	29.9	91.4
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8674	400	400	400	400	400	400	400	400	400	400	400	400
8653	400	400	400	400	b	b	b	b	b	b	b	b
8660	371	349	400	400	b	b	b	b	b	b	b	b
8668	400	400	400	400	b	b	b	b	b	b	b	b
8682	400	400	400	400	400	400	400	400	400	400	400	400
8684	400	400	400	400	b	b	b	b	b	b	b	b
8662	400	400	400	400	400	400	400	400	400	400	400	400
8688	237	322	400	400	400	400	400	400	400	400	342	400
MEAN	376	384	400	400	400	400	400	400	400	400	386	400
S.D.	57.1	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.0	0.0
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 3-M SEX: MALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8674	400	400	400	400	400
8653	b	b	b	b	b
8660	b	b	b	b	b
8668	b	b	b	b	b
8682	400	400	400	400	400
8684	b	b	b	b	b
8662	400	400	400	400	400
8688	400	400	358	213	242
MEAN	400	400	390	353	361
S.D.	0.0	0.0	21.0	93.5	79.0
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8661	379	343	400	399	398	388	400	400	400	400	400	400
8670	130	296	247	130	400	222	400	400	400	400	400	400
8681	316	190	216	239	387	391	400	400	400	400	400	400
8664	351	390	376	256	75	35	42	321	307	383	400	394
8675	213	370	325	336	368	296	400	277	400	400	400	400
8683	297	400	400	252	362	212	400	400	400	201	389	284
8658	400	400	400	307	374	327	400	400	400	400	400	400
8652	288	400	214	191	385	247	349	303	400	400	378	400
MEAN	297	349	322	264	344	265	349	363	388	373	396	385
S.D.	89.2	73.7	84.3	84.0	109.4	115.7	125.3	52.9	32.9	69.8	8.2	40.8
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8661	400	400	400	400	b	b	b	b	b	b	b	b
8670	400	326	400	400	b	b	b	b	b	b	b	b
8681	400	400	400	400	b	b	b	b	b	b	b	b
8664	400	400	400	400	b	b	b	b	b	b	b	b
8675	207	400	400	400	400	400	400	400	400	400	400	400
8683	400	400	400	400	400	400	400	400	400	400	400	400
8658	400	400	400	400	400	400	400	400	400	400	400	400
8652	400	400	400	400	400	400	400	400	400	400	400	400
MEAN	376	391	400	400	400	400	400	400	400	400	400	400
S.D.	68.2	26.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 4-M SEX: MALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8661	b	b	b	b	b
8670	b	b	b	b	b
8681	b	b	b	b	b
8664	b	b	b	b	b
8675	400	400	400	400	400
8683	400	400	400	194	400
8658	400	400	400	400	400
8652	400	400	400	400	400
MEAN	400	400	400	349	400
S.D.	0.0	0.0	0.0	103.0	0.0
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8721	301	376	400	333	389	267	371	400	400	400	400	400
8712	264	265	236	194	374	336	333	400	400	400	400	400
8710	394	380	400	400	400	400	383	400	400	400	393	305
8723	229	253	205	88	289	380	321	237	44	45	157	243
8705	280	254	236	304	253	212	215	302	238	269	121	150
8700	300	296	276	271	349	342	400	318	250	290	381	382
8699	339	259	348	294	350	302	208	309	298	312	400	400
8690	229	400	400	375	399	400	400	276	373	400	400	400
MEAN	292	310	313	282	350	330	329	330	300	315	332	335
S.D.	55.6	63.9	83.5	100.9	53.6	66.7	77.9	62.8	123.8	122.2	119.4	94.6
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8721	400	400	400	400	b	b	b	b	b	b	b	b
8712	361	400	400	343	b	b	b	b	b	b	b	b
8710	400	400	400	400	b	b	b	b	b	b	b	b
8723	103	301	317	367	b	b	b	b	b	b	b	b
8705	160	277	280	335	213	285	56	375	338	279	306	400
8700	400	183	400	400	400	400	400	400	400	335	240	400
8699	400	400	400	400	226	294	360	257	310	400	222	400
8690	400	400	400	400	400	400	400	400	400	400	310	400
MEAN	328	345	375	381	310	345	304	358	362	354	270	400
S.D.	123.0	82.7	48.0	28.2	104.3	63.9	166.4	68.4	45.3	58.4	45.1	0.0
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 1-F SEX: FEMALE
DOSE: 0 (mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8721	b	b	b	b	b
8712	b	b	b	b	b
8710	b	b	b	b	b
8723	b	b	b	b	b
8705	400	400	274	193	127
87D0	327	337	400	400	400
8699	190	269	146	262	256
8690	400	400	400	204	266
MEAN	329	352	305	265	262
S.D.	99.0	62.5	121.5	95.1	111.5
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8717	329	338	386	400	400	400	400	400	368	324	342	371
8703	303	297	333	272	318	256	227	348	400	400	276	400
8713	400	400	400	400	400	400	400	400	400	400	400	400
8693	194	250	214	341	317	190	392	400	190	238	314	236
8695	142	102	234	247	223	298	238	269	151	239	246	153
8709	271	278	275	211	400	400	400	400	400	400	400	400
8715	353	400	240	348	400	278	307	400	166	191	400	261
8697	199	387	362	259	301	268	293	283	400	305	364	308
MEAN	274	307	306	310	345	311	332	363	309	312	343	316
S.D.	89.0	100.6	73.7	72.1	65.9	79.8	75.1	56.4	117.2	83.6	59.7	92.8
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8717	400	400	400	400	b	b	b	b	b	b	b	b
8703	335	344	363	400	b	b	b	b	b	b	b	b
8713	400	400	400	400	b	b	b	b	b	b	b	b
8693	219	400	400	305	b	b	b	b	b	b	b	b
8695	186	240	400	263	192	139	225	183	270	260	188	235
8709	249	400	400	378	400	400	400	400	400	400	400	400
8715	231	400	316	349	260	331	400	400	346	400	400	400
8697	377	400	400	188	287	400	312	253	259	224	327	400
MEAN	300	373	385	335	285	318	334	309	319	321	329	359
S.D.	87.9	57.2	30.7	77.8	86.6	123.4	83.8	108.9	66.6	92.4	99.9	82.5
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 2-F SEX: FEMALE
DOSE: 0.1(mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8717	b	b	b	b	b
8703	b	b	b	b	b
8713	b	b	b	b	b
8693	b	b	b	b	b
8695	339	225	192	145	209
8709	400	400	400	400	400
8715	400	400	400	222	252
8697	400	327	400	400	251
MEAN	385	338	348	292	278
S.D.	30.5	82.8	104.0	128.9	83.8
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8692	209	280	152	286	262	234	306	381	196	170	247	300
8718	330	400	295	400	400	400	229	400	207	252	299	206
8706	292	255	392	361	400	379	400	387	400	400	333	328
8714	400	400	400	400	400	400	400	400	400	400	400	400
8701	328	289	180	166	310	140	212	304	205	278	400	400
8702	290	299	321	398	400	400	400	400	400	400	400	400
8720	260	400	209	246	187	200	199	315	311	355	296	294
8704	361	312	249	400	400	400	400	400	400	400	400	400
MEAN	309	329	275	332	345	319	318	373	315	332	347	341
S.D.	59.6	60.7	93.4	89.6	83.0	109.1	92.9	40.2	97.7	88.3	61.3	71.9
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8692	224	195	358	270	b	b	b	b	b	b	b	b
8718	329	400	377	276	b	b	b	b	b	b	b	b
8706	350	400	394	323	b	b	b	b	b	b	b	b
8714	400	400	400	400	b	b	b	b	b	b	b	b
8701	302	400	305	169	252	144	243	246	382	400	400	400
8702	400	400	400	400	400	400	400	400	400	400	400	400
8720	400	392	400	400	400	400	400	400	400	400	400	400
8704	400	400	400	400	400	400	400	400	400	400	400	400
MEAN	351	373	379	330	363	336	361	362	396	400	400	400
S.D.	63.9	72.1	33.6	86.3	74.0	128.0	78.5	77.0	9.0	0.0	0.0	0.0
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 3-F SEX: FEMALE
DOSE: 0.3 (mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8692	b	b	b	b	b
8718	b	b	b	b	b
8706	b	b	b	b	b
8714	b	b	b	b	b
8701	400	400	400	313	400
8702	400	400	400	400	400
8720	400	400	400	400	400
8704	400	400	400	400	400
MEAN	400	400	400	378	400
S.D.	0.0	0.0	0.0	43.5	0.0
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY -8	DAY -4	DAY 7	DAY 14	DAY 21	DAY 25	DAY 35	DAY 42	DAY 49	DAY 51	DAY 54	DAY 63
8696	159	217	184	127	333	137	188	373	206	229	275	152
8719	400	391	400	395	400	400	400	400	400	400	381	389
8711	248	298	155	231	400	395	400	400	400	400	389	400
8716	362	307	190	244	238	339	239	325	171	334	324	283
8725	192	350	166	53	261	283	257	353	368	285	307	357
8707	226	233	112	126	172	225	314	300	172	291	232	131
8689	340	221	274	337	273	314	400	400	400	400	347	400
8722	233	127	84	126	214	84	367	260	301	200	321	226
MEAN	270	268	196	205	286	272	321	351	302	317	322	292
S.D.	86.6	84.7	100.0	118.0	84.1	115.7	84.0	52.4	104.5	79.4	52.3	111.4
N	8	8	8	8	8	8	8	8	8	8	8	8

--: Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 70	DAY 77	DAY 84	DAY 91	DAY 98	DAY 105	DAY 112	DAY 119	DAY 126	DAY 133	DAY 140	DAY 147
8696	400	351	217	400	b	b	b	b	b	b	b	b
8719	400	400	334	335	b	b	b	b	b	b	b	b
8711	400	400	400	400	b	b	b	b	b	b	b	b
8716	400	380	400	400	b	b	b	b	b	b	b	b
8725	190	400	400	400	258	400	400	400	400	400	400	400
8707	235	317	400	334	378	400	400	400	400	400	400	400
8689	400	400	400	333	400	400	400	400	400	400	400	400
8722	277	310	393	396	400	400	400	400	400	400	400	400
MEAN	338	370	368	375	359	400	400	400	400	400	400	400
S.D.	89.0	38.7	65.1	33.8	68.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
N	8	8	8	8	4	4	4	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

INDIVIDUAL DAILY FOOD CONSUMPTION (Grams)

STUDY: 193 GROUP: 4-F SEX: FEMALE
DOSE: 1.0 (mg/kg)

ANIMAL #	DAY 154	DAY 161	DAY 168	DAY 175	DAY 182
8696	b	b	b	b	b
8719	b	b	b	b	b
8711	b	b	b	b	b
8716	b	b	b	b	b
8725	400	400	400	400	400
8707	400	400	225	331	293
8689	400	400	400	400	400
8722	400	400	400	400	343
MEAN	400	400	356	383	359
S.D.	0.0	0.0	87.5	34.5	51.6
N	4	4	4	4	4

--: Data Unavailable b: Scheduled Sacrifice

DRAFT

APPENDIX F

Individual Clinical Chemistry Data

Clinical Chemistry Test Directory

STUDY: UIC-18A

NO.	ABBR. / UNITS	DESCRIPTION / PRECISION	CALCULATED	OPERAND A	OPERAND B	---LOWER LIMIT--- MALE	---LOWER LIMIT--- FEMALE	---UPPER LIMIT--- MALE	---UPPER LIMIT--- FEMALE
1.	ALT	Alanine Aminotransferase							
	IU/L	Integer	NO			20	20	50	50
2.	AST	Aspartate Aminotransferase							
	IU/L	Integer	NO			20	20	50	50
3.	TP	Total Protein							
	g/dL	0.0	NO			5.5	5.5	7.5	7.5
4.	ALB	Albumin							
	g/dL	0.0	NO			2.7	2.7	4.0	4.0
5.	TBILI	Total Bilirubin							
	mg/dL	0.00	NO			0.00	0.00	0.50	0.50
6.	ALKP	Alkaline Phosphatase							
	IU/L	Integer	NO			50	50	200	150
7.	GGT	Gamma Glutamyl Transferase							
	IU/L	Integer	NO			0	0	10	10
8.	CHOL	Cholesterol							
	mg/dL	Integer	NO			150	150	250	250
9.	TRIG	Triglycerides							
	mg/dL	Integer	NO			20	20	70	70
10.	LDH	Lactate Dehydrogenase							
	IU/L	Integer	NO			25	25	150	150
11.	CK	Creatine Kinase							
	IU/L	Integer	NO			100	100	400	400
12.	BUN	Blood Urea Nitrogen							
	mg/dL	0.0	NO			8.0	8.0	20.0	20.0
13.	CREAT	Creatinine							
	mg/dL	0.00	NO			0.50	0.50	1.00	1.00
14.	NA	Sodium							
	mEq/L	Integer	NO			140	140	150	150
15.	K	Potassium							
	mEq/L	0.00	NO			4.00	4.00	5.25	5.25

(REPORT CONTINUED)

Clinical Chemistry Test Directory

STUDY: UIC-18A

NO.	ABBR. UNITS	DESCRIPTION PRECISION	CALCULATED	OPERAND A	OPERAND B	---LOWER LIMIT--- MALE	FEMALE	---UPPER LIMIT--- MALE	FEMALE
16.	CL mEq/L	Chloride Integer	NO			110	110	130	130
17.	CA mg/dL	Calcium 0.0	NO			9.0	9.0	12.0	12.0
18.	IP mg/dL	Inorganic Phosphorus 0.0	NO			4.0	4.0	8.0	8.0
19.	GLU mg/dL	Glucose Integer	NO			90	90	140	140
20.	HAPT mg/dL	Haptoglobin 0.0	NO			0.0	0.0	200.0	200.0
21.	GLOB g/dL	Globulin 0.0	Operand A - Operand B	TP	ALB	2.7	2.7	4.0	4.0
22.	A/G -	A/G Ratio 0.00	Operand A / Operand B	ALB	GLOB	0.70	0.70	1.50	1.50

(END OF REPORT)

DRAFT

HISTORICAL DATABASE REPORT

		ALB	ALKP	ALT	AST	BUN	CA	CHOL	CK
DOG BEAGLE Male									
CONTROL DATA	MEAN	3.2	118	35	35	13.2	10.4	180	82
	SD	0.17	44.1	9.6	6.7	2.71	0.37	28.8	121.0
	N	136	136	136	136	136	136	136	216
DOG BEAGLE Female									
CONTROL DATA	MEAN	3.3	104	31	36	13.7	10.5	183	66
	SD	0.17	27.8	7.5	9.1	3.21	0.44	36.3	101.6
	N	136	136	136	136	136	136	136	216
DOG BEAGLE Both									
CONTROL DATA	MEAN	3.2	111	33	35	13.4	10.5	182	74
	SD	0.17	37.5	8.9	8.0	2.97	0.41	32.7	111.9
	N	272	272	272	272	272	272	272	432

CONTROL DATA-189-336 days

LABCAT CC4.32

DRAFT

UIC/TRL - CLINICAL CHEMISTRY

HISTORICAL DATABASE REPORT

		CL	CREAT	GGT	GLU	HAPT	IP	K	LDH
DOG BEAGLE Male									
CONTROL DATA	MEAN	114	0.74	4	109	58.6	9	4.49	45
	SD	4.5	0.075	1.5	9.1	31.42	10.2	0.263	18.6
	N	136	112	78	136	68	152	136	80
DOG BEAGLE Female									
CONTROL DATA	MEAN	114	0.73	4	106	49.7	9	4.44	50
	SD	4.6	0.083	1.5	9.0	31.77	10.5	0.261	20.9
	N	136	112	79	136	46	152	136	80
DOG BEAGLE Both									
CONTROL DATA	MEAN	114	0.73	4	107	55.0	9	4.46	47
	SD	4.6	0.079	1.5	9.1	31.73	10.4	0.263	19.8
	N	272	224	157	272	114	304	272	160

CONTROL DATA-189-336 days

LABCAT CC4.32

UIC/TRL - CLINICAL CHEMISTRY

DRAFT

HISTORICAL DATABASE REPORT

		NA	TBILI	TP	TRIG
DOG BEAGLE Male					
CONTROL DATA	MEAN	145	0.14	10	38
	SD	1.6	0.027	10.1	10.0
	N	136	136	152	112
DOG BEAGLE Female					
CONTROL DATA	MEAN	146	0.15	10	39
	SD	1.5	0.036	10.3	9.8
	N	136	136	152	112
DOG BEAGLE Both					
CONTROL DATA	MEAN	146	0.15	10	39
	SD	1.6	0.033	10.2	9.9
	N	272	272	304	224

CONTROL DATA-189-336 days

LABCAT CC4.32

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alanine Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALT

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	33	27	33	38	38	--	--
8687	58	28	35	40	43	--	--
8669	29	21	34	35	37	--	--
8673	39	24	30	30	45	--	--
8667	43	27	41	52	47	39	43
8654	41	27	39	43	44	43	40
8680	32	23	27	26	34	48	29
8676	63	23	26	31	24	26	33
MEAN	42	25	33	37	39	39	36
SD	12.3	2.6	5.3	8.3	7.5	9.4	6.4
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	27	32	36	29	32	--	--
8663	33	25	24	30	28	--	--
8686	34	29	28	38	36	--	--
8665	30	22	31	33	33	31	36
8666	43	37	52	54	44	51	45
8655	63	27	29	36	31	38	39
8659	36	28	37	36	49	43	42
8677	41	34	32	41	46	--	--
MEAN	38	29	34	37	37	41	41
SD	11.3	4.9	8.5	7.9	7.9	8.4	3.9
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alanine Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALT

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	87	49	52	56	55	73	72
8653	51	35	30	35	45	--	--
8660	25	25	19	27	27	--	--
8668	32	23	24	28	25	--	--
8682	34	23	30	30	24	16	29
8684	38	29	45	40	45	--	--
8662	42	26	31	30	32	26	42
8688	34	24	24	31	31	39	35
MEAN	43	29	32	35	36	39	45
SD	19.4	8.9	11.2	9.6	11.4	24.9	19.1
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	36	30	35	34	37	--	--
8670	33	30	27	32	32	--	--
8681	34	23	25	34	34	--	--
8664	25	16	28	25	33	--	--
8675	29	20	24	37	28	33	32
8683	46	32	24	35	29	37	47
8658	40	37	33	36	44	40	47
8652	36	28	28	40	33	30	33
MEAN	35	27	28	34	34	35	40
SD	6.4	6.9	4.1	4.4	5.0	4.4	8.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: AST

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	26	24	32	34	34	--	--
8687	34	31	33	27	35	--	--
8669	31	32	66	30	40	--	--
8673	35	30	30	33	27	--	--
8667	33	26	37	38	33	32	31
8654	33	35	34	26	30	32	45
8680	37	38	30	30	29	41	44
8676	35	44	33	46	36	30	38
MEAN	33	33	37	33	33	34	40
SD	3.3	6.5	12.0	6.5	4.2	4.9	6.5
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	26	29	27	29	29	--	--
8663	32	25	34	32	34	--	--
8686	39	79	39	42	36	--	--
8665	35	37	39	40	42	43	55
8666	32	32	51	50	32	34	45
8655	29	30	40	40	37	46	32
8659	25	23	24	35	44	25	36
8677	37	52	41	22	40	--	--
MEAN	32	38	37	36	37	37	42
SD	5.0	18.7	8.5	8.7	5.1	9.5	10.2
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: AST

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	35	34	34	47	52	31	41
8653	33	27	33	30	52	--	--
8660	25	30	34	29	40	--	--
8668	30	23	36	28	32	--	--
8682	30	33	34	47	28	27	28
8684	34	31	48	45	41	--	--
8662	41	32	47	53	47	31	51
8688	38	37	38	52	38	44	48
MEAN	33	31	38	41	41	33	42
SD	5.0	4.3	6.1	10.6	8.8	7.4	10.2
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	37	42	58	46	50	--	--
8670	29	38	34	46	32	--	--
8681	45	40	50	75	58	--	--
8664	25	26	50	54	40	--	--
8675	37	29	48	61	44	41	37
8683	31	35	36	43	43	44	47
8658	37	41	60	39	39	29	41
8652	34	30	41	51	37	29	30
MEAN	34	35	47	52	43	36	39
SD	6.1	6.1	9.5	11.6	8.1	7.9	7.1
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Protein

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TP

SEX: MALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	6.6	5.6	6.2	6.4	5.9	--	--
8687	6.6	5.8	6.1	5.8	5.3	--	--
8669	6.1	5.5	6.0	6.3	6.1	--	--
8673	6.6	5.7	5.8	6.3	6.4	--	--
8667	6.1	5.4	5.5	6.1	6.2	6.3	6.5
8654	6.0	5.5	5.3	6.0	6.1	6.0	6.4
8680	6.5	6.3	5.9	6.9	6.4	6.6	6.7
8676	6.4	5.8	6.0	6.0	5.7	6.3	6.7
MEAN	6.4	5.7	5.9	6.2	6.0	6.3	6.6
SD	0.26	0.28	0.31	0.34	0.37	0.24	0.15
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	6.6	5.7	6.4	5.9	5.9	--	--
8663	6.1	5.7	5.7	6.3	5.7	--	--
8686	6.3	5.6	4.9	5.7	5.7	--	--
8665	6.2	5.5	6.0	5.8	6.1	6.2	6.1
8666	6.0	5.9	5.9	5.9	5.7	6.4	6.4
8655	6.0	5.8	6.2	6.1	6.4	5.6	6.6
8659	6.4	5.4	6.4	6.0	6.4	6.4	6.3
8677	6.6	6.3	6.2	6.5	6.5	--	--
MEAN	6.3	5.7	6.0	6.0	6.1	6.2	6.4
SD	0.24	0.28	0.49	0.27	0.35	0.38	0.21
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Protein

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TP

SEX: MALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	5.9	5.3	5.1	6.0	5.6	5.5	6.3
8653	6.2	5.7	5.7	6.2	6.1	--	--
8660	6.1	5.4	5.9	6.5	5.6	--	--
8668	6.5	5.3	5.7	6.2	6.2	--	--
8682	6.3	5.7	5.8	5.8	5.8	6.2	6.3
8684	6.2	5.5	6.1	6.3	6.5	--	--
8662	6.6	5.9	6.0	6.1	6.3	6.2	6.7
8688	5.8	5.8	6.5	6.3	6.2	6.8	6.7
MEAN	6.2	5.6	5.9	6.2	6.0	6.2	6.5
SD	0.27	0.23	0.40	0.21	0.33	0.53	0.23
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	6.4	5.6	5.8	5.8	6.0	--	--
8670	6.3	5.7	6.2	6.4	6.1	--	--
8681	6.1	5.6	5.6	6.7	6.2	--	--
8664	5.9	5.3	4.9	5.6	6.1	--	--
8675	6.8	5.8	6.2	6.3	6.3	6.5	6.2
8683	6.2	5.7	5.5	6.4	6.0	6.6	6.9
8658	6.4	6.0	5.7	6.4	6.3	6.4	6.7
8652	6.6	6.0	6.1	6.5	6.9	6.4	6.8
MEAN	6.3	5.7	5.8	6.3	6.2	6.5	6.7
SD	0.28	0.23	0.44	0.37	0.29	0.10	0.31
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Albumin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALB

SEX: MALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	3.1	3.1	3.3	3.2	3.0	--	--
8687	3.3	3.3	3.4	3.3	3.0	--	--
8669	2.8	2.9	3.0	3.1	3.1	--	--
8673	3.4	3.1	3.2	3.3	3.4	--	--
8667	3.2	3.2	3.2	3.3	3.2	3.1	3.6
8654	3.1	3.0	3.1	3.2	3.1	3.2	3.5
8680	3.2	3.3	3.2	3.4	3.3	3.3	3.8
8676	3.3	3.1	3.1	3.2	3.1	3.4	3.6
MEAN	3.2	3.1	3.2	3.3	3.2	3.3	3.6
SD	0.18	0.14	0.12	0.09	0.14	0.13	0.13
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	3.3	3.3	3.4	3.1	3.1	--	--
8663	3.0	3.2	2.9	3.3	3.1	--	--
8686	3.2	3.0	2.8	3.0	3.1	--	--
8665	3.1	3.1	3.1	3.0	3.0	3.0	3.2
8666	3.0	3.2	3.2	3.1	3.0	3.4	3.6
8655	3.1	3.2	3.3	3.3	3.4	3.2	3.7
8659	3.2	3.0	3.4	3.3	3.4	3.1	3.6
8677	3.5	3.6	3.4	3.4	3.5	--	--
MEAN	3.2	3.2	3.2	3.2	3.2	3.2	3.5
SD	0.17	0.19	0.24	0.16	0.20	0.17	0.22
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Albumin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALB

SEX: MALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	3.1	3.0	2.8	3.1	2.9	2.7	3.2
8653	2.9	3.0	3.1	3.1	2.8	--	--
8660	2.9	2.8	2.9	3.2	2.9	--	--
8668	3.2	3.1	2.8	3.0	3.2	--	--
8682	3.1	3.2	3.0	2.9	2.9	2.9	3.1
8684	3.3	3.1	3.2	3.2	3.4	--	--
8662	3.3	3.1	3.2	3.1	3.0	3.0	3.6
8688	3.3	3.3	3.3	3.3	3.2	3.3	3.7
MEAN	3.1	3.1	3.0	3.1	3.0	3.0	3.4
SD	0.17	0.15	0.19	0.12	0.21	0.25	0.29
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	3.1	3.1	2.9	3.0	3.0	--	--
8670	2.9	3.1	2.9	3.2	3.1	--	--
8681	3.2	3.1	2.8	3.2	3.1	--	--
8664	3.0	3.0	2.4	3.0	3.1	--	--
8675	3.3	3.2	2.8	3.2	3.1	2.9	3.3
8683	3.3	3.3	2.7	3.3	3.2	3.3	3.9
8658	3.1	3.3	2.9	3.0	2.8	3.1	3.5
8652	3.4	3.3	3.0	3.2	3.5	3.0	3.6
MEAN	3.2	3.2	2.8	3.1	3.1	3.1	3.6
SD	0.17	0.12	0.19	0.12	0.20	0.17	0.25
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Globulin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLOB

SEX: MALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	3.5	2.5	2.9	3.2	2.9	--	--
8687	3.3	2.5	2.7	2.5	2.3	--	--
8669	3.3	2.6	3.0	3.2	3.0	--	--
8673	3.2	2.6	2.6	3.0	3.0	--	--
8667	2.9	2.2	2.3	2.8	3.0	3.2	2.9
8654	2.9	2.5	2.2	2.8	3.0	2.8	2.9
8680	3.3	3.0	2.7	3.5	3.1	3.3	2.9
8676	3.1	2.7	2.9	2.8	2.6	2.9	3.1
MEAN	3.2	2.6	2.7	3.0	2.9	3.1	3.0
SD	0.21	0.23	0.29	0.32	0.27	0.24	0.10
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	3.3	2.4	3.0	2.8	2.8	--	--
8663	3.1	2.5	2.8	3.0	2.6	--	--
8686	3.1	2.6	2.1	2.7	2.6	--	--
8665	3.1	2.4	2.9	2.8	3.1	3.2	2.9
8666	3.0	2.7	2.7	2.8	2.7	3.0	2.8
8655	2.9	2.6	2.9	2.8	3.0	2.4	2.9
8659	3.2	2.4	3.0	2.7	3.0	3.3	2.7
8677	3.1	2.7	2.8	3.1	3.0	--	--
MEAN	3.1	2.5	2.8	2.8	2.9	3.0	2.8
SD	0.12	0.13	0.29	0.14	0.20	0.40	0.10
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Globulin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLOB

SEX: MALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	2.8	2.3	2.3	2.9	2.7	2.8	3.1
8653	3.3	2.7	2.6	3.1	3.3	--	--
8660	3.2	2.6	3.0	3.3	2.7	--	--
8668	3.3	2.2	2.9	3.2	3.0	--	--
8682	3.2	2.5	2.8	2.9	2.9	3.3	3.2
8684	2.9	2.4	2.9	3.1	3.1	--	--
8662	3.3	2.8	2.8	3.0	3.3	3.2	3.1
8688	2.5	2.5	3.2	3.0	3.0	3.5	3.0
MEAN	3.1	2.5	2.8	3.1	3.0	3.2	3.1
SD	0.30	0.20	0.27	0.14	0.23	0.29	0.08
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	3.3	2.5	2.9	2.8	3.0	--	--
8670	3.4	2.6	3.3	3.2	3.0	--	--
8681	2.9	2.5	2.8	3.5	3.1	--	--
8664	2.9	2.3	2.5	2.6	3.0	--	--
8675	3.5	2.6	3.4	3.1	3.2	3.6	2.9
8683	2.9	2.4	2.8	3.1	2.8	3.3	3.0
8658	3.3	2.7	2.8	3.4	3.5	3.3	3.2
8652	3.2	2.7	3.1	3.3	3.4	3.4	3.2
MEAN	3.2	2.5	3.0	3.1	3.1	3.4	3.1
SD	0.24	0.14	0.30	0.30	0.23	0.14	0.15
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: A/G Ratio

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: A/G

SEX: MALE
UNITS: -

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	0.89	1.24	1.14	1.00	1.03	--	--
8687	1.00	1.32	1.26	1.32	1.30	--	--
8669	0.85	1.12	1.00	0.97	1.03	--	--
8673	1.06	1.19	1.23	1.10	1.13	--	--
8667	1.10	1.45	1.39	1.18	1.07	0.97	1.24
8654	1.07	1.20	1.41	1.14	1.03	1.14	1.21
8680	0.97	1.10	1.19	0.97	1.06	1.00	1.31
8676	1.06	1.15	1.07	1.14	1.19	1.17	1.16
MEAN	1.00	1.22	1.21	1.10	1.11	1.07	1.23
SD	0.091	0.116	0.144	0.121	0.097	0.100	0.063
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	1.00	1.38	1.13	1.11	1.11	--	--
8663	0.97	1.28	1.04	1.10	1.19	--	--
8686	1.03	1.15	1.33	1.11	1.19	--	--
8665	1.00	1.29	1.07	1.07	0.97	0.94	1.10
8666	1.00	1.19	1.19	1.11	1.11	1.13	1.29
8655	1.07	1.23	1.14	1.18	1.13	1.33	1.28
8659	1.00	1.25	1.13	1.22	1.13	0.94	1.33
8677	1.13	1.33	1.21	1.10	1.17	--	--
MEAN	1.03	1.26	1.16	1.13	1.13	1.09	1.25
SD	0.052	0.074	0.090	0.049	0.071	0.186	0.102
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: A/G Ratio

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: A/G

SEX: MALE

UNITS: -

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	1.11	1.30	1.22	1.07	1.07	0.96	1.03
8653	0.88	1.11	1.19	1.00	0.85	--	--
8660	0.91	1.08	0.97	0.97	1.07	--	--
8668	0.97	1.41	0.97	0.94	1.07	--	--
8682	0.97	1.28	1.07	1.00	1.00	0.88	0.97
8684	1.14	1.29	1.10	1.03	1.10	--	--
8662	1.00	1.11	1.14	1.03	0.91	0.94	1.16
8688	1.32	1.32	1.03	1.10	1.07	0.94	1.23
MEAN	1.04	1.24	1.09	1.02	1.02	0.93	1.10
SD	0.145	0.121	0.094	0.052	0.091	0.035	0.119
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	0.94	1.24	1.00	1.07	1.00	--	--
8670	0.85	1.19	0.88	1.00	1.03	--	--
8681	1.10	1.24	1.00	0.91	1.00	--	--
8664	1.03	1.30	0.96	1.15	1.03	--	--
8675	0.94	1.23	0.82	1.03	0.97	0.81	1.14
8683	1.14	1.38	0.96	1.06	1.14	1.00	1.30
8658	0.94	1.22	1.04	0.88	0.80	0.94	1.09
8652	1.06	1.22	0.97	0.97	1.03	0.88	1.13
MEAN	1.00	1.25	0.95	1.01	1.00	0.91	1.17
SD	0.098	0.060	0.071	0.088	0.095	0.081	0.093
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Bilirubin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TBILI

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	0.18	0.14	0.17	0.17	0.12	--	--
8687	0.19	0.11	0.14	0.13	0.14	--	--
8669	0.15	0.12	0.13	0.13	0.17	--	--
8673	0.20	0.11	0.13	0.14	0.17	--	--
8667	0.16	0.12	0.15	0.15	0.17	0.15	0.17
8654	0.15	0.14	0.18	0.14	0.14	0.15	0.15
8680	0.17	0.17	0.13	0.12	0.16	0.17	0.22
8676	0.20	0.14	0.12	0.15	0.12	0.16	0.17
MEAN	0.18	0.13	0.14	0.14	0.15	0.16	0.18
SD	0.021	0.020	0.021	0.016	0.022	0.010	0.030
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	0.19	0.12	0.17	0.15	0.14	--	--
8663	0.15	0.11	0.12	0.14	0.16	--	--
8686	0.20	0.14	0.16	0.15	0.16	--	--
8665	0.15	0.15	0.19	0.20	0.15	0.20	0.20
8666	0.17	0.13	0.16	0.20	0.16	0.18	0.19
8655	0.13	0.11	0.20	0.18	0.14	0.16	0.18
8659	0.16	0.11	0.16	0.12	0.11	0.16	0.18
8677	0.20	0.12	0.14	0.15	0.12	--	--
MEAN	0.17	0.12	0.16	0.16	0.14	0.18	0.19
SD	0.026	0.015	0.025	0.029	0.019	0.019	0.010
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Bilirubin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TBILI

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	0.19	0.14	0.21	0.20	0.16	0.17	0.18
8653	0.18	0.12	0.24	0.14	0.24	--	--
8660	0.13	0.10	0.13	0.11	0.10	--	--
8668	0.20	0.14	0.23	0.17	0.17	--	--
8682	0.25	0.20	0.18	0.23	0.16	0.17	0.18
8684	0.22	0.13	0.27	0.20	0.20	--	--
8662	0.16	0.13	0.21	0.22	0.15	0.13	0.22
8688	0.18	0.13	0.23	0.23	0.18	0.21	0.30
MEAN	0.19	0.14	0.21	0.19	0.17	0.17	0.22
SD	0.036	0.029	0.042	0.044	0.040	0.033	0.057
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	0.18	0.14	0.28	0.18	0.19	--	--
8670	0.17	0.15	0.18	0.17	0.16	--	--
8681	0.20	0.12	0.18	0.18	0.16	--	--
8664	0.14	0.10	0.19	0.10	0.12	--	--
8675	0.20	0.12	0.20	0.15	0.14	0.11	0.13
8683	0.17	0.13	0.18	0.13	0.15	0.15	0.15
8658	0.17	0.13	0.23	0.15	0.12	0.23	0.18
8652	0.15	0.12	0.16	0.14	0.16	0.13	0.14
MEAN	0.17	0.13	0.20	0.15	0.15	0.16	0.15
SD	0.021	0.015	0.038	0.027	0.023	0.053	0.022
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alkaline Phosphatase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALKP

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	136	117	131	119	100	--	--
8687	79	68	78	70	52	--	--
8669	163	144	160	130	104	--	--
8673	178	146	136	130	110	--	--
8667	132	124	136	134	110	103	90
8654	167	147	146	153	126	94	109
8680	103	94	82	88	62	70	57
8676	145	122	115	85	75	75	71
MEAN	138	120	123	114	92	86	82
SD	33.5	27.7	29.4	29.1	26.2	15.6	22.6
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	117	103	89	76	76	--	--
8663	111	105	108	93	71	--	--
8686	160	139	106	124	108	--	--
8665	105	100	104	84	74	74	68
8666	280	233	207	169	133	121	114
8655	105	95	97	92	72	64	82
8659	118	83	84	67	57	47	42
8677	145	149	113	95	80	--	--
MEAN	143	126	114	100	84	77	77
SD	58.9	48.7	39.0	32.5	24.5	31.7	30.0
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alkaline Phosphatase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALKP

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	136	116	98	130	74	77	101
8653	69	67	62	72	64	--	--
8660	90	77	67	70	53	--	--
8668	95	88	89	84	80	--	--
8682	97	91	90	113	113	128	111
8684	152	138	120	92	92	--	--
8662	108	89	90	98	77	62	86
8688	117	100	103	87	72	67	56
MEAN	108	96	90	93	78	84	89
SD	26.6	22.4	18.7	20.3	18.1	30.3	24.0
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	186	174	132	137	104	--	--
8670	142	106	125	127	94	--	--
8681	91	85	95	86	60	--	--
8664	86	81	72	68	61	--	--
8675	73	61	75	65	63	58	51
8683	154	131	85	88	74	74	78
8658	173	155	95	123	143	119	161
8652	105	90	102	89	92	87	116
MEAN	126	110	98	98	86	85	102
SD	43.0	39.4	21.7	27.5	28.4	25.9	47.8
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GGT

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	6	5	5	7	6	--	--
8687	2	4	3	4	5	--	--
8669	4	3	2	4	6	--	--
8673	2	4	3	4	7	--	--
8667	2	0	2	5	7	5	7
8654	4	1	0	4	6	6	4
8680	1	4	4	6	7	5	4
8676	4	2	5	3	6	6	7
MEAN	3	3	3	5	6	6	6
SD	1.6	1.7	1.7	1.3	0.7	0.6	1.7
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	3	4	5	4	7	--	--
8663	1	3	3	5	6	--	--
8686	4	0	4	5	7	--	--
8665	5	4	4	4	6	6	4
8666	4	3	3	3	7	7	4
8655	4	3	2	3	5	5	6
8659	0	5	2	4	6	5	6
8677	3	4	4	5	6	--	--
MEAN	3	3	3	4	6	6	5
SD	1.7	1.5	1.1	0.8	0.7	1.0	1.2
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GGT

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	3	4	7	5	6	5	5
8653	1	3	4	2	6	--	--
8660	5	2	4	4	6	--	--
8668	2	4	2	6	5	--	--
8682	1	1	2	3	8	6	8
8684	3	0	5	4	6	--	--
8662	5	4	3	3	7	6	6
8688	6	4	4	4	6	6	5
MEAN	3	3	4	4	6	6	6
SD	1.9	1.6	1.6	1.2	0.9	0.5	1.4
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	6	5	4	4	7	--	--
8670	4	4	5	5	5	--	--
8681	4	1	5	4	6	--	--
8664	0	2	1	2	9	--	--
8675	1	11	4	4	6	5	0
8683	3	4	5	5	8	6	6
8658	3	4	2	3	5	6	5
8652	3	3	2	0	6	4	6
MEAN	3	4	4	3	7	5	4
SD	1.9	3.0	1.6	1.7	1.4	1.0	2.9
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Cholesterol

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CHOL

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	222	155	202	174	163	--	--
8687	211	173	181	162	114	--	--
8669	209	185	191	185	155	--	--
8673	217	156	146	162	153	--	--
8667	177	127	144	159	145	151	144
8654	237	144	156	174	176	175	153
8680	219	184	176	215	170	190	175
8676	227	157	157	159	154	175	174
MEAN	215	160	169	174	154	173	162
SD	17.7	19.9	21.5	19.0	18.9	16.1	15.5
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	204	136	169	147	134	--	--
8663	162	151	187	175	156	--	--
8686	235	177	129	207	180	--	--
8665	223	174	186	145	173	174	155
8666	158	131	129	121	113	141	125
8655	142	118	124	108	109	112	130
8659	208	164	194	164	162	170	152
8677	215	148	144	147	145	--	--
MEAN	193	150	158	152	147	149	141
SD	34.4	21.0	29.5	30.9	26.3	28.9	15.2
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Cholesterol

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CHOL

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	194	128	132	158	117	134	138
8653	181	162	173	187	174	--	--
8660	237	183	211	224	168	--	--
8668	223	160	151	184	160	--	--
8682	177	144	182	195	174	166	165
8684	181	126	137	130	144	--	--
8662	209	157	169	169	160	150	146
8688	179	147	168	144	139	172	147
MEAN	198	151	165	174	155	156	149
SD	22.9	18.8	25.5	30.1	19.9	17.1	11.4
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	214	178	176	186	165	--	--
8670	215	181	223	204	155	--	--
8681	202	162	169	165	167	--	--
8664	157	134	135	155	159	--	--
8675	256	164	188	165	185	189	150
8683	176	132	129	127	118	126	130
8658	230	210	185	211	230	282	253
8652	227	175	178	152	175	182	175
MEAN	210	167	173	171	169	195	177
SD	31.3	25.6	30.0	28.1	31.5	64.6	53.9
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Triglycerides

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TRIG

SEX: MALE
UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	53	38	35	43	34	--	--
8687	49	36	34	30	36	--	--
8669	40	39	40	46	38	--	--
8673	47	40	31	40	29	--	--
8667	33	39	24	35	40	32	37
8654	36	48	31	45	43	27	33
8680	45	66	24	35	33	37	31
8676	39	47	46	29	39	31	35
MEAN	43	44	33	38	37	32	34
SD	6.9	9.8	7.5	6.6	4.4	4.1	2.6
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	36	33	48	35	44	--	--
8663	35	31	27	26	33	--	--
8686	37	37	36	23	42	--	--
8665	35	47	40	40	32	25	25
8666	29	35	32	31	27	35	26
8655	30	42	29	31	29	24	40
8659	50	43	36	38	30	27	24
8677	38	38	43	39	32	--	--
MEAN	36	38	36	33	34	28	29
SD	6.4	5.4	7.1	6.2	6.1	5.0	7.5
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Triglycerides

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TRIG

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	50	40	28	36	26	26	37
8653	43	44	34	21	45	--	--
8660	40	34	42	49	42	--	--
8668	40	31	38	38	39	--	--
8682	38	55	54	36	25	38	32
8684	25	26	25	21	34	--	--
8662	40	39	33	51	30	29	38
8688	34	40	39	52	47	64	43
MEAN	39	39	37	38	36	39	38
SD	7.2	8.8	9.0	12.4	8.5	17.3	4.5
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	45	38	35	41	42	--	--
8670	38	46	45	67	38	--	--
8681	40	38	39	61	44	--	--
8664	49	43	48	52	84	--	--
8675	32	36	39	38	46	37	25
8683	33	41	35	37	35	30	33
8658	39	29	47	43	45	38	29
8652	39	30	37	60	53	37	32
MEAN	39	38	41	50	48	36	30
SD	5.6	5.9	5.3	11.7	15.4	3.7	3.6
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: LDH

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	24	23	37	31	40	--	--
8687	60	41	36	24	26	--	--
8669	33	38	81	33	44	--	--
8673	33	32	53	35	33	--	--
8667	24	50	54	59	74	48	59
8654	29	54	43	47	39	42	46
8680	56	69	32	40	28	55	60
8676	28	46	36	41	29	66	34
MEAN	36	44	47	39	39	53	50
SD	14.1	14.1	16.1	10.8	15.5	10.3	12.3
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	62	38	33	20	27	--	--
8663	35	27	27	20	34	--	--
8686	35	75	51	41	32	--	--
8665	20	31	25	35	37	38	40
8666	23	32	43	51	27	38	76
8655	29	43	43	67	23	59	54
8659	37	21	34	26	81	46	34
8677	39	85	36	28	28	--	--
MEAN	35	44	37	36	36	45	51
SD	12.8	23.3	8.8	16.4	18.7	9.9	18.7
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: LDH

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	41	42	20	57	27	49	38
8653	38	43	38	22	44	--	--
8660	26	29	53	25	20	--	--
8668	30	30	49	39	23	--	--
8682	47	37	23	43	36	41	46
8684	59	57	54	47	45	--	--
8662	39	34	58	62	40	59	59
8688	37	39	42	44	18	39	85
MEAN	40	39	42	42	32	47	57
SD	10.1	8.9	14.3	13.9	10.9	9.1	20.6
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	36	39	62	44	31	--	--
8670	27	35	27	52	46	--	--
8681	35	62	85	65	38	--	--
8664	68	24	85	67	54	--	--
8675	35	27	80	54	21	40	80
8683	37	51	70	52	55	55	62
8658	52	72	109	55	43	48	41
8652	20	42	47	141	52	42	39
MEAN	39	44	71	66	43	46	56
SD	14.9	16.7	25.4	31.1	12.0	6.8	19.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatine Kinase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CK

SEX: MALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	216	140	170	236	160	--	--
8687	347	229	130	118	91	--	--
8669	235	206	935	232	222	--	--
8673	227	230	195	146	157	--	--
8667	147	156	259	249	178	109	106
8654	271	434	170	334	193	158	157
8680	211	202	174	223	97	155	155
8676	142	263	118	150	140	159	178
MEAN	225	233	269	211	155	145	149
SD	65.8	90.7	272.5	70.1	45.0	24.2	30.5
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	148	137	104	78	97	--	--
8663	185	168	145	119	235	--	--
8686	275	912	285	259	134	--	--
8665	217	268	170	211	210	149	340
8666	140	176	176	165	106	95	152
8655	177	191	251	235	178	157	165
8659	183	124	93	179	1069	100	139
8677	268	422	203	203	223	--	--
MEAN	199	300	178	181	282	125	199
SD	50.5	265.3	66.8	59.9	322.5	32.3	94.6
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatine Kinase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CK

SEX: MALE
UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	154	147	326	290	168	128	239
8653	244	154	153	106	154	--	--
8660	190	172	142	128	186	--	--
8668	187	119	184	214	145	--	--
8682	233	214	105	329	105	160	306
8684	313	162	239	345	194	--	--
8662	230	190	213	220	144	138	238
8688	294	290	135	254	94	108	229
MEAN	231	181	187	236	149	134	253
SD	54.0	52.4	71.0	87.1	35.4	21.6	35.6
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	358	335	306	143	160	--	--
8670	234	255	165	162	177	--	--
8681	251	186	230	326	190	--	--
8664	133	104	316	182	181	--	--
8675	261	171	199	154	114	374	215
8683	237	348	126	278	135	161	240
8658	179	408	599	308	245	246	343
8652	141	186	141	186	146	92	129
MEAN	224	249	260	217	169	218	232
SD	73.2	105.3	154.0	74.2	40.0	121.4	88.1
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: BUN

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	9.8	8.9	12.3	11.4	14.2	--	--
8687	10.1	9.8	14.5	15.4	14.1	--	--
8669	12.3	12.8	10.9	13.5	12.3	--	--
8673	10.0	14.4	14.2	14.9	15.6	--	--
8667	10.2	11.4	12.1	12.6	13.0	19.0	13.5
8654	17.0	17.0	18.0	18.9	18.2	18.3	16.5
8680	7.3	12.4	11.8	11.6	12.3	13.1	12.1
8676	10.0	11.8	11.9	9.6	12.8	13.7	13.0
MEAN	10.8	12.3	13.2	13.5	14.1	16.0	13.8
SD	2.83	2.55	2.29	2.90	2.02	3.05	1.91
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	9.2	6.9	11.8	9.7	12.2	--	--
8663	11.6	11.8	13.7	15.7	19.7	--	--
8686	11.3	16.4	13.2	12.7	16.9	--	--
8665	12.9	12.7	15.3	17.7	19.0	17.1	18.7
8666	10.4	9.4	14.8	13.0	21.1	17.5	14.2
8655	11.1	9.3	10.3	9.4	11.9	13.6	16.6
8659	13.5	12.0	12.9	13.0	18.5	15.9	12.9
8677	13.6	13.3	12.2	15.1	18.2	--	--
MEAN	11.7	11.5	13.0	13.3	17.2	16.0	15.6
SD	1.55	2.91	1.62	2.86	3.39	1.75	2.57
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A - SEX: MALE
STUDY NO: 193
ABBR: BUN UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	12.0	7.5	10.8	8.4	12.7	14.1	12.2
8653	9.6	11.0	15.1	18.1	18.0	--	--
8660	13.6	13.4	14.7	18.5	18.6	--	--
8668	9.4	8.1	12.2	12.6	15.0	--	--
8682	16.7	19.7	20.9	18.3	17.3	16.9	16.8
8684	13.6	14.7	12.6	14.9	16.5	--	--
8662	13.9	12.3	15.4	19.0	17.8	16.9	13.5
8688	10.8	9.3	12.0	13.5	11.7	13.4	13.0
MEAN	12.5	12.0	14.2	15.4	16.0	15.3	13.9
SD	2.48	4.01	3.17	3.76	2.57	1.84	2.02
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	13.6	14.1	17.5	17.8	19.9	--	--
8670	11.5	11.0	11.3	13.8	15.7	--	--
8681	8.9	13.4	12.8	16.3	14.8	--	--
8664	9.3	10.3	9.4	14.2	18.5	--	--
8675	15.6	11.3	13.0	14.3	18.3	14.4	12.6
8683	13.5	13.0	11.9	13.3	13.7	16.0	15.0
8658	10.8	12.6	16.4	14.5	12.8	19.7	16.1
8652	10.6	11.6	15.5	15.5	17.0	19.9	15.5
MEAN	11.7	12.2	13.5	15.0	16.3	17.5	14.8
SD	2.32	1.31	2.76	1.49	2.50	2.74	1.53
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatinine

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CREAT

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	0.71	0.72	0.73	0.72	0.73	--	--
8687	0.79	0.71	0.86	0.84	0.86	--	--
8669	0.77	0.76	0.79	0.86	0.81	--	--
8673	0.84	0.73	0.73	0.81	0.82	--	--
8667	0.70	0.72	0.78	0.78	0.78	0.88	0.86
8654	0.84	0.76	0.73	0.79	0.74	0.81	0.83
8680	0.66	0.72	0.69	0.70	0.80	0.79	0.76
8676	0.73	0.67	0.72	0.76	0.77	0.87	0.94
MEAN	0.76	0.72	0.75	0.78	0.79	0.84	0.85
SD	0.066	0.029	0.054	0.055	0.043	0.044	0.075
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	0.54	0.57	0.68	0.69	0.70	--	--
8663	0.74	0.74	0.73	0.88	0.85	--	--
8686	0.79	0.86	0.76	0.80	0.79	--	--
8665	0.69	0.73	0.75	0.80	0.80	0.83	0.85
8666	0.81	0.78	0.88	0.88	0.90	0.93	0.87
8655	0.66	0.65	0.65	0.69	0.70	0.71	0.68
8659	0.67	0.66	0.69	0.74	0.80	0.84	0.84
8677	0.70	0.77	0.78	0.76	0.82	--	--
MEAN	0.70	0.72	0.74	0.78	0.80	0.83	0.81
SD	0.085	0.090	0.072	0.075	0.068	0.090	0.088
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatinine

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CREAT

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	0.80	0.72	0.68	0.73	0.77	0.74	0.84
8653	0.78	0.82	0.76	0.70	0.73	--	--
8660	0.78	0.76	0.83	0.80	0.84	--	--
8668	0.69	0.65	0.67	0.68	0.69	--	--
8682	0.84	0.77	0.68	0.71	0.64	0.68	0.72
8684	0.77	0.71	0.77	0.78	0.86	--	--
8662	0.73	0.63	0.82	0.79	0.72	0.70	0.70
8688	0.76	0.73	0.84	0.84	0.91	0.93	0.97
MEAN	0.77	0.72	0.76	0.75	0.77	0.76	0.81
SD	0.045	0.062	0.072	0.057	0.093	0.114	0.125
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	0.79	0.75	0.81	0.81	0.87	--	--
8670	0.70	0.74	0.72	0.81	0.72	--	--
8681	0.70	0.68	0.76	0.93	0.88	--	--
8664	0.55	0.63	0.62	0.69	0.71	--	--
8675	0.84	0.71	0.70	0.78	0.75	0.78	0.66
8683	0.77	0.71	0.75	0.86	0.81	0.94	0.98
8658	0.75	0.71	0.74	0.81	0.76	0.77	0.77
8652	0.65	0.67	0.80	0.67	0.84	0.90	0.79
MEAN	0.72	0.70	0.74	0.80	0.79	0.85	0.80
SD	0.090	0.039	0.060	0.085	0.067	0.085	0.133
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Sodium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: NA

SEX: MALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	149	148	146	147	149	--	--
8687	145	144	147	145	146	--	--
8669	147	146	145	147	145	--	--
8673	146	146	146	145	147	--	--
8667	145	144	146	145	147	148	145
8654	147	143	148	145	147	147	148
8680	148	145	146	146	148	146	148
8676	147	143	145	145	147	146	149
MEAN	147	145	146	146	147	147	148
SD	1.4	1.7	1.0	0.9	1.2	1.0	1.7
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	146	145	146	143	146	--	--
8663	147	147	144	147	148	--	--
8686	146	146	144	145	144	--	--
8665	145	144	142	142	145	146	145
8666	146	144	142	145	147	149	147
8655	146	145	144	142	146	144	146
8659	147	145	146	146	147	147	148
8677	145	148	145	145	147	--	--
MEAN	146	146	144	144	146	147	147
SD	0.8	1.4	1.6	1.8	1.3	2.1	1.3
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Sodium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: NA

SEX: MALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	145	144	144	144	145	142	147
8653	144	145	145	147	142	--	--
8660	146	144	145	146	146	--	--
8668	147	147	148	146	148	--	--
8682	148	147	145	147	148	148	149
8684	148	146	147	147	147	--	--
8662	149	146	145	149	146	149	144
8688	147	147	146	146	149	150	148
MEAN	147	146	146	147	146	147	147
SD	1.7	1.3	1.3	1.4	2.2	3.6	2.2
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	147	148	143	146	146	--	--
8670	144	147	147	145	148	--	--
8681	146	145	143	148	147	--	--
8664	143	143	143	143	141	--	--
8675	148	147	146	147	147	147	147
8683	146	145	147	146	148	147	148
8658	148	146	147	144	144	150	150
8652	148	146	147	148	148	147	147
MEAN	146	146	145	146	146	148	148
SD	1.9	1.6	2.0	1.8	2.5	1.5	1.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Potassium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: K

SEX: MALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	4.35	4.08	3.87	4.02	4.36	--	--
8687	4.39	4.44	4.43	4.23	4.29	--	--
8669	4.59	4.59	4.74	4.91	4.52	--	--
8673	4.81	4.37	4.44	4.49	4.29	--	--
8667	4.59	4.83	4.74	4.53	4.51	4.64	4.30
8654	4.72	4.36	4.52	4.79	4.52	4.64	4.50
8680	4.39	4.55	4.44	4.45	4.52	4.49	4.50
8676	4.56	4.74	4.35	4.52	4.50	4.44	4.30
MEAN	4.55	4.50	4.44	4.49	4.44	4.55	4.40
SD	0.165	0.237	0.272	0.283	0.106	0.103	0.115
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	4.37	4.56	4.40	4.43	4.26	--	--
8663	4.69	4.36	3.97	4.50	4.31	--	--
8686	3.98	4.48	4.23	4.37	4.48	--	--
8665	4.42	3.97	4.38	4.54	4.62	4.16	4.13
8666	4.37	4.47	4.26	4.58	4.29	4.86	4.34
8655	4.68	4.18	4.11	4.34	4.44	4.11	4.40
8659	4.71	4.84	4.37	4.25	4.65	4.30	4.47
8677	4.74	5.46	4.48	4.41	4.35	--	--
MEAN	4.50	4.54	4.28	4.43	4.43	4.36	4.34
SD	0.262	0.452	0.169	0.110	0.149	0.345	0.147
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Potassium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: K

SEX: MALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	4.35	4.12	3.88	4.17	3.85	4.42	4.07
8653	4.56	4.24	4.09	4.35	4.58	--	--
8660	4.76	4.55	4.33	4.73	4.17	--	--
8668	4.42	4.25	4.18	4.30	4.21	--	--
8682	4.25	4.50	4.28	4.12	4.20	4.69	4.32
8684	4.04	4.62	4.16	4.33	4.52	--	--
8662	4.83	4.74	4.11	4.24	4.11	4.66	4.18
8688	4.36	4.09	4.36	4.59	4.45	4.59	4.32
MEAN	4.45	4.39	4.17	4.35	4.26	4.59	4.22
SD	0.262	0.244	0.155	0.208	0.242	0.121	0.121
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	4.44	4.32	4.14	4.20	4.38	--	--
8670	4.41	4.13	4.30	4.52	4.31	--	--
8681	4.49	4.72	4.28	4.66	4.23	--	--
8664	4.57	4.39	4.41	4.41	4.55	--	--
8675	4.99	4.46	4.36	4.56	4.38	4.83	4.49
8683	4.34	4.54	4.33	4.51	4.65	5.19	4.59
8658	4.38	4.28	4.42	4.59	4.35	4.36	4.16
8652	4.42	4.52	4.37	4.36	4.80	4.59	4.36
MEAN	4.51	4.42	4.33	4.48	4.46	4.74	4.40
SD	0.208	0.182	0.090	0.147	0.193	0.355	0.186
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Chloride

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CL

SEX: MALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	113	112	110	113	111	--	--
8687	116	107	107	110	109	--	--
8669	114	109	109	112	112	--	--
8673	114	109	115	112	115	--	--
8667	113	111	112	109	115	113	113
8654	114	109	114	113	113	115	117
8680	113	107	113	111	113	113	113
8676	112	106	114	111	114	111	113
MEAN	114	109	112	111	113	113	114
SD	1.2	2.1	2.8	1.4	2.1	1.6	2.0
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	117	109	113	112	114	--	--
8663	114	107	109	110	112	--	--
8686	115	112	110	110	112	--	--
8665	113	110	108	111	111	115	115
8666	112	109	114	111	115	113	118
8655	114	110	112	108	113	114	115
8659	115	110	108	110	111	113	114
8677	113	104	110	107	114	--	--
MEAN	114	109	111	110	113	114	116
SD	1.6	2.4	2.3	1.6	1.5	1.0	1.7
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Chloride

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CL

SEX: MALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	117	108	108	113	111	113	115
8653	111	107	111	113	113	--	--
8660	111	107	109	111	113	--	--
8668	113	107	115	114	115	--	--
8682	117	113	114	114	118	116	116
8684	119	110	110	113	115	--	--
8662	111	109	112	112	115	112	116
8688	113	110	109	109	111	115	118
MEAN	114	109	111	112	114	114	116
SD	3.2	2.1	2.5	1.7	2.4	1.8	1.3
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	112	108	113	113	113	--	--
8670	112	111	111	110	116	--	--
8681	111	107	112	112	115	--	--
8664	113	106	118	112	112	--	--
8675	115	107	110	112	114	114	117
8683	114	104	111	110	112	115	114
8658	109	104	112	109	112	116	121
8652	111	104	111	111	111	113	111
MEAN	112	106	112	111	113	115	116
SD	1.9	2.4	2.5	1.4	1.7	1.3	4.3
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Calcium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CA

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	10.2	10.2	9.8	9.9	10.5	--	--
8687	10.6	10.4	10.3	10.0	10.5	--	--
8669	9.9	10.3	9.9	10.2	10.1	--	--
8673	10.4	10.0	9.8	9.9	10.4	--	--
8667	9.8	9.8	10.3	10.1	10.5	10.5	9.7
8654	10.2	9.9	10.0	9.7	10.1	10.5	9.7
8680	10.4	10.2	10.2	10.3	10.7	10.8	10.0
8676	10.8	10.4	10.3	10.4	10.7	10.9	10.2
MEAN	10.3	10.2	10.1	10.1	10.4	10.7	9.9
SD	0.34	0.23	0.23	0.23	0.23	0.21	0.24
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	10.4	10.1	10.1	9.4	10.3	--	--
8663	9.9	10.5	9.9	10.1	10.3	--	--
8686	10.5	10.4	9.8	10.0	10.0	--	--
8665	10.4	10.3	9.9	9.6	10.4	10.3	9.7
8666	10.1	10.2	10.0	9.8	10.3	10.7	10.0
8655	10.3	10.4	10.2	9.5	10.6	10.0	9.7
8659	10.1	10.3	10.2	10.0	10.9	10.4	9.5
8677	10.7	11.0	10.4	10.3	10.6	--	--
MEAN	10.3	10.4	10.1	9.8	10.4	10.4	9.7
SD	0.26	0.27	0.20	0.32	0.27	0.29	0.21
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Calcium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CA

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	10.4	9.9	9.8	9.9	10.1	9.6	9.6
8653	9.9	10.2	10.0	9.9	9.4	--	--
8660	9.9	10.2	10.0	10.1	10.4	--	--
8668	10.3	10.1	9.9	10.2	10.4	--	--
8682	10.3	10.2	9.9	9.8	9.8	10.2	9.2
8684	10.3	10.7	10.5	10.2	10.6	--	--
8662	10.2	9.9	9.8	9.1	9.8	10.2	8.9
8688	10.9	10.4	10.6	10.1	10.4	11.3	10.1
MEAN	10.3	10.2	10.1	9.9	10.1	10.3	9.5
SD	0.32	0.26	0.31	0.36	0.41	0.71	0.52
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	10.3	10.4	9.7	9.7	10.2	--	--
8670	10.0	10.2	10.0	10.1	10.6	--	--
8681	10.4	10.4	9.9	10.3	10.5	--	--
8664	10.2	10.4	9.9	10.3	10.4	--	--
8675	10.6	10.2	10.1	10.0	10.3	10.8	10.0
8683	10.4	10.4	9.9	10.2	10.4	10.8	10.1
8658	10.0	10.0	9.9	9.9	10.0	9.9	9.4
8652	10.5	10.5	10.4	10.1	10.9	10.6	10.1
MEAN	10.3	10.3	10.0	10.1	10.4	10.5	9.9
SD	0.22	0.16	0.21	0.21	0.27	0.43	0.34
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Inorganic Phosphorus

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: IP

SEX: MALE
UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	5.4	5.5	6.0	5.6	5.8	--	--
8687	5.5	6.0	5.5	5.2	5.1	--	--
8669	5.8	7.1	6.9	6.8	5.1	--	--
8673	6.0	5.9	5.8	5.6	6.1	--	--
8667	6.3	5.8	6.2	6.4	4.2	5.1	3.9
8654	5.2	5.9	5.6	6.0	6.1	5.0	4.4
8680	5.4	5.6	6.1	5.9	4.9	5.2	3.6
8676	6.0	5.7	5.5	5.1	5.2	4.3	4.4
MEAN	5.7	5.9	6.0	5.8	5.3	4.9	4.1
SD	0.38	0.50	0.47	0.58	0.65	0.41	0.39
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	5.7	5.8	6.8	5.1	5.0	--	--
8663	5.2	6.5	5.8	5.9	4.5	--	--
8686	5.7	6.9	5.7	5.6	4.7	--	--
8665	5.6	4.6	5.9	4.3	4.8	4.3	3.9
8666	5.3	5.8	5.6	4.5	5.4	5.4	3.9
8655	5.8	6.4	5.1	4.8	5.9	4.7	4.6
8659	5.8	6.1	5.3	5.4	6.0	5.1	4.2
8677	6.1	6.7	7.2	6.5	5.3	--	--
MEAN	5.7	6.1	5.9	5.3	5.2	4.9	4.2
SD	0.29	0.73	0.72	0.74	0.55	0.48	0.33
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Inorganic Phosphorus

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: IP

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	5.6	5.0	5.1	4.5	4.7	4.5	3.9
8653	4.9	5.6	5.1	4.9	3.3	--	--
8660	5.6	5.9	5.6	5.8	4.8	--	--
8668	4.9	5.5	4.9	5.5	5.3	--	--
8682	5.1	5.5	6.0	5.4	4.6	4.4	4.7
8684	5.0	6.1	5.4	5.2	5.0	--	--
8662	5.3	5.5	4.7	4.1	3.8	4.7	2.7
8688	6.0	5.8	5.7	5.3	5.3	5.5	2.8
MEAN	5.3	5.6	5.3	5.1	4.6	4.8	3.5
SD	0.40	0.33	0.44	0.56	0.71	0.50	0.95
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	5.3	5.8	5.4	5.3	5.2	--	--
8670	6.0	6.0	5.7	5.9	5.7	--	--
8681	5.4	6.0	5.4	4.9	5.1	--	--
8664	4.8	5.7	5.4	5.5	5.2	--	--
8675	5.8	5.9	5.4	5.9	5.9	5.9	4.0
8683	6.0	5.5	5.7	6.2	6.0	5.2	3.9
8658	4.8	5.4	4.4	5.0	5.2	4.1	4.2
8652	6.0	6.0	5.5	3.8	5.7	4.5	4.0
MEAN	5.5	5.8	5.4	5.3	5.5	4.9	4.0
SD	0.52	0.24	0.41	0.76	0.36	0.79	0.13
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Glucose

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLU

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	99	104	104	94	101	--	--
8687	101	115	113	98	85	--	--
8669	107	115	107	109	120	--	--
8673	121	109	107	106	113	--	--
8667	107	99	93	97	105	101	98
8654	96	95	94	98	92	101	90
8680	107	121	104	107	117	119	106
8676	121	108	116	107	114	109	108
MEAN	107	108	105	102	106	108	101
SD	9.3	8.7	8.1	5.8	12.5	8.5	8.2
N	8	8	8	8	8	4	4
GROUP: 2-M:0.1 mg base/kg/day							
8685	113	122	116	119	129	--	--
8663	98	115	121	109	116	--	--
8686	122	116	105	101	117	--	--
8665	96	104	106	107	102	106	101
8666	112	111	106	102	110	112	99
8655	97	115	113	106	113	106	99
8659	100	108	107	102	110	102	98
8677	115	124	112	99	120	--	--
MEAN	107	114	111	106	115	107	99
SD	10.0	6.7	5.8	6.4	8.0	4.1	1.3
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Glucose

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLU

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	117	111	106	113	122	112	113
8653	95	106	96	104	104	--	--
8660	98	96	101	95	101	--	--
8668	107	103	104	103	108	--	--
8682	117	118	115	99	110	109	129
8684	106	106	110	102	107	--	--
8662	106	107	107	107	118	100	105
8688	92	111	112	92	103	108	98
MEAN	105	107	106	102	109	107	111
SD	9.3	6.5	6.1	6.6	7.4	5.1	13.3
N	8	8	8	8	8	4	4
GROUP: 4-M:1.0 mg base/kg/day							
8661	114	111	124	110	113	--	--
8670	104	104	104	108	98	--	--
8681	99	94	95	106	105	--	--
8664	91	97	90	97	103	--	--
8675	100	93	101	86	96	100	89
8683	109	114	109	114	112	135	109
8658	108	106	100	99	100	101	109
8652	104	99	110	86	96	109	102
MEAN	104	102	104	101	103	111	102
SD	7.1	7.8	10.4	10.6	6.7	16.3	9.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Haptoglobin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: HAPT

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-M:0 mg base/kg/day							
8656	55.1	50.7	41.1	25.1	18.2	--	--
8687	16.7	47.1	17.3	-- B	-- B	--	--
8669	92.3	70.8	70.1	-- B	-- B	--	--
8673	49.7	88.6	87.2	78.8	72.6	--	--
8667	19.7	71.3	18.2	17.3	-- B	103.8	-- B
8654	-- B	-- B	-- B	-- B	-- B	-- B	23.0
8680	44.9	108.1	50.3	100.2	34.4	76.1	48.7
8676	76.9	129.3	140.0	107.5	106.5	130.9	126.0
MEAN	50.8	80.8	60.6	65.8	57.9	103.6	65.9
SD	27.65	29.97	43.32	42.13	39.61	27.40	53.61
N	7	7	7	5	4	3	3
GROUP: 2-M:0.1 mg base/kg/day							
8685	22.2	35.2	114.5	58.6	41.6	--	--
8663	37.5	67.8	26.9	37.8	37.4	--	--
8686	26.8	-- B	34.2	-- B	22.4	--	--
8665	22.1	34.5	17.7	-- B	-- B	23.0	-- B
8666	19.4	71.2	22.8	20.0	24.2	-- B	-- B
8655	23.6	55.4	51.3	-- B	37.9	42.1	61.2
8659	48.5	114.1	120.1	91.2	74.5	101.3	76.2
8677	135.9	110.0	141.2	123.1	112.5	--	--
MEAN	42.0	69.7	66.1	66.1	50.1	55.5	68.7
SD	39.18	32.24	50.55	41.42	32.43	40.83	10.61
N	8	7	8	5	7	3	2

(--) - Data Unavailable

B - Below Linearity

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Haptoglobin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: HAPT

SEX: MALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-M:0.3 mg base/kg/day							
8674	37.0	84.5	131.9	154.8	65.0	72.5	57.9
8653	-- B	-- B	18.1	-- B	-- B	--	--
8660	70.9	82.8	115.2	75.5	82.5	--	--
8668	38.1	46.7	119.6	69.8	67.4	--	--
8682	19.7	-- B	29.8	36.3	32.7	99.9	49.6
8684	19.7	94.2	72.1	49.8	-- B	--	--
8662	55.4	94.1	66.8	75.4	-- B	29.9	-- B
8688	67.9	114.4	111.5	88.0	75.2	91.9	17.0
MEAN	44.1	86.1	83.1	78.5	64.6	73.6	41.5
SD	21.17	22.34	43.10	37.88	19.09	31.29	21.62
N	7	6	8	7	5	4	3
GROUP: 4-M:1.0 mg base/kg/day							
8661	18.6	20.2	85.8	98.5	69.9	--	--
8670	42.1	76.9	188.0	60.3	81.1	--	--
8681	20.8	-- B	189.1	33.1	23.0	--	--
8664	25.6	37.4	217.9	37.8	40.4	--	--
8675	19.8	89.1	200.0	62.3	64.1	99.6	34.3
8683	39.2	81.7	279.5	134.4	123.1	88.4	112.4
8658	50.2	76.4	71.0	37.2	56.4	-- B	-- B
8652	105.4	108.9	237.7	17.1	92.7	105.4	115.0
MEAN	40.2	70.1	183.6	60.1	68.8	97.8	87.2
SD	28.85	30.68	71.58	38.91	31.06	8.64	45.86
N	8	7	8	8	8	3	3

(--) - Data Unavailable

B - Below Linearity

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alanine Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALT

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	32	33	46	49	54	--	--
8712	41	26	25	34	36	--	--
8710	30	27	32	38	37	--	--
8723	29	33	20	29	16	--	--
8705	32	24	25	18	23	33	23
8700	35	33	38	36	47	36	35
8699	36	26	34	33	27	27	37
8690	27	26	33	28	37	36	27
MEAN	33	29	32	33	35	33	31
SD	4.5	3.8	8.3	8.9	12.4	4.2	6.6
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	41	28	26	28	26	--	--
8703	37	34	34	36	34	--	--
8713	30	26	32	30	28	--	--
8693	33	31	33	35	39	--	--
8695	34	29	25	34	32	21	28
8709	26	30	29	31	28	20	33
8715	31	31	33	38	37	33	27
8697	25	23	34	26	27	34	33
MEAN	32	29	31	32	31	27	30
SD	5.4	3.4	3.6	4.2	4.9	7.5	3.2
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alanine Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALT

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	22	21	19	17	24	--	--
8718	18	18	20	24	28	--	--
8706	24	17	21	27	28	--	--
8714	25	27	17	28	24	--	--
8701	34	26	27	32	32	25	34
8702	24	32	44	38	29	23	29
8720	26	25	31	32	30	23	32
8704	36	23	26	32	33	29	43
MEAN	26	24	26	29	29	25	35
SD	6.0	5.0	8.8	6.3	3.3	2.8	6.0
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	25	22	35	26	31	--	--
8719	27	27	22	23	20	--	--
8711	29	29	29	31	31	--	--
8716	27	24	29	33	42	--	--
8725	42	30	25	27	28	37	28
8707	30	25	27	24	30	27	24
8689	34	28	26	27	38	23	34
8722	25	23	19	23	30	25	23
MEAN	30	26	27	27	31	28	27
SD	5.7	2.9	4.8	3.7	6.6	6.2	5.0
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: AST

SEX: FEMALE
UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	36	32	48	46	49	--	--
8712	52	27	41	45	47	--	--
8710	38	33	48	72	42	--	--
8723	31	33	27	27	23	--	--
8705	40	34	34	31	38	53	41
8700	31	35	28	36	52	32	45
8699	31	44	42	27	36	25	38
8690	32	26	41	28	32	32	29
MEAN	36	33	39	39	40	36	38
SD	7.2	5.5	8.2	15.4	9.6	12.1	6.8
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	37	30	25	38	46	--	--
8703	27	36	29	31	35	--	--
8713	46	44	44	42	42	--	--
8693	34	28	28	30	36	--	--
8695	26	27	39	34	44	19	34
8709	24	34	32	32	43	24	34
8715	21	22	31	37	38	29	36
8697	24	22	26	20	34	25	26
MEAN	30	30	32	33	40	24	33
SD	8.4	7.4	6.6	6.6	4.6	4.1	4.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Aspartate Aminotransferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: AST

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	24	29	31	26	30	--	--
8718	23	30	36	26	34	--	--
8706	25	21	27	30	31	--	--
8714	51	41	40	49	45	--	--
8701	29	31	41	36	38	49	47
8702	30	40	60	55	51	43	55
8720	21	26	37	31	37	36	35
8704	30	34	41	44	44	34	55
MEAN	29	32	39	37	39	41	48
SD	9.5	6.7	9.8	11.0	7.4	6.9	9.5
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	23	28	43	42	43	--	--
8719	42	33	49	52	61	--	--
8711	37	35	58	43	47	--	--
8716	24	34	40	41	60	--	--
8725	37	26	36	39	50	23	26
8707	27	21	40	40	55	32	41
8689	29	34	59	45	52	30	39
8722	18	30	39	35	55	27	34
MEAN	30	30	46	42	53	28	35
SD	8.3	4.9	8.9	5.0	6.2	3.9	6.7
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Protein

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TP

SEX: FEMALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	6.0	6.2	6.1	6.2	6.2	--	--
8712	6.6	5.8	5.5	6.0	6.0	--	--
8710	6.4	6.0	5.6	6.2	6.5	--	--
8723	5.8	5.3	6.0	5.7	6.0	--	--
8705	6.5	6.0	6.3	6.1	6.7	6.3	6.9
8700	5.4	5.3	5.9	5.4	5.7	6.0	6.1
8699	5.5	5.3	6.3	5.7	6.1	6.0	6.5
8690	6.0	5.6	6.4	6.1	6.2	6.5	6.9
MEAN	6.0	5.7	6.0	5.9	6.2	6.2	6.6
SD	0.45	0.36	0.33	0.29	0.31	0.24	0.38
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	6.1	5.4	5.1	5.7	6.0	--	--
8703	6.1	6.2	6.1	5.8	6.1	--	--
8713	5.9	5.5	6.0	5.4	6.2	--	--
8693	6.6	5.9	6.4	5.6	6.4	--	--
8695	6.1	5.7	5.8	6.4	6.4	6.4	6.6
8709	7.0	6.1	5.9	5.9	6.4	6.3	6.1
8715	6.4	5.4	5.5	6.2	6.3	6.4	6.4
8697	6.2	5.8	6.5	6.6	6.9	6.6	7.1
MEAN	6.3	5.8	5.9	6.0	6.3	6.4	6.6
SD	0.35	0.31	0.46	0.41	0.27	0.13	0.42
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Protein

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TP

SEX: FEMALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	6.5	5.4	5.9	5.7	5.9	--	--
8718	6.3	5.6	5.8	5.7	6.2	--	--
8706	6.2	5.9	6.2	6.2	6.3	--	--
8714	6.2	5.6	5.2	5.9	6.8	--	--
8701	6.0	6.0	5.9	5.9	6.4	6.2	6.7
8702	5.8	6.0	6.1	5.9	5.9	6.1	6.8
8720	6.4	5.6	6.4	6.5	6.3	6.2	6.1
8704	5.7	5.5	5.4	5.3	6.2	6.1	6.3
MEAN	6.1	5.7	5.9	5.9	6.3	6.2	6.5
SD	0.28	0.23	0.40	0.36	0.29	0.06	0.33
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	5.8	6.1	5.5	5.3	6.2	--	--
8719	5.8	5.3	5.7	5.9	6.2	--	--
8711	6.7	5.6	5.6	5.7	6.3	--	--
8716	6.5	6.7	6.0	6.0	6.7	--	--
8725	6.7	6.5	6.0	6.0	6.2	6.3	6.2
8707	6.2	5.9	5.3	5.6	6.1	6.3	6.5
8689	6.6	6.0	5.8	6.5	6.7	6.6	6.5
8722	5.9	5.4	5.5	5.5	6.2	5.8	6.6
MEAN	6.3	5.9	5.7	5.8	6.3	6.3	6.5
SD	0.40	0.50	0.25	0.37	0.24	0.33	0.17
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Albumin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALB

SEX: FEMALE
UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	3.2	3.3	3.5	3.5	3.1	--	--
8712	3.5	3.1	3.1	3.1	3.1	--	--
8710	3.2	3.3	3.1	3.4	3.3	--	--
8723	3.2	3.1	3.3	3.1	3.0	--	--
8705	3.1	3.1	3.4	3.1	3.1	3.3	3.5
8700	2.9	3.0	3.2	3.1	3.2	3.3	3.4
8699	2.9	3.1	3.3	3.2	3.2	2.9	3.5
8690	3.2	3.2	3.4	3.3	3.4	3.1	3.5
MEAN	3.2	3.2	3.3	3.2	3.2	3.2	3.5
SD	0.19	0.11	0.15	0.16	0.13	0.19	0.05
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	3.3	3.1	2.9	3.2	3.1	--	--
8703	3.3	3.3	3.4	3.1	3.3	--	--
8713	3.1	2.7	3.3	2.9	3.2	--	--
8693	3.4	3.4	3.2	3.2	3.3	--	--
8695	3.3	3.4	3.4	3.6	3.4	3.2	3.5
8709	3.5	3.3	3.3	3.2	3.2	3.2	3.3
8715	3.4	3.0	3.1	3.2	3.2	3.4	3.2
8697	3.1	3.2	3.5	3.6	3.6	3.3	3.4
MEAN	3.3	3.2	3.3	3.3	3.3	3.3	3.4
SD	0.14	0.24	0.19	0.24	0.16	0.10	0.13
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Albumin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALB

SEX: FEMALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	3.1	2.7	3.1	3.0	2.8	--	--
8718	3.2	2.7	3.1	3.1	3.1	--	--
8706	3.1	3.2	3.2	3.2	3.1	--	--
8714	2.9	3.0	2.9	3.3	3.3	--	--
8701	3.5	3.2	3.3	3.3	3.3	3.2	3.5
8702	3.2	3.0	3.2	3.2	3.0	3.0	3.4
8720	3.4	3.0	3.4	3.5	3.1	3.3	3.6
8704	3.0	3.0	3.1	3.1	3.1	2.9	3.5
MEAN	3.2	3.0	3.2	3.2	3.1	3.1	3.5
SD	0.20	0.19	0.15	0.16	0.16	0.18	0.08
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	3.2	3.2	3.1	3.1	3.1	--	--
8719	3.1	3.0	2.8	3.0	3.1	--	--
8711	3.5	3.2	3.0	3.0	3.3	--	--
8716	3.4	3.5	3.0	3.1	3.1	--	--
8725	3.7	3.4	2.9	3.2	3.3	3.0	3.4
8707	3.2	3.2	2.8	3.1	3.2	3.3	3.5
8689	3.2	3.0	3.0	3.3	3.1	3.0	3.4
8722	3.2	3.1	2.6	3.0	3.3	3.1	3.4
MEAN	3.3	3.2	2.9	3.1	3.2	3.1	3.4
SD	0.20	0.18	0.16	0.11	0.10	0.14	0.05
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Globulin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLOB

SEX: FEMALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	2.8	2.9	2.6	2.7	3.1	--	--
8712	3.1	2.7	2.4	2.9	2.9	--	--
8710	3.2	2.7	2.5	2.8	3.2	--	--
8723	2.6	2.2	2.7	2.6	3.0	--	--
8705	3.4	2.9	2.9	3.0	3.6	3.0	3.4
8700	2.5	2.3	2.7	2.3	2.5	2.7	2.7
8699	2.6	2.2	3.0	2.5	2.9	3.1	3.0
8690	2.8	2.4	3.0	2.8	2.8	3.4	3.4
MEAN	2.9	2.5	2.7	2.7	3.0	3.1	3.1
SD	0.32	0.30	0.23	0.23	0.32	0.29	0.34
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	2.8	2.3	2.2	2.5	2.9	--	--
8703	2.8	2.9	2.7	2.7	2.8	--	--
8713	2.8	2.8	2.7	2.5	3.0	--	--
8693	3.2	2.5	3.2	2.4	3.1	--	--
8695	2.8	2.3	2.4	2.8	3.0	3.2	3.1
8709	3.5	2.8	2.6	2.7	3.2	3.1	2.8
8715	3.0	2.4	2.4	3.0	3.1	3.0	3.2
8697	3.1	2.6	3.0	3.0	3.3	3.3	3.7
MEAN	3.0	2.6	2.7	2.7	3.1	3.2	3.2
SD	0.26	0.24	0.33	0.23	0.16	0.13	0.37
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Globulin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLOB

SEX: FEMALE

UNITS: g/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	3.4	2.7	2.8	2.7	3.1	--	--
8718	3.1	2.9	2.7	2.6	3.1	--	--
8706	3.1	2.7	3.0	3.0	3.2	--	--
8714	3.3	2.6	2.3	2.6	3.5	--	--
8701	2.5	2.8	2.6	2.6	3.1	3.0	3.2
8702	2.6	3.0	2.9	2.7	2.9	3.1	3.4
8720	3.0	2.6	3.0	3.0	3.2	2.9	2.5
8704	2.7	2.5	2.3	2.2	3.1	3.2	2.8
MEAN	3.0	2.7	2.7	2.7	3.2	3.1	3.0
SD	0.33	0.17	0.28	0.25	0.17	0.13	0.40
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	2.6	2.9	2.4	2.2	3.1	--	--
8719	2.7	2.3	2.9	2.9	3.1	--	--
8711	3.2	2.4	2.6	2.7	3.0	--	--
8716	3.1	3.2	3.0	2.9	3.6	--	--
8725	3.0	3.1	3.1	2.8	2.9	3.3	2.8
8707	3.0	2.7	2.5	2.5	2.9	3.0	3.0
8689	3.4	3.0	2.8	3.2	3.6	3.6	3.1
8722	2.7	2.3	2.9	2.5	2.9	2.7	3.2
MEAN	3.0	2.7	2.8	2.7	3.1	3.2	3.0
SD	0.28	0.37	0.25	0.31	0.30	0.39	0.17
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: A/G Ratio

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: A/G

SEX: FEMALE

UNITS: -

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	1.14	1.14	1.35	1.30	1.00	--	--
8712	1.13	1.15	1.29	1.07	1.07	--	--
8710	1.00	1.22	1.24	1.21	1.03	--	--
8723	1.23	1.41	1.22	1.19	1.00	--	--
8705	0.91	1.07	1.17	1.03	0.86	1.10	1.03
8700	1.16	1.30	1.19	1.35	1.28	1.22	1.26
8699	1.12	1.41	1.10	1.28	1.10	0.94	1.17
8690	1.14	1.33	1.13	1.18	1.21	0.91	1.03
MEAN	1.10	1.25	1.21	1.20	1.07	1.04	1.12
SD	0.101	0.128	0.082	0.110	0.131	0.145	0.113
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	1.18	1.35	1.32	1.28	1.07	--	--
8703	1.18	1.14	1.26	1.15	1.18	--	--
8713	1.11	0.96	1.22	1.16	1.07	--	--
8693	1.06	1.36	1.00	1.33	1.06	--	--
8695	1.18	1.48	1.42	1.29	1.13	1.00	1.13
8709	1.00	1.18	1.27	1.19	1.00	1.03	1.18
8715	1.13	1.25	1.29	1.07	1.03	1.13	1.00
8697	1.00	1.23	1.17	1.20	1.09	1.00	0.92
MEAN	1.11	1.24	1.24	1.21	1.08	1.04	1.06
SD	0.077	0.159	0.123	0.086	0.056	0.062	0.119
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: A/G Ratio

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: A/G

SEX: FEMALE

UNITS: -

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	0.91	1.00	1.11	1.11	0.90	--	--
8718	1.03	0.93	1.15	1.19	1.00	--	--
8706	1.00	1.19	1.07	1.07	0.97	--	--
8714	0.88	1.15	1.26	1.27	0.94	--	--
8701	1.40	1.14	1.27	1.27	1.06	1.07	1.09
8702	1.23	1.00	1.10	1.19	1.03	0.97	1.00
8720	1.13	1.15	1.13	1.17	0.97	1.14	1.44
8704	1.11	1.20	1.35	1.41	1.00	0.91	1.25
MEAN	1.09	1.10	1.18	1.21	0.98	1.02	1.20
SD	0.171	0.102	0.100	0.106	0.050	0.102	0.193
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	1.23	1.10	1.29	1.41	1.00	--	--
8719	1.15	1.30	0.97	1.03	1.00	--	--
8711	1.09	1.33	1.15	1.11	1.10	--	--
8716	1.10	1.09	1.00	1.07	0.86	--	--
8725	1.23	1.10	0.94	1.14	1.14	0.91	1.21
8707	1.07	1.19	1.12	1.24	1.10	1.10	1.17
8689	0.94	1.00	1.07	1.03	0.86	0.83	1.10
8722	1.19	1.35	0.90	1.20	1.14	1.15	1.06
MEAN	1.13	1.18	1.06	1.15	1.03	1.00	1.14
SD	0.097	0.130	0.129	0.128	0.116	0.152	0.068
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Bilirubin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TBILI

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	0.14	0.14	0.19	0.18	0.18	--	--
8712	0.24	0.17	0.24	0.26	0.18	--	--
8710	0.16	0.13	0.19	0.30	0.16	--	--
8723	0.19	0.14	0.19	0.21	0.17	--	--
8705	0.13	0.15	0.18	0.13	0.17	0.15	0.21
8700	0.11	0.13	0.16	0.17	0.17	0.17	0.18
8699	0.16	0.17	0.19	0.19	0.18	0.16	0.27
8690	0.14	0.14	0.17	0.13	0.20	0.12	0.19
MEAN	0.16	0.15	0.19	0.20	0.18	0.15	0.21
SD	0.041	0.016	0.024	0.060	0.012	0.022	0.040
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	0.16	0.13	0.16	0.19	0.16	--	--
8703	0.14	0.15	0.19	0.24	0.19	--	--
8713	0.19	0.16	0.21	0.15	0.18	--	--
8693	0.14	0.15	0.17	0.19	0.16	--	--
8695	0.14	0.13	0.17	0.22	0.18	0.16	0.19
8709	0.17	0.14	0.18	0.20	0.19	0.14	0.23
8715	0.19	0.17	0.24	0.23	0.15	0.21	0.25
8697	0.13	0.17	0.14	0.18	0.17	0.22	0.22
MEAN	0.16	0.15	0.18	0.20	0.17	0.18	0.22
SD	0.024	0.016	0.031	0.029	0.015	0.039	0.025
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Total Bilirubin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TBILI

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	0.11	0.14	0.16	0.15	0.12	--	--
8718	0.14	0.14	0.18	0.14	0.15	--	--
8706	0.10	0.12	0.14	0.13	0.12	--	--
8714	0.18	0.14	0.27	0.16	0.13	--	--
8701	0.11	0.11	0.21	0.18	0.18	0.18	0.20
8702	0.17	0.16	0.21	0.27	0.25	0.19	0.24
8720	0.15	0.12	0.20	0.14	0.14	0.10	0.10
8704	0.15	0.13	0.26	0.16	0.17	0.11	0.16
MEAN	0.14	0.13	0.20	0.17	0.16	0.15	0.18
SD	0.029	0.016	0.045	0.045	0.043	0.047	0.060
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	0.13	0.18	0.31	0.20	0.18	--	--
8719	0.14	0.13	0.22	0.13	0.12	--	--
8711	0.17	0.18	0.32	0.18	0.19	--	--
8716	0.14	0.12	0.14	0.10	0.12	--	--
8725	0.18	0.15	0.18	0.15	0.21	0.13	0.14
8707	0.15	0.11	0.18	0.18	0.17	0.16	0.17
8689	0.14	0.16	0.24	0.20	0.19	0.12	0.16
8722	0.14	0.13	0.18	0.13	0.19	0.11	0.21
MEAN	0.15	0.15	0.22	0.16	0.17	0.13	0.17
SD	0.017	0.027	0.065	0.037	0.034	0.022	0.029
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alkaline Phosphatase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALKP

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	140	133	143	134	142	--	--
8712	104	79	86	74	71	--	--
8710	109	109	105	104	96	--	--
8723	99	103	102	75	66	--	--
8705	114	103	84	129	106	87	78
8700	112	106	104	86	89	95	79
8699	150	121	129	107	85	73	69
8690	131	104	108	113	89	75	81
MEAN	120	107	108	103	93	83	77
SD	18.3	15.6	19.9	22.9	23.6	10.4	5.3
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	122	114	102	95	105	--	--
8703	88	78	66	58	50	--	--
8713	93	86	81	77	61	--	--
8693	111	97	87	68	58	--	--
8695	137	123	104	90	89	71	73
8709	95	94	76	79	86	119	103
8715	124	120	108	94	85	80	83
8697	76	71	65	57	45	39	47
MEAN	106	98	86	77	72	77	77
SD	21.0	19.5	17.0	15.2	21.6	32.9	23.3
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Alkaline Phosphatase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: ALKP

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	69	55	62	52	62	--	--
8718	114	102	86	77	61	--	--
8706	105	88	76	88	78	--	--
8714	91	88	82	78	74	--	--
8701	96	86	85	74	71	63	92
8702	96	97	104	105	86	91	128
8720	239	192	156	123	105	141	92
8704	125	102	95	89	75	84	85
MEAN	117	101	93	86	77	95	99
SD	52.0	39.6	28.2	21.3	14.1	33.0	19.4
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	83	71	54	61	52	--	--
8719	134	112	89	77	70	--	--
8711	93	88	83	73	72	--	--
8716	83	89	108	81	90	--	--
8725	74	63	68	65	61	82	129
8707	96	70	77	74	68	58	61
8689	77	73	127	90	79	142	143
8722	104	109	111	95	98	88	121
MEAN	93	84	90	77	74	93	114
SD	19.4	18.4	24.3	11.6	15.0	35.5	36.2
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GGT

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	4	3	2	3	5	--	--
8712	0	3	5	4	6	--	--
8710	4	3	4	6	6	--	--
8723	2	2	1	2	5	--	--
8705	2	4	6	4	10	1	7
8700	1	2	3	2	4	5	2
8699	2	3	2	5	6	5	12
8690	3	5	4	4	6	0	3
MEAN	2	3	3	4	6	3	6
SD	1.4	1.0	1.7	1.4	1.8	2.6	4.5
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	0	2	4	3	6	--	--
8703	4	3	5	5	6	--	--
8713	1	3	5	6	8	--	--
8693	3	1	3	3	6	--	--
8695	1	3	3	4	6	5	5
8709	3	4	5	1	9	6	6
8715	3	3	5	4	5	5	6
8697	2	4	4	4	6	3	6
MEAN	2	3	4	4	7	5	6
SD	1.4	1.0	0.9	1.5	1.3	1.3	0.5
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Gamma Glutamyl Transferase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GGT

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	3	1	3	5	7	--	--
8718	3	2	2	5	6	--	--
8706	5	4	4	4	7	--	--
8714	5	3	5	6	7	--	--
8701	3	4	4	5	8	5	2
8702	1	4	6	4	9	7	11
8720	4	3	4	3	7	6	8
8704	2	1	3	3	6	6	4
MEAN	3	3	4	4	7	6	6
SD	1.4	1.3	1.2	1.1	1.0	0.8	4.0
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	2	2	4	4	6	--	--
8719	4	3	3	5	6	--	--
8711	4	4	4	3	8	--	--
8716	1	5	3	4	6	--	--
8725	3	2	5	5	6	2	6
8707	3	4	4	4	6	4	7
8689	5	4	0	4	7	6	5
8722	0	1	3	6	10	5	5
MEAN	3	3	3	4	7	4	6
SD	1.7	1.4	1.5	0.9	1.5	1.7	1.0
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Cholesterol

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CHOL

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	232	229	239	226	235	--	--
8712	191	168	153	157	149	--	--
8710	216	185	147	185	191	--	--
8723	168	142	164	140	236	--	--
8705	199	186	206	166	162	161	182
8700	154	135	167	141	143	155	134
8699	181	145	180	155	196	243	145
8690	199	153	227	199	200	192	308
MEAN	193	168	185	171	189	188	192
SD	25.1	31.3	34.6	30.1	35.7	40.2	79.9
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	220	184	193	157	180	--	--
8703	155	152	167	141	169	--	--
8713	191	150	168	144	168	--	--
8693	235	181	190	165	196	--	--
8695	182	156	159	169	181	264	203
8709	230	175	168	157	192	205	168
8715	197	146	140	176	179	185	167
8697	208	164	199	224	211	232	196
MEAN	202	164	173	167	185	222	184
SD	26.7	14.8	19.8	26.0	14.5	34.3	18.7
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Cholesterol

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CHOL

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	178	138	174	173	212	--	--
8718	244	190	208	206	184	--	--
8706	216	202	228	215	174	--	--
8714	169	137	120	150	182	--	--
8701	165	166	156	149	205	146	137
8702	217	181	190	183	170	221	180
8720	217	166	189	189	179	227	129
8704	179	153	150	131	159	183	116
MEAN	198	167	177	175	183	194	141
SD	28.9	23.6	34.4	29.4	17.6	37.6	27.7
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	141	133	127	123	141	--	--
8719	177	149	191	154	196	--	--
8711	191	140	149	121	150	--	--
8716	175	158	143	128	138	--	--
8725	194	180	165	162	174	181	209
8707	202	165	142	163	145	153	172
8689	227	190	208	257	291	225	184
8722	179	159	169	157	183	181	286
MEAN	186	159	162	158	177	185	213
SD	24.8	19.2	27.2	43.7	50.7	29.8	51.2
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Triglycerides

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TRIG

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	37	35	37	44	43	--	--
8712	47	54	56	55	49	--	--
8710	44	37	45	55	46	--	--
8723	42	26	31	36	35	--	--
8705	49	56	40	47	55	41	34
8700	36	29	52	28	36	30	28
8699	50	46	44	41	46	31	41
8690	35	38	55	37	38	58	34
MEAN	43	40	45	43	44	40	34
SD	6.0	11.0	8.9	9.4	6.9	13.0	5.3
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	28	27	25	25	28	--	--
8703	31	45	52	22	32	--	--
8713	33	27	37	23	42	--	--
8693	57	36	47	33	44	--	--
8695	34	30	35	46	42	51	33
8709	54	64	47	39	53	45	37
8715	35	31	32	30	29	29	28
8697	38	33	47	46	39	25	23
MEAN	39	37	40	33	39	38	30
SD	10.8	12.5	9.4	9.8	8.5	12.5	6.1
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Triglycerides

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: TRIG

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	39	28	52	40	36	--	--
8718	37	39	41	32	34	--	--
8706	55	37	51	53	47	--	--
8714	42	30	32	30	53	--	--
8701	29	37	38	40	55	51	27
8702	40	36	29	41	48	31	36
8720	34	23	38	44	51	57	15
8704	33	43	42	46	33	49	26
MEAN	39	34	40	41	45	47	26
SD	7.8	6.6	8.1	7.4	8.9	11.2	8.6
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	37	46	46	49	50	--	--
8719	32	28	49	31	38	--	--
8711	42	35	74	53	57	--	--
8716	40	29	42	41	46	--	--
8725	48	46	50	48	69	40	21
8707	40	35	59	52	49	32	30
8689	44	47	77	83	70	52	43
8722	41	46	58	36	52	23	52
MEAN	41	39	57	49	54	37	37
SD	4.7	8.1	12.8	15.8	11.1	12.3	13.7
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: LDH

SEX: FEMALE
UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	43	67	112	39	59	--	--
8712	41	29	53	57	44	--	--
8710	46	50	61	119	21	--	--
8723	38	47	64	80	19	--	--
8705	74	38	35	30	48	60	31
8700	66	57	56	52	82	57	59
8699	46	30	142	26	37	32	40
8690	31	55	54	23	34	57	28
MEAN	48	47	72	53	43	52	40
SD	14.5	13.4	35.8	32.6	20.6	13.1	14.0
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	54	39	39	65	25	--	--
8703	43	64	32	37	37	--	--
8713	47	29	54	46	47	--	--
8693	42	28	42	29	29	--	--
8695	27	31	39	25	47	49	39
8709	67	49	37	43	110	25	30
8715	40	33	40	52	45	30	77
8697	51	32	29	30	21	106	41
MEAN	46	38	39	41	45	53	47
SD	11.7	12.5	7.4	13.4	28.1	37.1	20.7
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Lactate Dehydrogenase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: LDH

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	77	119	81	38	75	--	--
8718	29	50	47	21	32	--	--
8706	34	20	21	32	37	--	--
8714	41	29	45	46	38	--	--
8701	37	29	58	38	51	50	54
8702	106	52	57	51	36	102	32
8720	32	50	33	28	26	27	31
8704	24	41	33	40	21	24	50
MEAN	48	49	47	37	40	51	42
SD	28.7	30.7	18.7	9.6	16.9	36.1	12.0
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	52	173	127	60	57	--	--
8719	36	59	58	35	57	--	--
8711	19	27	91	36	35	--	--
8716	48	45	156	39	56	--	--
8725	43	70	125	90	139	121	46
8707	33	35	65	40	84	40	38
8689	78	64	221	48	62	98	59
8722	39	37	184	55	86	42	60
MEAN	44	64	128	50	72	75	51
SD	17.2	46.7	57.1	18.4	31.6	40.7	10.6
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatine Kinase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CK

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	178	152	240	-155	188	--	--
8712	805	155	213	174	213	--	--
8710	167	125	133	288	82	--	--
8723	153	111	165	136	102	--	--
8705	151	130	165	90	83	210	163
8700	263	224	129	133	495	130	213
8699	186	156	172	81	75	60	195
8690	217	172	244	117	223	135	183
MEAN	265	153	183	147	183	134	189
SD	221.3	34.8	44.8	64.9	140.6	61.3	21.0
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	163	112	109	299	128	--	--
8703	167	181	126	115	255	--	--
8713	580	233	277	178	452	--	--
8693	307	167	228	106	82	--	--
8695	137	128	145	264	173	104	171
8709	174	235	126	132	591	136	242
8715	122	125	90	109	133	75	149
8697	188	126	103	101	71	162	93
MEAN	230	163	151	163	236	119	164
SD	152.2	49.4	66.4	77.6	189.1	37.9	61.6
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatine Kinase

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CK

SEX: FEMALE

UNITS: IU/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	320	360	127	178	120	--	--
8718	121	183	127	86	86	--	--
8706	180	99	75	132	130	--	--
8714	225	167	121	210	113	--	--
8701	155	132	157	162	120	208	205
8702	168	171	291	171	159	203	184
8720	129	116	91	102	76	101	100
8704	151	194	176	128	124	81	346
MEAN	181	178	146	146	116	148	209
SD	64.7	80.9	67.0	41.5	25.8	66.6	102.1
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	128	285	365	136	97	--	--
8719	241	166	100	129	160	--	--
8711	148	170	409	171	114	--	--
8716	133	162	142	104	116	--	--
8725	174	131	142	184	273	252	131
8707	178	125	91	153	181	129	272
8689	179	209	236	127	128	138	271
8722	188	155	190	118	267	157	126
MEAN	171	175	209	140	167	169	200
SD	36.1	51.2	119.6	27.1	69.0	56.6	82.6
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: BUN

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	11.7	12.3	15.0	14.9	18.3	--	--
8712	14.0	7.3	17.0	15.3	14.2	--	--
8710	15.6	16.1	16.4	17.9	20.4	--	--
8723	13.3	7.8	10.7	14.9	18.0	--	--
8705	10.5	9.7	15.0	15.5	16.6	13.9	16.8
8700	11.9	11.0	10.5	11.4	14.1	10.6	12.8
8699	16.4	18.4	23.5	23.3	25.9	20.8	22.8
8690	10.1	10.2	15.4	13.9	19.0	15.3	15.2
MEAN	12.9	11.6	15.4	15.9	18.3	15.2	16.9
SD	2.30	3.89	4.06	3.50	3.78	4.25	4.26
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	13.0	8.8	12.5	12.6	13.6	--	--
8703	12.5	12.0	11.8	13.1	13.5	--	--
8713	13.2	13.7	16.2	17.1	21.9	--	--
8693	10.6	9.9	11.5	11.3	13.7	--	--
8695	17.0	18.3	16.7	17.4	15.7	18.8	18.5
8709	15.8	15.9	17.4	16.4	21.2	19.5	19.0
8715	13.2	9.9	15.4	14.8	17.2	15.5	13.4
8697	10.1	7.8	15.9	9.7	12.5	9.0	12.1
MEAN	13.2	12.0	14.7	14.1	16.2	15.7	15.8
SD	2.33	3.67	2.36	2.83	3.64	4.80	3.51
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Blood Urea Nitrogen

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: BUN

SEX: FEMALE
UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	10.5	9.2	11.1	18.6	19.3	--	--
8718	12.4	11.1	13.8	14.9	10.9	--	--
8706	9.8	11.0	13.8	13.9	13.6	--	--
8714	12.5	14.2	18.4	16.6	27.9	--	--
8701	8.9	7.5	10.9	11.2	17.1	10.0	11.1
8702	11.3	12.3	13.0	19.7	22.5	14.8	14.5
8720	9.6	9.3	9.3	9.3	14.6	11.9	11.3
8704	10.5	11.3	14.1	14.6	14.3	13.6	12.9
MEAN	10.7	10.7	13.1	14.9	17.5	12.6	12.5
SD	1.30	2.07	2.76	3.50	5.53	2.09	1.59
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	6.9	6.0	10.5	10.0	11.5	--	--
8719	12.2	14.1	16.9	17.0	17.3	--	--
8711	13.2	9.8	17.2	17.6	19.8	--	--
8716	16.4	15.1	12.4	15.8	18.2	--	--
8725	13.7	10.6	12.0	14.4	14.7	14.8	12.6
8707	13.7	16.0	13.9	16.7	16.8	14.0	23.7
8689	13.3	11.4	16.3	18.1	18.1	15.7	16.3
8722	10.0	9.5	9.5	12.6	16.2	11.3	17.2
MEAN	12.4	11.6	13.6	15.3	16.6	14.0	17.5
SD	2.85	3.34	2.97	2.79	2.55	1.90	4.62
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatinine

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CREAT

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	0.79	0.78	0.90	0.89	0.91	--	--
8712	0.78	0.77	0.83	0.74	0.89	--	--
8710	0.81	0.81	0.82	0.87	0.86	--	--
8723	0.77	0.73	0.83	0.75	0.79	--	--
8705	0.76	0.82	0.85	0.82	0.83	0.85	0.85
8700	0.64	0.69	0.66	0.63	0.73	0.71	0.73
8699	0.83	0.84	0.79	0.81	0.83	0.80	0.94
8690	0.75	0.77	0.76	0.71	0.79	0.80	0.80
MEAN	0.77	0.78	0.81	0.78	0.83	0.79	0.83
SD	0.057	0.049	0.072	0.087	0.059	0.058	0.088
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	0.77	0.66	0.66	0.68	0.77	--	--
8703	0.72	0.77	0.86	0.80	0.90	--	--
8713	0.92	0.91	0.97	0.89	0.93	--	--
8693	0.72	0.71	0.78	0.77	0.82	--	--
8695	0.88	0.93	0.84	0.95	0.92	0.79	0.87
8709	0.90	0.89	0.69	0.74	0.80	0.74	0.93
8715	0.84	0.75	0.80	0.80	0.89	0.86	0.82
8697	0.82	0.77	0.82	0.76	0.89	0.84	0.86
MEAN	0.82	0.80	0.80	0.80	0.87	0.81	0.87
SD	0.078	0.099	0.098	0.085	0.060	0.054	0.045
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Creatinine

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CREAT

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	0.67	0.70	0.73	0.73	0.71	--	--
8718	0.68	0.68	0.70	0.68	0.75	--	--
8706	0.66	0.70	0.73	0.76	0.80	--	--
8714	0.89	0.85	0.98	0.88	0.98	--	--
8701	0.59	0.59	0.67	0.64	0.69	0.64	0.62
8702	0.64	0.72	0.69	0.66	0.66	0.60	0.68
8720	0.63	0.63	0.72	0.64	0.71	0.65	0.73
8704	0.70	0.70	0.69	0.65	0.71	0.64	0.88
MEAN	0.68	0.70	0.74	0.71	0.75	0.63	0.73
SD	0.090	0.076	0.100	0.083	0.101	0.022	0.111
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	0.57	0.60	0.66	0.57	0.80	--	--
8719	0.77	0.73	0.75	0.79	0.96	--	--
8711	0.96	0.83	0.89	0.85	0.94	--	--
8716	0.80	0.75	0.77	0.83	1.01	--	--
8725	0.69	0.69	0.71	0.76	0.87	0.60	0.66
8707	0.75	0.75	0.79	0.73	0.90	0.82	0.73
8689	0.72	0.78	0.71	0.75	0.83	0.64	0.66
8722	0.79	0.81	0.77	0.75	0.86	0.68	0.78
MEAN	0.76	0.74	0.76	0.75	0.90	0.69	0.71
SD	0.110	0.073	0.069	0.085	0.070	0.096	0.059
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Sodium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: NA

SEX: FEMALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	146	146	147	146	148	--	--
8712	146	146	147	146	148	--	--
8710	145	143	143	146	147	--	--
8723	147	145	146	145	146	--	--
8705	147	147	144	143	146	145	145
8700	147	149	145	145	148	145	145
8699	147	149	146	145	146	145	145
8690	145	147	146	146	149	145	145
MEAN	146	147	146	145	147	145	145
SD	0.9	2.0	1.4	1.0	1.2	0.0	0.0
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	147	147	145	145	146	--	--
8703	147	149	146	145	148	--	--
8713	144	146	143	144	146	--	--
8693	146	149	146	146	146	--	--
8695	148	149	146	147	149	146	146
8709	148	149	144	145	147	144	143
8715	147	146	146	145	147	147	144
8697	147	148	148	146	148	146	147
MEAN	147	148	146	145	147	146	145
SD	1.3	1.4	1.5	0.9	1.1	1.3	1.8
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Sodium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: NA

SEX: FEMALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	146	147	145	-145	145	--	--
8718	147	147	145	146	145	--	--
8706	146	147	145	144	147	--	--
8714	146	147	143	145	151	--	--
8701	148	146	146	146	146	148	146
8702	145	148	145	145	146	144	146
8720	145	147	146	145	149	145	145
8704	147	146	146	146	145	145	144
MEAN	146	147	145	145	147	146	145
SD	1.0	0.6	1.0	0.7	2.2	1.7	1.0
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	145	145	144	143	145	--	--
8719	146	148	148	145	148	--	--
8711	147	148	147	144	146	--	--
8716	146	147	146	146	148	--	--
8725	147	145	146	145	147	145	145
8707	147	149	146	142	148	145	144
8689	144	145	146	147	148	147	145
8722	147	147	146	144	146	143	142
MEAN	146	147	146	145	147	145	144
SD	1.1	1.6	1.1	1.6	1.2	1.6	1.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF WR242511 WITH A THIRTEEN WEEK RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Potassium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: K

SEX: FEMALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	4.21	4.55	4.58	4.56	4.76	--	--
8712	4.07	4.13	4.55	4.54	4.50	--	--
8710	4.52	4.50	4.84	4.65	4.41	--	--
8723	4.52	4.29	4.75	4.32	4.76	--	--
8705	4.34	4.70	4.80	4.49	4.62	4.42	4.22
8700	4.33	4.13	4.70	4.47	4.31	4.45	4.31
8699	4.26	3.97	4.03	3.95	4.18	4.42	4.06
8690	4.64	4.49	4.58	4.36	4.48	4.72	4.53
MEAN	4.36	4.35	4.60	4.42	4.50	4.50	4.28
SD	0.188	0.253	0.256	0.217	0.206	0.146	0.196
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	4.56	4.02	4.64	4.55	4.53	--	--
8703	4.49	4.06	4.72	4.23	4.47	--	--
8713	4.36	4.44	4.67	4.44	4.62	--	--
8693	4.74	4.26	4.47	4.39	4.57	--	--
8695	4.30	4.37	4.29	4.34	4.06	4.40	4.52
8709	4.54	4.26	4.53	4.31	4.79	4.69	4.30
8715	4.67	4.19	4.46	4.20	4.44	4.20	4.52
8697	4.73	4.32	4.70	4.62	4.67	4.70	4.37
MEAN	4.55	4.24	4.56	4.39	4.52	4.50	4.43
SD	0.163	0.145	0.149	0.147	0.217	0.242	0.111
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Potassium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: K

SEX: FEMALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	5.04	4.47	4.67	4.49	4.36	--	--
8718	4.61	4.70	4.39	4.46	4.12	--	--
8706	4.19	3.96	4.47	4.05	4.22	--	--
8714	4.60	4.50	4.43	4.44	4.56	--	--
8701	4.30	4.37	4.47	4.23	4.64	4.52	3.87
8702	3.86	4.34	4.34	4.16	4.11	4.68	4.06
8720	4.32	3.95	4.22	4.15	3.92	4.16	4.33
8704	4.45	4.28	4.20	4.51	4.05	4.31	4.16
MEAN	4.42	4.32	4.40	4.31	4.25	4.42	4.11
SD	0.347	0.259	0.151	0.183	0.253	0.229	0.192
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	4.44	3.98	4.42	4.08	4.46	--	--
8719	4.39	4.52	4.23	4.16	4.58	--	--
8711	4.27	4.26	4.41	4.26	4.49	--	--
8716	4.31	4.81	4.40	4.41	4.54	--	--
8725	4.30	4.41	4.84	4.38	4.63	4.53	3.65
8707	4.24	4.28	4.62	4.24	3.97	4.21	4.15
8689	4.76	4.42	4.57	4.29	4.42	4.48	4.13
8722	4.24	4.43	4.56	4.41	4.55	4.24	4.35
MEAN	4.37	4.39	4.51	4.28	4.46	4.37	4.07
SD	0.173	0.237	0.183	0.120	0.207	0.163	0.297
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Chloride

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CL

SEX: FEMALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	110	109	108	109	113	--	--
8712	113	107	114	111	113	--	--
8710	113	109	109	111	111	--	--
8723	115	107	110	114	113	--	--
8705	109	107	108	112	112	108	111
8700	112	109	106	108	114	110	113
8699	112	111	110	111	117	109	118
8690	112	107	108	108	112	107	115
MEAN	112	108	109	111	113	109	114
SD	1.9	1.5	2.4	2.1	1.8	1.3	3.0
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	112	110	110	108	115	--	--
8703	107	109	108	109	111	--	--
8713	110	105	105	110	114	--	--
8693	107	107	105	108	111	--	--
8695	105	110	107	112	115	109	113
8709	113	111	110	107	115	110	114
8715	110	110	109	111	111	112	111
8697	107	107	108	106	113	110	114
MEAN	109	109	108	109	113	110	113
SD	2.8	2.1	2.0	2.0	1.9	1.3	1.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Chloride

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CL

SEX: FEMALE

UNITS: mEq/L

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	104	108	107	111	114	--	--
8718	110	108	105	110	112	--	--
8706	110	106	104	107	112	--	--
8714	113	110	111	110	114	--	--
8701	109	107	114	112	113	113	115
8702	105	107	108	111	115	113	115
8720	105	106	106	110	111	109	113
8704	108	110	114	115	117	111	113
MEAN	108	108	109	111	114	112	114
SD	3.1	1.6	3.9	2.3	1.9	1.9	1.2
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	104	106	108	110	115	--	--
8719	109	108	108	106	113	--	--
8711	115	111	112	109	118	--	--
8716	111	107	111	112	112	--	--
8725	111	106	107	110	114	110	113
8707	110	109	115	107	114	111	116
8689	109	108	110	109	115	110	114
8722	115	108	110	108	113	109	113
MEAN	111	108	110	109	114	110	114
SD	3.5	1.6	2.6	1.9	1.8	0.8	1.4
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Calcium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CA

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	11.7	10.5	10.3	9.9	10.7	--	--
8712	11.4	9.7	10.1	9.8	11.0	--	--
8710	11.9	10.6	10.4	10.2	10.8	--	--
8723	11.2	10.2	10.4	10.3	10.4	--	--
8705	10.9	10.3	10.7	10.1	10.8	10.3	10.3
8700	10.3	9.9	10.2	9.6	10.0	9.7	10.1
8699	10.5	10.4	10.5	10.1	10.8	9.6	9.9
8690	11.5	10.4	10.5	10.1	10.5	10.1	10.0
MEAN	11.2	10.3	10.4	10.0	10.6	9.9	10.1
SD	0.57	0.31	0.19	0.23	0.32	0.33	0.17
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	11.1	9.9	9.5	9.5	10.5	--	--
8703	10.6	10.2	10.5	9.9	10.7	--	--
8713	10.8	10.5	10.3	10.0	11.1	--	--
8693	10.8	10.5	10.3	10.1	10.9	--	--
8695	10.6	10.6	10.4	10.1	10.8	9.7	10.0
8709	11.0	10.2	10.2	10.0	10.4	9.9	9.7
8715	11.1	10.3	10.1	10.0	11.0	10.0	9.8
8697	10.7	10.2	10.3	10.3	11.1	10.0	10.3
MEAN	10.8	10.3	10.2	10.0	10.8	9.9	10.0
SD	0.21	0.23	0.31	0.23	0.26	0.14	0.26
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Calcium

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: CA

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	10.7	10.0	9.8	9.7	10.3	--	--
8718	11.2	10.1	10.4	9.8	10.7	--	--
8706	10.8	10.7	10.4	10.1	10.7	--	--
8714	10.5	10.6	10.1	10.5	11.4	--	--
8701	10.8	10.2	10.1	9.7	10.6	9.3	9.9
8702	10.5	10.4	10.0	9.1	10.5	9.0	9.5
8720	11.0	9.9	10.3	9.9	10.7	9.6	9.8
8704	10.7	9.9	9.8	9.4	10.4	9.4	9.8
MEAN	10.8	10.2	10.1	9.8	10.7	9.3	9.8
SD	0.24	0.31	0.24	0.42	0.33	0.25	0.17
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	10.4	10.2	9.9	9.6	10.9	--	--
8719	11.3	10.3	9.9	10.0	10.6	--	--
8711	11.8	10.1	9.6	9.4	10.4	--	--
8716	11.8	11.0	10.0	10.1	10.8	--	--
8725	11.6	10.2	9.7	10.0	10.5	9.6	9.7
8707	10.7	10.5	10.0	9.5	10.6	9.6	10.0
8689	10.5	10.1	9.6	10.0	10.5	9.6	9.9
8722	11.2	9.7	9.8	9.7	10.7	9.3	10.0
MEAN	11.2	10.3	9.8	9.8	10.6	9.5	9.9
SD	0.57	0.37	0.16	0.27	0.17	0.15	0.14
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Inorganic Phosphorus

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: IP

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	6.2	5.4	4.5	4.5	5.0	--	--
8712	7.1	5.4	6.1	5.9	6.5	--	--
8710	6.2	6.4	5.7	5.6	6.3	--	--
8723	6.3	5.1	5.1	3.7	5.8	--	--
8705	4.7	5.1	6.5	5.5	5.5	3.6	4.4
8700	5.8	4.7	5.5	4.3	4.3	3.6	3.7
8699	4.2	5.1	4.5	4.7	6.0	4.8	3.7
8690	7.1	5.3	6.9	5.6	6.5	4.8	4.7
MEAN	6.0	5.3	5.6	5.0	5.7	4.2	4.1
SD	1.04	0.49	0.88	0.78	0.78	0.69	0.51
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	6.6	4.5	4.9	4.2	6.5	--	--
8703	5.4	4.0	5.8	4.4	4.9	--	--
8713	6.8	5.3	5.5	5.2	5.4	--	--
8693	5.4	4.8	5.8	4.9	5.7	--	--
8695	5.1	5.6	5.7	4.6	5.1	4.4	4.1
8709	5.9	4.1	5.9	4.3	4.4	5.7	3.8
8715	5.4	4.3	4.5	4.0	5.1	4.2	3.2
8697	5.1	5.3	6.2	5.3	5.8	3.8	3.4
MEAN	5.7	4.7	5.5	4.6	5.4	4.5	3.6
SD	0.66	0.61	0.56	0.48	0.64	0.82	0.40
N	8	8	8	8	8	4	4

(--) - Data Unavailable

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Inorganic Phosphorus

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: IP

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	5.7	4.3	4.7	4.8	5.1	--	--
8718	7.0	5.6	5.1	5.3	6.0	--	--
8706	5.7	5.4	5.9	4.8	5.7	--	--
8714	7.1	5.0	5.2	5.3	5.9	--	--
8701	5.7	5.0	5.1	4.3	5.3	3.5	2.7
8702	5.5	4.7	4.4	4.2	4.6	3.7	3.7
8720	6.8	5.4	5.4	5.3	6.1	4.6	4.4
8704	6.5	5.2	5.1	5.0	5.2	4.5	4.3
MEAN	6.3	5.1	5.1	4.9	5.5	4.1	3.8
SD	0.67	0.42	0.45	0.44	0.52	0.56	0.78
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	6.4	4.7	4.6	5.2	6.3	--	--
8719	6.4	5.4	5.4	6.1	6.0	--	--
8711	6.5	5.0	4.8	4.9	5.7	--	--
8716	5.7	5.5	5.3	4.4	5.5	--	--
8725	5.8	6.5	5.6	4.9	5.4	3.7	3.8
8707	5.7	5.9	5.5	4.4	5.4	3.8	4.7
8689	6.8	4.5	4.7	5.3	5.2	5.0	4.6
8722	6.1	4.1	5.0	5.2	5.8	3.9	4.1
MEAN	6.2	5.2	5.1	5.1	5.7	4.1	4.3
SD	0.41	0.78	0.39	0.55	0.36	0.61	0.42
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Glucose

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLU

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	114	107	106	100	108	--	--
8712	103	107	94	101	101	--	--
8710	118	113	107	104	119	--	--
8723	110	106	120	108	122	--	--
8705	116	109	94	102	108	100	107
8700	114	105	94	97	111	103	92
8699	116	112	102	101	120	102	97
8690	102	88	98	100	104	94	107
MEAN	112	106	102	102	112	100	101
SD	6.1	7.8	9.0	3.2	7.8	4.0	7.5
N	8	8	8	8	8	4	4
GROUP: 2-F:0.1 mg base/kg/day							
8717	111	103	105	96	125	--	--
8703	123	117	97	108	112	--	--
8713	117	101	107	106	120	--	--
8693	123	110	111	101	113	--	--
8695	97	91	92	89	95	97	98
8709	143	122	95	95	105	94	98
8715	109	102	100	101	105	104	104
8697	109	98	109	100	107	100	104
MEAN	117	106	102	100	110	99	101
SD	13.7	10.2	7.0	6.1	9.4	4.3	3.5
N	8	8	8	8	8	4	4

(--) - Data Unavailable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Glucose

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: GLU

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	107	95	99	102	102	--	--
8718	113	102	111	98	104	--	--
8706	102	95	99	86	107	--	--
8714	103	97	82	86	99	--	--
8701	118	107	98	97	102	109	106
8702	108	102	95	100	98	103	106
8720	129	110	108	118	116	108	109
8704	120	121	112	114	123	113	123
MEAN	113	104	101	100	106	108	111
SD	9.3	8.9	9.9	11.5	8.8	4.1	8.1
N	8	8	8	8	8	4	4
GROUP: 4-F:1.0 mg base/kg/day							
8696	105	89	93	82	107	--	--
8719	113	94	91	96	109	--	--
8711	121	104	96	104	101	--	--
8716	104	105	89	91	92	--	--
8725	137	122	111	105	108	101	115
8707	136	105	101	100	103	108	109
8689	110	104	87	108	112	95	116
8722	120	110	98	107	102	101	122
MEAN	118	104	96	99	104	101	116
SD	12.8	9.9	7.7	9.0	6.2	5.3	5.3
N	8	8	8	8	8	4	4

(--) - Data Unavailable

THIRTEEN WEEK ORAL TOXICITY STUDY OF
WR242511 WITH A THIRTEEN WEEK
RECOVERY PERIOD IN DOGS

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Haptoglobin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: HAPT

SEX: FEMALE

UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 1-F:0 mg base/kg/day							
8721	41.7	25.5	-- B	-- B	-- B	--	--
8712	-- B	-- B	30.3	-- B	-- B	--	--
8710	-- B	-- B	-- B	-- B	-- B	--	--
8723	36.3	43.5	90.2	22.6	47.4	--	--
8705	-- B	-- B	-- B	118.0	39.4	-- B	40.4
8700	-- B	-- B	-- B	-- B	-- B	-- B	-- B
8699	-- B	17.2	-- B	-- B	28.5	27.6	-- B
8690	-- B	100.4	17.6	88.8	30.5	68.6	31.9
MEAN	39.0	46.7	46.0	76.5	36.5	48.1	36.2
SD	3.82	37.48	38.77	48.88	8.70	28.99	6.01
N	2	4	3	3	4	2	2
GROUP: 2-F:0.1 mg base/kg/day							
8717	23.1	106.2	19.9	-- B	-- B	--	--
8703	29.9	-- B	26.1	18.0	-- B	--	--
8713	-- B	17.6	-- B	-- B	-- B	--	--
8693	70.8	84.6	169.5	61.9	72.7	--	--
8695	17.6	16.6	-- B	-- B	31.5	-- B	-- B
8709	-- B	-- B	-- B	-- B	-- B	59.1	-- B
8715	22.4	28.5	-- B	-- B	27.3	65.0	25.5
8697	-- B	17.5	-- B	-- B	-- B	-- B	-- B
MEAN	32.8	45.2	71.8	40.0	43.8	62.1	25.5
SD	21.71	39.75	84.64	31.04	25.09	4.17	NA
N	5	6	3	2	3	2	1

(--) - Data Unavailable
B - Below Linearity

NA - Not Applicable

DRAFT

IND. ANIMAL CLINICAL CHEMISTRY REPORT BY GROUP
TEST: Haptoglobin

STUDY ID: UIC-18A
STUDY NO: 193
ABBR: HAPT

SEX: FEMALE
UNITS: mg/dL

Animal ID	Week -3	Week -1	Week 4	Week 8	Week 13	Week 18	Week 26
GROUP: 3-F:0.3 mg base/kg/day							
8692	84.8	44.7	89.6	27.0	-- B	--	--
8718	48.6	68.4	-- B	-- B	22.0	--	--
8706	59.7	54.9	120.8	88.9	91.6	--	--
8714	-- B	-- B	76.6	-- B	77.6	--	--
8701	35.1	64.6	37.9	22.7	30.2	24.4	-- B
8702	26.8	-- B	-- B	-- B	-- B	-- B	-- B
8720	63.9	61.6	93.3	68.5	75.5	98.4	41.3
8704	23.0	21.4	27.5	16.6	20.0	44.3	-- B
MEAN	48.8	52.6	74.3	44.7	52.8	55.7	41.3
SD	22.29	17.41	35.43	32.04	32.16	38.29	NA
N	7	6	6	5	6	3	1
GROUP: 4-F:1.0 mg base/kg/day							
8696	32.4	23.3	60.4	83.8	45.6	--	--
8719	-- B	-- B	193.3	60.9	71.5	--	--
8711	24.4	23.0	126.5	36.2	40.0	--	--
8716	36.6	66.4	304.2	91.0	123.6	--	--
8725	18.4	28.4	216.3	30.4	-- B	-- B	-- B
8707	-- B	18.4	117.4	-- B	-- B	-- B	-- B
8689	19.5	23.3	196.6	51.5	34.3	105.5	18.6
8722	37.2	39.0	244.8	45.9	-- B	-- B	-- B
MEAN	28.1	31.7	182.4	57.1	63.0	105.5	18.6
SD	8.43	16.64	77.86	23.03	36.74	NA	NA
N	6	7	8	7	5	1	1

(--) - Data Unavailable
B - Below Linearity
NA - Not Applicable